BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84. [PMID: 26707365 DOI: 10.1002/hep.28431] [Cited by in Crossref: 3251] [Cited by in F6Publishing: 3077] [Article Influence: 541.8] [Reference Citation Analysis]
Number Citing Articles
1 Malnick S, Maor Y. The Interplay between Alcoholic Liver Disease, Obesity, and the Metabolic Syndrome. Visc Med 2020;36:198-205. [PMID: 32775350 DOI: 10.1159/000507233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Reig M, Gambato M, Man NK, Roberts JP, Victor D, Orci LA, Toso C. Should Patients With NAFLD/NASH Be Surveyed for HCC? Transplantation 2019;103:39-44. [DOI: 10.1097/tp.0000000000002361] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 8.7] [Reference Citation Analysis]
3 Flister KFT, Pinto BAS, França LM, Coêlho CFF, Dos Santos PC, Vale CC, Kajihara D, Debbas V, Laurindo FRM, Paes AMA. Long-term exposure to high-sucrose diet down-regulates hepatic endoplasmic reticulum-stress adaptive pathways and potentiates de novo lipogenesis in weaned male mice. J Nutr Biochem 2018;62:155-66. [PMID: 30300835 DOI: 10.1016/j.jnutbio.2018.09.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
4 Liu W, Zheng KI, Pan X, Ma H, Zhu P, Wu X, Rios RS, Targher G, Byrne CD, Wang X, Chen Y, Zheng M. Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease. Journal of Gastroenterology and Hepatology 2020;35:1057-64. [DOI: 10.1111/jgh.14894] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
5 Dzyubak B, Li J, Chen J, Mara KC, Therneau TM, Venkatesh SK, Ehman RL, Allen AM, Yin M. Automated Analysis of Multiparametric Magnetic Resonance Imaging/Magnetic Resonance Elastography Exams for Prediction of Nonalcoholic Steatohepatitis. J Magn Reson Imaging 2021;54:122-31. [PMID: 33586159 DOI: 10.1002/jmri.27549] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Chai B, Wang W, Wang F, Zhou G, Zheng C. Transcatheter chemoembolization plus percutaneous radiofrequency ablation versus laparoscopic radiofrequency ablation: improved outcome for inoperable hepatocellular carcinoma. Int J Hyperthermia 2021;38:1685-94. [PMID: 34843653 DOI: 10.1080/02656736.2021.1970825] [Reference Citation Analysis]
7 Younossi ZM, Pham H, Felix S, Stepanova M, Jeffers T, Younossi E, Allawi H, Lam B, Cable R, Afendy M, Younoszai Z, Afendy A, Rafiq N, Alzubaidi N, Ousman Y, Bailey M, Chris Z, Castillo-Catoni M, Fozdar P, Ramirez M, Husain M, Hudson E, Schneider I, Golabi P, Nader F. Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease Using Noninvasive Tests From Primary Care and Endocrinology Real-World Practices. Clin Transl Gastroenterol 2021;12:e00340. [PMID: 33825721 DOI: 10.14309/ctg.0000000000000340] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
8 Åberg F, Färkkilä M, Männistö V. Interaction Between Alcohol Use and Metabolic Risk Factors for Liver Disease: A Critical Review of Epidemiological Studies. Alcohol Clin Exp Res 2020;44:384-403. [DOI: 10.1111/acer.14271] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
9 Vasanthakumar A, Davis JW, Abunimeh M, Söderholm J, Zha J, Dumas EO, Cohen DE, Waring JF, Lagging M. Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens. PLoS One 2018;13:e0198296. [PMID: 29851985 DOI: 10.1371/journal.pone.0198296] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Armstrong MJ, Marchesini G. Referral pathways for NAFLD fibrosis in primary care - No longer a 'needle in a haystack'. J Hepatol 2019;71:246-8. [PMID: 31229270 DOI: 10.1016/j.jhep.2019.05.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
11 Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Askling J, Hultcrantz R, Kechagias S. Cardiovascular risk factors in non-alcoholic fatty liver disease. Liver Int 2019;39:197-204. [DOI: 10.1111/liv.13973] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
12 Beyaz Coşkun A, Sağdiçoğlu Celep AG. Therapeutic modulation methods of gut microbiota and gut-liver axis. Crit Rev Food Sci Nutr 2021;:1-11. [PMID: 33749411 DOI: 10.1080/10408398.2021.1902263] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Smith AD, Porter KK, Elkassem AA, Sanyal R, Lockhart ME. Current Imaging Techniques for Noninvasive Staging of Hepatic Fibrosis. American Journal of Roentgenology 2019;213:77-89. [DOI: 10.2214/ajr.19.21144] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
14 Faulkner CS, White CM, Shah VH, Jophlin LL. A single nucleotide polymorphism of PLIN2 is associated with nonalcoholic steatohepatitis and causes phenotypic changes in hepatocyte lipid droplets: A pilot study. Biochim Biophys Acta Mol Cell Biol Lipids 2020;1865:158637. [PMID: 31981756 DOI: 10.1016/j.bbalip.2020.158637] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Yoo ER, Kim D, Vazquez‐montesino LM, Escober JA, Li AA, Tighe SP, Fernandes CT, Cholankeril G, Ahmed A. Diet quality and its association with nonalcoholic fatty liver disease and all‐cause and cause‐specific mortality. Liver Int 2020;40:815-24. [DOI: 10.1111/liv.14374] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Zhao M, Song C, Luo T, Huang T, Lin S. Fatty Liver Disease Prediction Model Based on Big Data of Electronic Physical Examination Records. Front Public Health 2021;9:668351. [PMID: 33912534 DOI: 10.3389/fpubh.2021.668351] [Reference Citation Analysis]
17 Zarei A, Stasi C, Mahmoodi M, Masoumi SJ, Zare M, Jalali M. Effect of soy consumption on liver enzymes, lipid profile, anthropometry indices, and oxidative stress in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials. Iran J Basic Med Sci 2020;23:1245-50. [PMID: 33149855 DOI: 10.22038/ijbms.2020.46854.10797] [Reference Citation Analysis]
18 Ishida N, Yamada H, Hirose M. Euphausia pacifica (North Pacific Krill): Review of Chemical Features and Potential Benefits of 8-HEPE against Metabolic Syndrome, Dyslipidemia, NAFLD, and Atherosclerosis. Nutrients 2021;13:3765. [PMID: 34836021 DOI: 10.3390/nu13113765] [Reference Citation Analysis]
19 Shingina A, DeWitt PE, Dodge JL, Biggins SW, Gralla J, Sprague D, Bambha K. Future Trends in Demand for Liver Transplant: Birth Cohort Effects Among Patients With NASH and HCC. Transplantation. 2019;103:140-148. [PMID: 30451739 DOI: 10.1097/tp.0000000000002497] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 4.7] [Reference Citation Analysis]
20 Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021;397:2212-24. [PMID: 33894145 DOI: 10.1016/S0140-6736(20)32511-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 12.0] [Reference Citation Analysis]
21 Aarts S, Reiche M, den Toom M, Gijbels M, Beckers L, Gerdes N, Lutgens E. Depletion of CD40 on CD11c+ cells worsens the metabolic syndrome and ameliorates hepatic inflammation during NASH. Sci Rep 2019;9:14702. [PMID: 31604965 DOI: 10.1038/s41598-019-50976-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
22 Dehghanseresht N, Jafarirad S, Alavinejad SP, Mansoori A. Association of the dietary patterns with the risk of non-alcoholic fatty liver disease among Iranian population: a case-control study. Nutr J 2020;19:63. [PMID: 32605646 DOI: 10.1186/s12937-020-00580-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Fernández-Ramos D, Lopitz-Otsoa F, Delacruz-Villar L, Bilbao J, Pagano M, Mosca L, Bizkarguenaga M, Serrano-Macia M, Azkargorta M, Iruarrizaga-Lejarreta M, Sot J, Tsvirkun D, van Liempd SM, Goni FM, Alonso C, Martínez-Chantar ML, Elortza F, Hayardeny L, Lu SC, Mato JM. Arachidyl amido cholanoic acid improves liver glucose and lipid homeostasis in nonalcoholic steatohepatitis via AMPK and mTOR regulation. World J Gastroenterol 2020; 26(34): 5101-5117 [PMID: 32982112 DOI: 10.3748/wjg.v26.i34.5101] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
24 Ortigão R, Pimentel-Nunes P, Dinis-Ribeiro M, Libânio D. Gastrointestinal Microbiome - What We Need to Know in Clinical Practice. GE Port J Gastroenterol 2020;27:336-51. [PMID: 32999906 DOI: 10.1159/000505036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Zhang X, Wei Y, Li C, Wang W, Zhang R, Jia J, Yan B. Intracellular Exposure Dose-Associated Susceptibility of Steatotic Hepatocytes to Metallic Nanoparticles. Int J Mol Sci 2021;22:12643. [PMID: 34884447 DOI: 10.3390/ijms222312643] [Reference Citation Analysis]
26 Noureddin M, Zelber-Sagi S, Wilkens LR, Porcel J, Boushey CJ, Le Marchand L, Rosen HR, Setiawan VW. Diet Associations With Nonalcoholic Fatty Liver Disease in an Ethnically Diverse Population: The Multiethnic Cohort. Hepatology 2020;71:1940-52. [PMID: 31553803 DOI: 10.1002/hep.30967] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 13.0] [Reference Citation Analysis]
27 Saif M, Kwanten WJ, Carr JA, Chen IX, Posada JM, Srivastava A, Zhang J, Zheng Y, Pinter M, Chatterjee S, Softic S, Kahn CR, van Leyen K, Bruns OT, Jain RK, Bawendi MG. Non-invasive monitoring of chronic liver disease via near-infrared and shortwave-infrared imaging of endogenous lipofuscin. Nat Biomed Eng 2020;4:801-13. [PMID: 32572196 DOI: 10.1038/s41551-020-0569-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
28 Schulze RJ, Schott MB, Casey CA, Tuma PL, McNiven MA. The cell biology of the hepatocyte: A membrane trafficking machine. J Cell Biol 2019;218:2096-112. [PMID: 31201265 DOI: 10.1083/jcb.201903090] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 8.7] [Reference Citation Analysis]
29 Ke Z, Zhao Y, Tan S, Chen H, Li Y, Zhou Z, Huang C. Citrus reticulata Blanco peel extract ameliorates hepatic steatosis, oxidative stress and inflammation in HF and MCD diet-induced NASH C57BL/6 J mice. J Nutr Biochem 2020;83:108426. [PMID: 32559586 DOI: 10.1016/j.jnutbio.2020.108426] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
30 Santos-laso A, Perugorria MJ, Banales JM. O-GlcNAcylation: Undesired tripmate but an opportunity for treatment in NAFLD-HCC. Journal of Hepatology 2017;67:218-20. [DOI: 10.1016/j.jhep.2017.04.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
31 Li J, Zhu L, Zhang YM, Chen H, Miao YF, Kang HX, Ren HY, Wan MH, Long D, Tang WF. Sheng-Jiang Powder Ameliorates High Fat Diet Induced Nonalcoholic Fatty Liver Disease via Inhibiting Activation of Akt/mTOR/S6 Pathway in Rats. Evid Based Complement Alternat Med. 2018;2018:6190254. [PMID: 30402130 DOI: 10.1155/2018/6190254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
32 Fujii H, Enomoto M, Fukumoto S, Kimura T, Nadatani Y, Takashima S, Hagihara A, Uchida-Kobayashi S, Tamori A, Nishimoto N, Kawada N. Validation of a two-step approach combining serum biomarkers and liver stiffness measurement to predict advanced fibrosis. JGH Open 2021;5:801-8. [PMID: 34263075 DOI: 10.1002/jgh3.12590] [Reference Citation Analysis]
33 Männistö VT, Salomaa V, Färkkilä M, Jula A, Männistö S, Erlund I, Sundvall J, Lundqvist A, Perola M, Åberg F. Incidence of liver-related morbidity and mortality in a population cohort of non-alcoholic fatty liver disease. Liver Int 2021. [PMID: 34219352 DOI: 10.1111/liv.15004] [Reference Citation Analysis]
34 Labenz C, Huber Y, Kalliga E, Nagel M, Ruckes C, Straub BK, Galle PR, Wörns MA, Anstee QM, Schuppan D, Schattenberg JM. Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany. Aliment Pharmacol Ther 2018;48:1109-16. [PMID: 30288767 DOI: 10.1111/apt.14976] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 12.0] [Reference Citation Analysis]
35 Kumar S, Miller CM, Hashimoto K, Quintini C, Kumar A, Balci NC, Pinna AD. Liver Transplantation in the United Arab Emirates From Deceased and Living Donors: Initial 2-Year Experience. Transplantation 2021;105:1881-3. [PMID: 34416746 DOI: 10.1097/TP.0000000000003455] [Reference Citation Analysis]
36 Kanno R, Koshizuka T, Miyazaki N, Kobayashi T, Ishioka K, Ozaki C, Chiba H, Suzutani T. Protection of Fatty Liver by the Intake of Fermented Soybean Paste, Miso, and Its Pre-Fermented Mixture. Foods 2021;10:291. [PMID: 33535476 DOI: 10.3390/foods10020291] [Reference Citation Analysis]
37 Koopman N, Molinaro A, Nieuwdorp M, Holleboom AG. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2019;50:628-639. [PMID: 31373710 DOI: 10.1111/apt.15416] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
38 Gidener T, Ahmed OT, Larson JJ, Mara KC, Therneau TM, Venkatesh SK, Ehman RL, Yin M, Allen AM. Liver Stiffness by Magnetic Resonance Elastography Predicts Future Cirrhosis, Decompensation, and Death in NAFLD. Clin Gastroenterol Hepatol 2021;19:1915-1924.e6. [PMID: 33010409 DOI: 10.1016/j.cgh.2020.09.044] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
39 Chaim FDM, Pascoal LB, Chaim FHM, Palma BB, Damázio TA, da Costa LBE, Carvalho R, Cazzo E, Gestic MA, Utrini MP, Milanski M, Chaim EA, Leal RF. Histological grading evaluation of non-alcoholic fatty liver disease after bariatric surgery: a retrospective and longitudinal observational cohort study. Sci Rep 2020;10:8496. [PMID: 32444690 DOI: 10.1038/s41598-020-65556-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
40 Kelava T, Turcic P, Markotic A, Ostojic A, Sisl D, Mrzljak A. Importance of genetic polymorphisms in liver transplantation outcomes. World J Gastroenterol 2020; 26(12): 1273-1285 [PMID: 32256016 DOI: 10.3748/wjg.v26.i12.1273] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Serrano-Maciá M, Simón J, González-Rellan MJ, Azkargorta M, Goikoetxea-Usandizaga N, Lopitz-Otsoa F, De Urturi DS, Rodríguez-Agudo R, Lachiondo-Ortega S, Mercado-Gomez M, Gutiérrez de Juan V, Bizkarguenaga M, Fernández-Ramos D, Buque X, Baselli GA, Valenti LVC, Iruzubieta P, Crespo J, Villa E, Banales JM, Avila MA, Marin JJG, Aspichueta P, Sutherland J, Barrio R, Mayor U, Elortza F, Xirodimas DP, Nogueiras R, Delgado TC, Martínez-Chantar ML. Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis. Mol Metab 2021;53:101275. [PMID: 34153521 DOI: 10.1016/j.molmet.2021.101275] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Dai W, Sun Y, Jiang Z, Du K, Xia N, Zhong G. Key genes associated with non-alcoholic fatty liver disease and acute myocardial infarction. Med Sci Monit 2020;26:e922492. [PMID: 32594092 DOI: 10.12659/MSM.922492] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
43 GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5:245-266. [PMID: 31981519 DOI: 10.1016/s2468-1253(19)30349-8] [Cited by in Crossref: 167] [Cited by in F6Publishing: 75] [Article Influence: 83.5] [Reference Citation Analysis]
44 Mizuno N, Seko Y, Kataoka S, Okuda K, Furuta M, Takemura M, Taketani H, Hara T, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Itoh Y. Increase in the skeletal muscle mass to body fat mass ratio predicts the decline in transaminase in patients with nonalcoholic fatty liver disease. J Gastroenterol 2019;54:160-70. [PMID: 29948305 DOI: 10.1007/s00535-018-1485-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
45 Cai J, Zhang XJ, Li H. Progress and challenges in the prevention and control of nonalcoholic fatty liver disease. Med Res Rev. 2019;39:328-348. [PMID: 29846945 DOI: 10.1002/med.21515] [Cited by in Crossref: 36] [Cited by in F6Publishing: 43] [Article Influence: 9.0] [Reference Citation Analysis]
46 An JY, Peña MA, Cunha GM, Booker MT, Taouli B, Yokoo T, Sirlin CB, Fowler KJ. Abbreviated MRI for Hepatocellular Carcinoma Screening and Surveillance. Radiographics 2020;40:1916-31. [PMID: 33136476 DOI: 10.1148/rg.2020200104] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
47 Na A, Jo JJ, Kwon OK, Shrestha R, Cho PJ, Kim KM, Ki SH, Lee TH, Jeon TW, Jeong TC, Lee S. Investigation of nonalcoholic fatty liver disease-induced drug metabolism by comparative global toxicoproteomics. Toxicology and Applied Pharmacology 2018;352:28-37. [DOI: 10.1016/j.taap.2018.05.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
48 Song M, Yuan F, Li X, Ma X, Yin X, Rouchka EC, Zhang X, Deng Z, Prough RA, McClain CJ. Analysis of sex differences in dietary copper-fructose interaction-induced alterations of gut microbial activity in relation to hepatic steatosis.Biol Sex Differ. 2021;12:3. [PMID: 33407877 DOI: 10.1186/s13293-020-00346-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Derra A, Bator M, Menżyk T, Kukla M. Underrated enemy - from nonalcoholic fatty liver disease to cancers of the gastrointestinal tract. Clin Exp Hepatol 2018;4:55-71. [PMID: 29904722 DOI: 10.5114/ceh.2018.75955] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
50 Zhu X, Yan H, Chang X, Xia M, Zhang L, Wang L, Sun X, Yang X, Gao X, Bian H. Association between non-alcoholic fatty liver disease-associated hepatic fibrosis and bone mineral density in postmenopausal women with type 2 diabetes or impaired glucose regulation. BMJ Open Diabetes Res Care 2020;8:e000999. [PMID: 32759166 DOI: 10.1136/bmjdrc-2019-000999] [Reference Citation Analysis]
51 Vali Y, Lee J, Boursier J, Spijker R, Löffler J, Verheij J, Brosnan MJ, Böcskei Z, Anstee QM, Bossuyt PM, Zafarmand MH, Pavlides M, Levick C, Duffin K, Hyde C, Bauer T, Bedossa P, Leeming D, Daly A, Hanf R, Ortiz P, Oresic M, Schuppan D, Hanauer G, Chen Y, Shumbayawonda E, Bjerring PN, Zwinderman K. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. Journal of Hepatology 2020;73:252-62. [DOI: 10.1016/j.jhep.2020.03.036] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 16.0] [Reference Citation Analysis]
52 Schulz M, Tacke F. Identifying High-Risk NASH Patients: What We Know so Far. Hepat Med 2020;12:125-38. [PMID: 32982495 DOI: 10.2147/HMER.S265473] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
53 Leivas G, Maraschin CK, Blume CA, Telo GH, Trindade MRM, Trindade EN, Diemen VV, Cerski CTS, Schaan BD. Accuracy of ultrasound diagnosis of nonalcoholic fatty liver disease in patients with classes II and III obesity: A pathological image study. Obes Res Clin Pract 2021;15:461-5. [PMID: 34511367 DOI: 10.1016/j.orcp.2021.09.002] [Reference Citation Analysis]
54 Sobhonslidsuk A, Chanprasertyothin S, Pongrujikorn T, Kaewduang P, Promson K, Petraksa S, Ongphiphadhanakul B. The Association of Gut Microbiota with Nonalcoholic Steatohepatitis in Thais. Biomed Res Int 2018;2018:9340316. [PMID: 29682571 DOI: 10.1155/2018/9340316] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
55 de Conti A, Tryndyak V, Willett RA, Borowa-Mazgaj B, Watson A, Patton R, Khare S, Muskhelishvili L, Olson GR, Avigan MI, Cerniglia CE, Ross SA, Sanyal AJ, Beland FA, Rusyn I, Pogribny IP. Characterization of the variability in the extent of nonalcoholic fatty liver induced by a high-fat diet in the genetically diverse Collaborative Cross mouse model. FASEB J 2020;34:7773-85. [PMID: 32304142 DOI: 10.1096/fj.202000194R] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Hu XY, Li Y, Li LQ, Zheng Y, Lv JH, Huang SC, Zhang W, Liu L, Zhao L, Liu Z, Zhao XJ. Risk factors and biomarkers of non-alcoholic fatty liver disease: an observational cross-sectional population survey. BMJ Open 2018;8:e019974. [PMID: 29626047 DOI: 10.1136/bmjopen-2017-019974] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
57 Masson W, Lobo M, Masson G, Molinero G, Casciato P. Statin use in patients with elevated serum hepatic transaminases at baseline: A meta-analysis. Nutr Metab Cardiovasc Dis 2021;31:1357-64. [PMID: 33715945 DOI: 10.1016/j.numecd.2021.01.026] [Reference Citation Analysis]
58 Yu S, Wang H, Hu T, Yu C, Liu H, Chen X, Jiang J, Deng M. Disease burden of liver cancer attributable to specific etiologies in China from 1990 to 2019: An age-period-cohort analysis. Sci Prog 2021;104:368504211018081. [PMID: 34003688 DOI: 10.1177/00368504211018081] [Reference Citation Analysis]
59 Lombardi R, Fargion S, Fracanzani AL. Brain involvement in non-alcoholic fatty liver disease (NAFLD): A systematic review. Dig Liver Dis 2019;51:1214-22. [PMID: 31176631 DOI: 10.1016/j.dld.2019.05.015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
60 VoPham T. Environmental risk factors for liver cancer and nonalcoholic fatty liver disease. Curr Epidemiol Rep 2019;6:50-66. [PMID: 31080703 DOI: 10.1007/s40471-019-0183-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
61 Almahmoud MH, Al Khawaja NM, Alkinani A, Khader Y, Ajlouni KM. Prevalence of fatty liver disease and its associated factors among Jordanian patients with type 2 diabetes mellitus: A cross-sectional study. Ann Med Surg (Lond) 2021;68:102677. [PMID: 34401141 DOI: 10.1016/j.amsu.2021.102677] [Reference Citation Analysis]
62 Kalas MA, Chavez L, Leon M, Taweesedt PT, Surani S. Abnormal liver enzymes: A review for clinicians. World J Hepatol 2021; 13(11): 1688-1698 [PMID: 34904038 DOI: 10.4254/wjh.v13.i11.1688] [Reference Citation Analysis]
63 Eskridge W, Vierling JM, Gosbee W, Wan GA, Hyunh ML, Chang HE. Screening for undiagnosed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): A population-based risk factor assessment using vibration controlled transient elastography (VCTE). PLoS One 2021;16:e0260320. [PMID: 34847156 DOI: 10.1371/journal.pone.0260320] [Reference Citation Analysis]
64 Millings EJ, De Rosa MC, Fleet S, Watanabe K, Rausch R, Egli D, Li G, Leduc CA, Zhang Y, Fischer SG, Leibel RL. ILDR2 has a negligible role in hepatic steatosis. PLoS One 2018;13:e0197548. [PMID: 29847571 DOI: 10.1371/journal.pone.0197548] [Reference Citation Analysis]
65 Mann JP, Vreugdenhil A, Socha P, Jańczyk W, Baumann U, Rajwal S, Casswall T, Marcus C, van Mourik I, O'rahilly S, Savage DB, Noble-jamieson G, Lacaille F, Dabbas M, Dubern B, Kelly DA, Nobili V, Anstee QM. European paediatric non-alcoholic fatty liver disease registry (EU-PNAFLD): Design and rationale. Contemporary Clinical Trials 2018;75:67-71. [DOI: 10.1016/j.cct.2018.11.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
66 Chenxu G, Minxuan X, Yuting Q, Tingting G, Jing F, Jinxiao L, Sujun W, Yongjie M, Deshuai L, Qiang L, Linfeng H, Xuyuan N, Mingxing W, Ping H, Jun T. Loss of RIP3 initiates annihilation of high-fat diet initialized nonalcoholic hepatosteatosis: A mechanism involving Toll-like receptor 4 and oxidative stress. Free Radical Biology and Medicine 2019;134:23-41. [DOI: 10.1016/j.freeradbiomed.2018.12.034] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
67 Ren F, Chen Q, Meng C, Chen H, Zhou Y, Zhang H, Chen W. Serum metabonomics revealed the mechanism of Ganoderma amboinense polysaccharides in preventing non-alcoholic fatty liver disease (NAFLD) induced by high-fat diet. Journal of Functional Foods 2021;82:104496. [DOI: 10.1016/j.jff.2021.104496] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
68 Rowe IA. The devotion to surrogate outcomes in drug development for liver disease. Nat Rev Gastroenterol Hepatol 2018;15:1-2. [DOI: 10.1038/nrgastro.2017.155] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
69 Cimini FA, Barchetta I, Ciccarelli G, Leonetti F, Silecchia G, Chiappetta C, Di Cristofano C, Capoccia D, Bertoccini L, Ceccarelli V, Carletti R, Fraioli A, Baroni MG, Morini S, Cavallo MG. Adipose tissue remodelling in obese subjects is a determinant of presence and severity of fatty liver disease. Diabetes Metab Res Rev 2021;37:e3358. [PMID: 32469428 DOI: 10.1002/dmrr.3358] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
70 Boursier J, Shreay S, Fabron C, Torreton E, Fraysse J. Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: Analysis of a French national hospital database. EClinicalMedicine 2020;25:100445. [PMID: 32775971 DOI: 10.1016/j.eclinm.2020.100445] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
71 Petta S, Wong VW, Cammà C, Hiriart JB, Wong GL, Vergniol J, Chan AW, Di Marco V, Merrouche W, Chan HL, Marra F, Le-Bail B, Arena U, Craxì A, de Ledinghen V. Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD. Aliment Pharmacol Ther 2017;46:617-27. [PMID: 28752524 DOI: 10.1111/apt.14219] [Cited by in Crossref: 79] [Cited by in F6Publishing: 69] [Article Influence: 15.8] [Reference Citation Analysis]
72 Shetty A, Giron F, Divatia MK, Ahmad MI, Kodali S, Victor D. Nonalcoholic Fatty Liver Disease after Liver Transplant. J Clin Transl Hepatol 2021;9:428-35. [PMID: 34221929 DOI: 10.14218/JCTH.2020.00072] [Reference Citation Analysis]
73 Tang J, Yan Z, Feng Q, Yu L, Wang H. The Roles of Neutrophils in the Pathogenesis of Liver Diseases. Front Immunol 2021;12:625472. [PMID: 33763069 DOI: 10.3389/fimmu.2021.625472] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
74 Emma MR, Giannitrapani L, Cabibi D, Porcasi R, Pantuso G, Augello G, Giglio RV, Re NL, Capitano AR, Montalto G, Soresi M, Cervello M. Hepatic and circulating levels of PCSK9 in morbidly obese patients: Relation with severity of liver steatosis. Biochim Biophys Acta Mol Cell Biol Lipids 2020;1865:158792. [PMID: 32777481 DOI: 10.1016/j.bbalip.2020.158792] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
75 Eguchi Y, Wong G, Lee EI, Akhtar O, Lopes R, Sumida Y. Epidemiology of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A focused literature review. JGH Open 2020;4:808-17. [PMID: 33102749 DOI: 10.1002/jgh3.12349] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
76 Lisboa QC, Nardelli MJ, Pereira PA, Miranda DM, Ribeiro SN, Costa RSN, Versiani CA, Vidigal PVT, Ferrari TCA, Couto CA. PNPLA3 and TM6SF2 polymorphisms in Brazilian patients with nonalcoholic fatty liver disease. World J Hepatol 2020; 12(10): 792-806 [PMID: 33200017 DOI: 10.4254/wjh.v12.i10.792] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
77 Roskilly A, Rowe IA. Surveillance for hepatocellular cancer. Clin Med (Lond). 2018;18:s66-s69. [PMID: 29700096 DOI: 10.7861/clinmedicine.18-2-s66] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
78 Magalhães VDS, Jost TDA, Pasqual HM, Becker ALG, Marques LM, Manica M, Delani BLL, Langaro JP, Afonso DT, Hoppe L, Orsolin A, Vartha APP. Non-alcoholic fatty liver disease and associated risk factors in health care professionals in a community hospital in Brazil. Rev Bras Med Trab 2021;18:449-56. [PMID: 33688327 DOI: 10.47626/1679-4435-2020-582] [Reference Citation Analysis]
79 Tsochatzis EA, Newsome PN. Non-alcoholic fatty liver disease and the interface between primary and secondary care. Lancet Gastroenterol Hepatol 2018;3:509-17. [PMID: 29893235 DOI: 10.1016/S2468-1253(18)30077-3] [Cited by in Crossref: 50] [Cited by in F6Publishing: 22] [Article Influence: 16.7] [Reference Citation Analysis]
80 Polyzos SA, Kechagias S, Tsochatzis EA. Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. Aliment Pharmacol Ther 2021;54:1013-25. [PMID: 34416040 DOI: 10.1111/apt.16575] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
81 Roy MA, Duche PR, Timme-Laragy AR. The sulfate metabolite of 3,3'-dichlorobiphenyl (PCB-11) impairs Cyp1a activity and increases hepatic neutral lipids in zebrafish larvae (Danio rerio). Chemosphere 2020;260:127609. [PMID: 32693259 DOI: 10.1016/j.chemosphere.2020.127609] [Reference Citation Analysis]
82 Coccia F, Testa M, Guarisco G, Bonci E, Di Cristofano C, Silecchia G, Leonetti F, Gastaldelli A, Capoccia D. Noninvasive assessment of hepatic steatosis and fibrosis in patients with severe obesity. Endocrine 2020;67:569-78. [PMID: 31858390 DOI: 10.1007/s12020-019-02155-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
83 Mahamid M, Khoury T, Mahamid B, Sbeit W, Mari A, Nseir W. The interplay between abdominal aortic aneurysm, metabolic syndrome and fatty liver disease: a retrospective case-control study. Diabetes Metab Syndr Obes 2019;12:1743-9. [PMID: 31564942 DOI: 10.2147/DMSO.S205568] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Lupsor-Platon M, Serban T, Silion AI, Tirpe A, Florea M. Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: A Step Forward for Better Evaluation Using Ultrasound Elastography. Cancers (Basel) 2020;12:E2778. [PMID: 32998257 DOI: 10.3390/cancers12102778] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
85 Maskarinec G, Garber AK, Wong MC, Kelly N, Kazemi L, Buchthal SD, Fearnbach N, Heymsfield SB, Shepherd JA. Predictors of liver fat among children and adolescents from five different ethnic groups. Obes Sci Pract 2021;7:53-62. [PMID: 33680492 DOI: 10.1002/osp4.459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
86 Brouwers MCGJ, Simons N, Stehouwer CDA, Isaacs A. Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality. Diabetologia 2020;63:253-60. [PMID: 31713012 DOI: 10.1007/s00125-019-05024-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 11.0] [Reference Citation Analysis]
87 Du C, Shen L, Ma Z, Du J, Jin S. Bioinformatic Analysis of Crosstalk Between circRNA, miRNA, and Target Gene Network in NAFLD. Front Genet 2021;12:671523. [PMID: 33995497 DOI: 10.3389/fgene.2021.671523] [Reference Citation Analysis]
88 Schuster S, Johnson CD, Hennebelle M, Holtmann T, Taha AY, Kirpich IA, Eguchi A, Ramsden CE, Papouchado BG, McClain CJ, Feldstein AE. Oxidized linoleic acid metabolites induce liver mitochondrial dysfunction, apoptosis, and NLRP3 activation in mice. J Lipid Res 2018;59:1597-609. [PMID: 30084831 DOI: 10.1194/jlr.M083741] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
89 Dai H, Xiang J, Hou Y, Xuan L, Wang T, Li M, Zhao Z, Xu Y, Lu J, Chen Y, Wang W, Ning G, Bi Y, Xu M. Fat mass to fat-free mass ratio and the risk of non-alcoholic fatty liver disease and fibrosis in non-obese and obese individuals. Nutr Metab (Lond) 2021;18:21. [PMID: 33608033 DOI: 10.1186/s12986-021-00551-6] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
90 Singh SP, Barik RK. NonInvasive Biomarkers in Nonalcoholic Fatty Liver Disease: Are We There Yet? J Clin Exp Hepatol 2020;10:88-98. [PMID: 32025168 DOI: 10.1016/j.jceh.2019.09.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
91 Wang J, Ye C, Fei S. Association between APOC3 polymorphisms and non-alcoholic fatty liver disease risk: a meta-analysis. Afr Health Sci 2020;20:1800-8. [PMID: 34394242 DOI: 10.4314/ahs.v20i4.34] [Reference Citation Analysis]
92 Du K, Li S, Li C, Li P, Miao C, Luo T, Qiu B, Ding W. Modeling nonalcoholic fatty liver disease on a liver lobule chip with dual blood supply. Acta Biomater 2021:S1742-7061(21)00444-X. [PMID: 34265474 DOI: 10.1016/j.actbio.2021.07.013] [Reference Citation Analysis]
93 Ma B, Sun H, Zhu B, Wang S, Du L, Wang X, Qu S. Hepatic Steatosis Is Associated with Elevated Serum Iron in Patients with Obesity and Improves after Laparoscopic Sleeve Gastrectomy. Obes Facts 2021;14:64-71. [PMID: 33352578 DOI: 10.1159/000511736] [Reference Citation Analysis]
94 Zhao Z, Wang C, Zhang L, Zhao Y, Duan C, Zhang X, Gao L, Li S. Lactobacillus plantarum NA136 improves the non-alcoholic fatty liver disease by modulating the AMPK/Nrf2 pathway. Appl Microbiol Biotechnol 2019;103:5843-50. [DOI: 10.1007/s00253-019-09703-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
95 Ghani RA, Saqlain M, Zafar MM, Jabeen S, Naqvi SM, Raja GK. Identification of Metabolic risk phenotypes predisposing to Non-Alcoholic Fatty Liver Disease in a Pakistani Cohort. Pak J Med Sci 2017;33:121-6. [PMID: 28367184 DOI: 10.12669/pjms.331.11445] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
96 Zakaria Z, Othman ZA, Suleiman JB, Che Jalil NA, Ghazali WSW, Nna VU, Mohamed M. Hepatoprotective Effect of Bee Bread in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Rats: Impact on Oxidative Stress and Inflammation. Antioxidants (Basel) 2021;10:2031. [PMID: 34943134 DOI: 10.3390/antiox10122031] [Reference Citation Analysis]
97 Perrar I, Buyken AE, Penczynski KJ, Remer T, Kuhnle GG, Herder C, Roden M, Della Corte K, Nöthlings U, Alexy U. Relevance of fructose intake in adolescence for fatty liver indices in young adulthood. Eur J Nutr 2021;60:3029-41. [PMID: 33464363 DOI: 10.1007/s00394-020-02463-2] [Reference Citation Analysis]
98 Choi DH, Jung CH, Mok JO, Kim CH, Kang SK, Kim BY. Nonalcoholic Fatty Liver Disease and Abdominal Fat Accumulation According to Vitamin D Status in Patients with Type 2 Diabetes. J Obes Metab Syndr 2018;27:53-60. [PMID: 31089541 DOI: 10.7570/jomes.2018.27.1.53] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
99 Caussy C, Hsu C, Singh S, Bassirian S, Kolar J, Faulkner C, Sinha N, Bettencourt R, Gara N, Valasek MA, Schnabl B, Richards L, Brenner DA, Hofmann AF, Loomba R. Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD. Aliment Pharmacol Ther 2019;49:183-93. [PMID: 30506692 DOI: 10.1111/apt.15035] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
100 Brown ZJ, Heinrich B, Greten TF. Establishment of Orthotopic Liver Tumors by Surgical Intrahepatic Tumor Injection in Mice with Underlying Non-Alcoholic Fatty Liver Disease. Methods Protoc 2018;1:E21. [PMID: 31164564 DOI: 10.3390/mps1020021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
101 Pinter M, Scheiner B, Peck-Radosavljevic M. Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. Gut 2021;70:204-14. [PMID: 32747413 DOI: 10.1136/gutjnl-2020-321702] [Cited by in Crossref: 25] [Cited by in F6Publishing: 32] [Article Influence: 12.5] [Reference Citation Analysis]
102 Valenti L, Pedica F, Colombo M. Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. Dig Liver Dis 2021:S1590-8658(21)00337-6. [PMID: 34294580 DOI: 10.1016/j.dld.2021.06.023] [Reference Citation Analysis]
103 Cariou B, Byrne CD, Loomba R, Sanyal AJ. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes Obes Metab 2021;23:1069-83. [PMID: 33464677 DOI: 10.1111/dom.14322] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
104 Cai X, Aierken X, Ahmat A, Cao Y, Zhu Q, Wu T, Li N. A Nomogram Model Based on Noninvasive Bioindicators to Predict 3-Year Risk of Nonalcoholic Fatty Liver in Nonobese Mainland Chinese: A Prospective Cohort Study. Biomed Res Int 2020;2020:8852198. [PMID: 33204721 DOI: 10.1155/2020/8852198] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
105 Colombo M, Lleo A. The impact of antiviral therapy on hepatocellular carcinoma epidemiology. Hepat Oncol 2018;5:HEP03. [PMID: 30302194 DOI: 10.2217/hep-2017-0024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
106 Golabi P, Paik J, Fukui N, Locklear CT, de Avilla L, Younossi ZM. Patients With Lean Nonalcoholic Fatty Liver Disease Are Metabolically Abnormal and Have a Higher Risk for Mortality. Clin Diabetes. 2019;37:65-72. [PMID: 30705499 DOI: 10.2337/cd18-0026] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
107 Li Q, Li M, Li F, Zhou W, Dang Y, Zhang L, Ji G. Qiang-Gan formula extract improves non-alcoholic steatohepatitis via regulating bile acid metabolism and gut microbiota in mice. J Ethnopharmacol 2020;258:112896. [PMID: 32325178 DOI: 10.1016/j.jep.2020.112896] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
108 Huang Y, Joseph J, de Boer WB, Cheng W, Adams LA, MacQuillan G, Garas G, Raftopoulos S, Jeffrey GP. Long-term Liver-related Outcomes of Patients With Chronic Liver Diseases in Australia. Clin Gastroenterol Hepatol 2020;18:496-504.e3. [PMID: 31319186 DOI: 10.1016/j.cgh.2019.07.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
109 Arai T, Atsukawa M, Tsubota A, Koeda M, Yoshida Y, Okubo T, Nakagawa A, Itokawa N, Kondo C, Nakatsuka K, Masu T, Kato K, Shimada N, Hatori T, Emoto N, Kage M, Iwakiri K. Association of vitamin D levels and vitamin D-related gene polymorphisms with liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease. Dig Liver Dis. 2019;51:1036-1042. [PMID: 30683615 DOI: 10.1016/j.dld.2018.12.022] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
110 Simon TG, Chan AT. Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma. Clin Liver Dis 2020;24:549-76. [PMID: 33012445 DOI: 10.1016/j.cld.2020.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Chang TY, Chang SH, Lin YH, Ho WC, Wang CY, Jeng WJ, Wan YL, Tsui PH. Utility of quantitative ultrasound in community screening for hepatic steatosis. Ultrasonics 2021;111:106329. [PMID: 33338730 DOI: 10.1016/j.ultras.2020.106329] [Reference Citation Analysis]
112 Boyle M, Masson S, Anstee QM. The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease. Journal of Hepatology 2018;68:251-67. [DOI: 10.1016/j.jhep.2017.11.006] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 13.0] [Reference Citation Analysis]
113 Horn P, Newsome PN. Emerging therapeutic targets for NASH: key innovations at the preclinical level. Expert Opin Ther Targets 2020;24:175-86. [PMID: 32053033 DOI: 10.1080/14728222.2020.1728742] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
114 Vieira Barbosa J, Milligan S, Frick A, Broestl J, Younossi Z, Afdhal NH, Lai M. Fibrosis-4 Index as an Independent Predictor of Mortality and Liver-Related Outcomes in NAFLD. Hepatol Commun 2021. [PMID: 34970870 DOI: 10.1002/hep4.1841] [Reference Citation Analysis]
115 Pisano G, Lombardi R, Fracanzani AL. Vascular Damage in Patients with Nonalcoholic Fatty Liver Disease: Possible Role of Iron and Ferritin. Int J Mol Sci 2016;17:E675. [PMID: 27164079 DOI: 10.3390/ijms17050675] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
116 Dhaliwal HS, Singh R, Abraham AM, Sharma R, Goyal NK, Soloman R, Bansal P, Goyal A. Perception of Illness and Its Association with Treatment Willingness in Patients with Newly Diagnosed Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2021. [PMID: 33409801 DOI: 10.1007/s10620-020-06794-2] [Reference Citation Analysis]
117 Wang G, Jiao T, Xu Y, Li D, Si Q, Hao J, Zhao J, Zhang H, Chen W. Bifidobacterium adolescentis and Lactobacillus rhamnosus alleviate non-alcoholic fatty liver disease induced by a high-fat, high-cholesterol diet through modulation of different gut microbiota-dependent pathways. Food Funct. 2020;11:6115-6127. [PMID: 32573567 DOI: 10.1039/c9fo02905b] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
118 Tan EX, Lee JW, Jumat NH, Chan WK, Treeprasertsuk S, Goh GB, Fan JG, Song MJ, Charatcharoenwitthaya P, Duseja A, Imajo K, Nakajima A, Seki Y, Kasama K, Kakizaki S, Lesmana LA, Zheng KI, Zheng MH, Koh CJ, Ho KY, Goh KL, Wong VW, Dan YY. Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study. Metabolism 2021;126:154911. [PMID: 34648769 DOI: 10.1016/j.metabol.2021.154911] [Reference Citation Analysis]
119 Liu T, Xu L, Chen FH, Zhou YB. Association of serum vitamin D level and nonalcoholic fatty liver disease: a meta-analysis. Eur J Gastroenterol Hepatol 2020;32:140-7. [PMID: 31895886 DOI: 10.1097/MEG.0000000000001486] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
120 Zhou Y, Tao J, Calvisi DF, Chen X. Role of Lipogenesis Rewiring in Hepatocellular Carcinoma. Semin Liver Dis 2021. [PMID: 34311471 DOI: 10.1055/s-0041-1731709] [Reference Citation Analysis]
121 Su L, Zhou L, Chen FJ, Wang H, Qian H, Sheng Y, Zhu Y, Yu H, Gong X, Cai L, Yang X, Xu L, Zhao TJ, Li JZ, Chen XW, Li P. Cideb controls sterol-regulated ER export of SREBP/SCAP by promoting cargo loading at ER exit sites. EMBO J 2019;38:e100156. [PMID: 30858281 DOI: 10.15252/embj.2018100156] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
122 Huang Q, Zou X, Wen X, Zhou X, Ji L. NAFLD or MAFLD: Which Has Closer Association With All-Cause and Cause-Specific Mortality?-Results From NHANES III. Front Med (Lausanne) 2021;8:693507. [PMID: 34277667 DOI: 10.3389/fmed.2021.693507] [Reference Citation Analysis]
123 Pădureanu V, Dop D, Drăgoescu AN, Pădureanu R, Mușetescu AE, Nedelcu L. Non-alcoholic fatty liver disease and hematologic manifestations (Review). Exp Ther Med 2021;22:1355. [PMID: 34659501 DOI: 10.3892/etm.2021.10790] [Reference Citation Analysis]
124 Albhaisi S, Sanyal AJ. Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis. Front Endocrinol (Lausanne) 2021;12:665987. [PMID: 34040583 DOI: 10.3389/fendo.2021.665987] [Reference Citation Analysis]
125 Sequeira IR, Woodhead JST, Chan A, D'Souza RF, Wan J, Hollingsworth KG, Plank LD, Cohen P, Poppitt SD, Merry TL. Plasma mitochondrial derived peptides MOTS-c and SHLP2 positively associate with android and liver fat in people without diabetes. Biochim Biophys Acta Gen Subj 2021;1865:129991. [PMID: 34419510 DOI: 10.1016/j.bbagen.2021.129991] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Ratziu V, Sanyal AJ, Loomba R, Rinella M, Harrison S, Anstee QM, Goodman Z, Bedossa P, MacConell L, Shringarpure R, Shah A, Younossi Z. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. Contemp Clin Trials 2019;84:105803. [PMID: 31260793 DOI: 10.1016/j.cct.2019.06.017] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 18.7] [Reference Citation Analysis]
127 Lu FB, Hu ED, Xu LM, Chen L, Wu JL, Li H, Chen DZ, Chen YP. The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol 2018;12:491-502. [PMID: 29609501 DOI: 10.1080/17474124.2018.1460202] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 8.3] [Reference Citation Analysis]
128 Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, Diehl AM, Djedjos CS, Han L, Myers RP, Subramanian GM, McHutchison JG, Goodman ZD, Afdhal NH, Charlton MR; GS-US-384-1497 Investigators. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology. 2018;67:549-559. [PMID: 28892558 DOI: 10.1002/hep.29514] [Cited by in Crossref: 249] [Cited by in F6Publishing: 254] [Article Influence: 49.8] [Reference Citation Analysis]
129 Du Y, Paglicawan L, Soomro S, Abunofal O, Baig S, Vanarsa K, Hicks J, Mohan C. Epigallocatechin-3-Gallate Dampens Non-Alcoholic Fatty Liver by Modulating Liver Function, Lipid Profile and Macrophage Polarization. Nutrients 2021;13:599. [PMID: 33670347 DOI: 10.3390/nu13020599] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
130 Strey CBM, de Carli LA, Fantinelli M, Gobbato SS, Bassols GF, Losekann A, Coral GP. Impact of Diabetes Mellitus and Insulin on Nonalcoholic Fatty Liver Disease in the Morbidly Obese. Ann Hepatol 2018;17:585-91. [PMID: 29893699 DOI: 10.5604/01.3001.0012.0922] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
131 Ooi GJ, Mgaieth S, Eslick GD, Burton PR, Kemp WW, Roberts SK, Brown WA. Systematic review and meta-analysis: non-invasive detection of non-alcoholic fatty liver disease related fibrosis in the obese: Non-invasive tests for NAFLD. Obesity Reviews 2018;19:281-94. [DOI: 10.1111/obr.12628] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
132 Wang X, Du H, Shao S, Bo T, Yu C, Chen W, Zhao L, Li Q, Wang L, Liu X, Su X, Sun M, Song Y, Gao L, Zhao J. Cyclophilin D deficiency attenuates mitochondrial perturbation and ameliorates hepatic steatosis. Hepatology 2018;68:62-77. [DOI: 10.1002/hep.29788] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
133 Nakanishi N, Hashimoto Y, Okamura T, Ohbora A, Kojima T, Hamaguchi M, Fukui M. A weight regain of 1.5 kg or more and lack of exercise are associated with nonalcoholic fatty liver disease recurrence in men. Sci Rep 2021;11:19992. [PMID: 34620897 DOI: 10.1038/s41598-021-99036-y] [Reference Citation Analysis]
134 Neves C, Rodrigues T, Sereno J, Simões C, Castelhano J, Gonçalves J, Bento G, Gonçalves S, Seiça R, Domingues MR, Castelo-Branco M, Matafome P. Dietary Glycotoxins Impair Hepatic Lipidemic Profile in Diet-Induced Obese Rats Causing Hepatic Oxidative Stress and Insulin Resistance. Oxid Med Cell Longev 2019;2019:6362910. [PMID: 31341532 DOI: 10.1155/2019/6362910] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
135 Hsu C, Caussy C, Imajo K, Chen J, Singh S, Kaulback K, Le MD, Hooker J, Tu X, Bettencourt R, Yin M, Sirlin CB, Ehman RL, Nakajima A, Loomba R. Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants. Clin Gastroenterol Hepatol 2019;17:630-637.e8. [PMID: 29908362 DOI: 10.1016/j.cgh.2018.05.059] [Cited by in Crossref: 94] [Cited by in F6Publishing: 91] [Article Influence: 23.5] [Reference Citation Analysis]
136 Chen X, Xiao J, Pang J, Chen S, Wang Q, Ling W. Pancreatic β-Cell Dysfunction Is Associated with Nonalcoholic Fatty Liver Disease. Nutrients 2021;13:3139. [PMID: 34579016 DOI: 10.3390/nu13093139] [Reference Citation Analysis]
137 Han L, Zhang Y, Li J, Xiao Y, Lu M, Li Y, Wang M. Phloretin attenuation of hepatic steatosis via an improvement of mitochondrial dysfunction by activating AMPK-dependent signaling pathways in C57BL/6J mice and HepG2 cells. Food Funct 2021. [PMID: 34788781 DOI: 10.1039/d1fo02577e] [Reference Citation Analysis]
138 Zhou Y, Yu S, Cai C, Zhong L, Yu H, Shen W. LXRɑ participates in the mTOR/S6K1/SREBP-1c signaling pathway during sodium palmitate-induced lipogenesis in HepG2 cells. Nutr Metab (Lond) 2018;15:31. [PMID: 29743930 DOI: 10.1186/s12986-018-0268-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
139 Chen XY, Cai CZ, Yu ML, Feng ZM, Zhang YW, Liu PH, Zeng H, Yu CH. LB100 ameliorates nonalcoholic fatty liver disease via the AMPK/Sirt1 pathway. World J Gastroenterol 2019; 25(45): 6607-6618 [PMID: 31832001 DOI: 10.3748/wjg.v25.i45.6607] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
140 Borges-canha M, Neves JS, Mendonça F, Silva MM, Costa C, Cabral PM, Guerreiro V, Lourenço R, Meira P, Salazar D, Ferreira MJ, Pedro J, Leite A, Viana S, Sande A, Belo S, Lau E, Freitas P, Carvalho D; CRIO group. The Impact of Bariatric Surgery on Hepatic Function and Predictors of Liver Steatosis and Fibrosis. OBES SURG 2020;30:2935-41. [DOI: 10.1007/s11695-020-04622-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
141 Sayiner M, Stepanova M, Pham H, Noor B, Walters M, Younossi ZM. Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease. BMJ Open Gastroenterol 2016;3:e000106. [PMID: 27648297 DOI: 10.1136/bmjgast-2016-000106] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
142 Alsaqal S, Hockings P, Ahlström H, Gummesson A, Hedström A, Hulthe J, Johansson L, Niessen HG, Schoelch C, Schultheis C, Vessby J, Wanders A, Rorsman F, Ebeling Barbier C. The Combination of MR Elastography and Proton Density Fat Fraction Improves Diagnosis of Nonalcoholic Steatohepatitis. J Magn Reson Imaging 2021. [PMID: 34953171 DOI: 10.1002/jmri.28040] [Reference Citation Analysis]
143 Lee DU, Fan GH, Hastie DJ, Addonizio EA, Prakasam VN, Ahern RR, Suh J, Seog KJ, Karagozian R. The clinical impact of cirrhosis on the postoperative outcomes of patients undergoing bariatric surgery: propensity score-matched analysis of 2011-2017 US hospitals. Expert Rev Gastroenterol Hepatol 2021;:1-10. [PMID: 33706616 DOI: 10.1080/17474124.2021.1902803] [Reference Citation Analysis]
144 López-Pastor AR, Infante-Menéndez J, Escribano Ó, Gómez-Hernández A. miRNA Dysregulation in the Development of Non-Alcoholic Fatty Liver Disease and the Related Disorders Type 2 Diabetes Mellitus and Cardiovascular Disease. Front Med (Lausanne) 2020;7:527059. [PMID: 33102495 DOI: 10.3389/fmed.2020.527059] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
145 Safcak D, Drazilova S, Gazda J, Andrasina I, Adamcova-Selcanova S, Barila R, Mego M, Rac M, Skladany L, Zigrai M, Janicko M, Jarcuska P. Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: Clinical Patterns, Outcomes, and Prognostic Factors for Overall Survival-A Retrospective Analysis of a Slovak Cohort. J Clin Med 2021;10:3186. [PMID: 34300352 DOI: 10.3390/jcm10143186] [Reference Citation Analysis]
146 Chung GE, Cho EJ, Yoo JJ, Chang Y, Cho Y, Park SH, Shin DW, Han K, Yu SJ. Nonalcoholic fatty liver disease is associated with the development of obstructive sleep apnea. Sci Rep 2021;11:13473. [PMID: 34188101 DOI: 10.1038/s41598-021-92703-0] [Reference Citation Analysis]
147 Tsai MC, Liu YY, Lin CC, Wang CC, Wu YJ, Yong CC, Chen KD, Chuah SK, Yao CC, Huang PY, Chen CH, Hu TH, Chen CL. Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan. Nutrients 2020;12:E820. [PMID: 32204538 DOI: 10.3390/nu12030820] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
148 Yang JS, Qi W, Farias-Pereira R, Choi S, Clark JM, Kim D, Park Y. Permethrin and ivermectin modulate lipid metabolism in steatosis-induced HepG2 hepatocyte. Food Chem Toxicol 2019;125:595-604. [PMID: 30738135 DOI: 10.1016/j.fct.2019.02.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
149 De Muynck K, Vanderborght B, Van Vlierberghe H, Devisscher L. The Gut-Liver Axis in Chronic Liver Disease: A Macrophage Perspective. Cells 2021;10:2959. [PMID: 34831182 DOI: 10.3390/cells10112959] [Reference Citation Analysis]
150 Xia Y, Zhao Z, Zhang S, Liu Y, Meng G, Zhang Q, Liu L, Wu H, Gu Y, Wang Y, Zhang T, Wang X, Sun S, Zhou M, Jia Q, Song K, Wu Q, Niu K, Zhao Y. Complex Dietary Topologies in Non-alcoholic Fatty Liver Disease: A Network Science Analysis. Front Nutr 2020;7:579086. [PMID: 33117844 DOI: 10.3389/fnut.2020.579086] [Reference Citation Analysis]
151 Fetzer DT, Rodgers SK, Seow JH, Dawkins AA, Joshi G, Gabriel H, Kamaya A. Ultrasound Evaluation in Patients at Risk for Hepatocellular Carcinoma. Radiol Clin North Am. 2019;57:563-583. [PMID: 30928078 DOI: 10.1016/j.rcl.2019.01.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
152 Wang SJ, Chen Q, Liu MY, Yu HY, Xu JQ, Wu JQ, Zhang Y, Wang T. Regulation effects of rosemary (Rosmarinus officinalis Linn.) on hepatic lipid metabolism in OA induced NAFLD rats. Food Funct 2019;10:7356-65. [PMID: 31650134 DOI: 10.1039/c9fo01677e] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
153 Rim JH, Youk T, Gee HY, Cho J, Yoo J. Dynamic Chronological Changes in Serum Triglycerides Are Associated With the Time Point for Non-alcoholic Fatty Liver Disease Development in the Nationwide Korean Population Cohort. Front Med (Lausanne) 2021;8:637241. [PMID: 33777980 DOI: 10.3389/fmed.2021.637241] [Reference Citation Analysis]
154 Qi W, Clark JM, Timme-Laragy AR, Park Y. Perfluorobutanesulfonic Acid (PFBS) Induces Fat Accumulation in HepG2 Human Hepatoma. Toxicol Environ Chem 2020;102:585-606. [PMID: 33762794 DOI: 10.1080/02772248.2020.1808894] [Reference Citation Analysis]
155 Gorospe F, Istanboulian L, Puts M, Wong D, Lee E, Dale C. Identifying and mapping biopsychosocial factors associated with pain in adults with advanced liver disease: protocol for a scoping review. BMJ Open 2019;9:e033064. [PMID: 31719094 DOI: 10.1136/bmjopen-2019-033064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
156 Mak LY, Lee CH, Cheung KS, Wong DK, Liu F, Hui RW, Fung J, Xu A, Lam KS, Yuen MF, Seto WK. Association of adipokines with hepatic steatosis and fibrosis in chronic hepatitis B patients on long-term nucleoside analogue. Liver Int 2019;39:1217-25. [PMID: 30912255 DOI: 10.1111/liv.14104] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
157 Diwan TS, Rice TC, Heimbach JK, Schauer DP. Liver Transplantation and Bariatric Surgery: Timing and Outcomes. Liver Transpl. 2018;24:1280-1287. [PMID: 30080949 DOI: 10.1002/lt.25303] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 13.3] [Reference Citation Analysis]
158 Li B, Zhang C, Zhan YT. Nonalcoholic Fatty Liver Disease Cirrhosis: A Review of Its Epidemiology, Risk Factors, Clinical Presentation, Diagnosis, Management, and Prognosis. Can J Gastroenterol Hepatol 2018;2018:2784537. [PMID: 30065915 DOI: 10.1155/2018/2784537] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
159 Lefere S, Van de Velde F, Hoorens A, Raevens S, Van Campenhout S, Vandierendonck A, Neyt S, Vandeghinste B, Vanhove C, Debbaut C, Verhelst X, Van Dorpe J, Van Steenkiste C, Casteleyn C, Lapauw B, Van Vlierberghe H, Geerts A, Devisscher L. Angiopoietin-2 Promotes Pathological Angiogenesis and Is a Therapeutic Target in Murine Nonalcoholic Fatty Liver Disease. Hepatology 2019;69:1087-104. [PMID: 30259536 DOI: 10.1002/hep.30294] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis]
160 Kimura T, Tanaka N, Fujimori N, Sugiura A, Yamazaki T, Joshita S, Komatsu M, Umemura T, Matsumoto A, Tanaka E. Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis. World J Gastroenterol 2018; 24(13): 1440-1450 [PMID: 29632425 DOI: 10.3748/wjg.v24.i13.1440] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
161 Dong Y, Li G. Cardiac abnormalities in patients with nonalcoholic fatty liver disease : Insights from auxiliary examinations. Herz 2021;46:158-63. [PMID: 31538216 DOI: 10.1007/s00059-019-04855-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
162 Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, Diehl AM, Djedjos CS, Han L, Myers RP. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology. 2017;. [PMID: 28892558 DOI: 10.1002/hep.29514.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
163 Austin P, Gerber L, Paik JM, Price JK, Escheik C, Younossi ZM. Aerobic capacity and exercise performance in nonalcoholic fatty liver disease. J Sports Med Phys Fitness 2019;59. [DOI: 10.23736/s0022-4707.19.09231-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
164 Chen Z, Xu YY, Wu R, Han YX, Yu Y, Ge JF, Chen FH. Impaired learning and memory in rats induced by a high-fat diet: Involvement with the imbalance of nesfatin-1 abundance and copine 6 expression. J Neuroendocrinol 2017;29. [PMID: 28211103 DOI: 10.1111/jne.12462] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
165 Asai A, Yokohama K, Ohama H, Tsuchimoto Y, Fukunishi S, Higuchi K. Association between Administration of Antithrombotics and Intraperitoneal Hemorrhage in Patients Undergoing Percutaneous Interventions for Liver Diseases. J Clin Med 2021;10:2527. [PMID: 34200283 DOI: 10.3390/jcm10112527] [Reference Citation Analysis]
166 Ayoub C, Azar Y, Abou-Khalil Y, Ghaleb Y, Elbitar S, Halaby G, Jambart S, Gannagé-Yared MH, Yaghi C, Saade Riachy C, El Khoury R, Rabès JP, Varret M, Boileau C, El Khoury P, Abifadel M. Identification of a Variant in APOB Gene as a Major Cause of Hypobetalipoproteinemia in Lebanese Families. Metabolites 2021;11:564. [PMID: 34564380 DOI: 10.3390/metabo11090564] [Reference Citation Analysis]
167 Triay Bagur A, Hutton C, Irving B, Gyngell ML, Robson MD, Brady M. Magnitude-intrinsic water-fat ambiguity can be resolved with multipeak fat modeling and a multipoint search method. Magn Reson Med 2019;82:460-75. [PMID: 30874334 DOI: 10.1002/mrm.27728] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
168 Ge X, Zheng L, Wang M, Du Y, Jiang J. Prevalence trends in non-alcoholic fatty liver disease at the global, regional and national levels, 1990-2017: a population-based observational study. BMJ Open 2020;10:e036663. [PMID: 32747349 DOI: 10.1136/bmjopen-2019-036663] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
169 Li XX, Lu XY, Zhang SJ, Chiu AP, Lo LH, Largaespada DA, Chen QB, Keng VW. Sodium tanshinone IIA sulfonate ameliorates hepatic steatosis by inhibiting lipogenesis and inflammation. Biomed Pharmacother 2019;111:68-75. [PMID: 30576936 DOI: 10.1016/j.biopha.2018.12.019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
170 Xu F, Guo W. The progress of epigenetics in the development and progression of non-alcoholic fatty liver disease. Liver Research 2020;4:118-23. [DOI: 10.1016/j.livres.2020.08.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
171 Zhou Z, Xu MJ, Cai Y, Wang W, Jiang JX, Varga ZV, Feng D, Pacher P, Kunos G, Torok NJ, Gao B. Neutrophil-Hepatic Stellate Cell Interactions Promote Fibrosis in Experimental Steatohepatitis. Cell Mol Gastroenterol Hepatol 2018;5:399-413. [PMID: 29552626 DOI: 10.1016/j.jcmgh.2018.01.003] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 11.5] [Reference Citation Analysis]
172 Al-Fayoumi S, Hashiguchi T, Shirakata Y, Mascarenhas J, Singer JW. Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis. J Exp Pharmacol 2018;10:9-17. [PMID: 29785143 DOI: 10.2147/JEP.S150729] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
173 Suo J, Zhao X, Guo X, Zhao X. Met-enkephalin improves metabolic syndrome in high fat diet challenged mice through promotion of adipose tissue browning. Toxicology and Applied Pharmacology 2018;359:12-23. [DOI: 10.1016/j.taap.2018.09.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
174 Brunner KT, Henneberg CJ, Wilechansky RM, Long MT. Nonalcoholic Fatty Liver Disease and Obesity Treatment. Curr Obes Rep 2019;8:220-8. [PMID: 30945129 DOI: 10.1007/s13679-019-00345-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
175 Li H, Yu XH, Ou X, Ouyang XP, Tang CK. Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis. Prog Lipid Res 2021;83:101109. [PMID: 34097928 DOI: 10.1016/j.plipres.2021.101109] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
176 França LM, Coêlho CFF, Freitas LNC, Souza ILS, Chagas VT, Debbas V, de Lima TM, de Souza HP, Laurindo FRM, Paes AMA. Syzygium cumini Leaf Extract Reverts Hypertriglyceridemia via Downregulation of the Hepatic XBP-1s/PDI/MTP Axis in Monosodium L-Glutamate-Induced Obese Rats. Oxid Med Cell Longev 2019;2019:9417498. [PMID: 31015892 DOI: 10.1155/2019/9417498] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
177 Longo M, Paolini E, Meroni M, Dongiovanni P. Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC. Int J Mol Sci 2021;22:4173. [PMID: 33920670 DOI: 10.3390/ijms22084173] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
178 Olubamwo OO, Virtanen JK, Pihlajamaki J, Tuomainen TP. Association of fatty liver index with risk of incident type 2 diabetes by metabolic syndrome status in an Eastern Finland male cohort: a prospective study. BMJ Open 2019;9:e026949. [PMID: 31278098 DOI: 10.1136/bmjopen-2018-026949] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
179 Zhang D, Wu S, Lan Y, Chen S, Wang Y, Sun Y, Liao W, Wang L. Blood manganese and nonalcoholic fatty liver disease: A cohort-based case-control study. Chemosphere 2022;287:132316. [PMID: 34592210 DOI: 10.1016/j.chemosphere.2021.132316] [Reference Citation Analysis]
180 Angelini G, Castagneto Gissey L, Del Corpo G, Giordano C, Cerbelli B, Severino A, Manco M, Basso N, Birkenfeld AL, Bornstein SR, Genco A, Mingrone G, Casella G. New insight into the mechanisms of ectopic fat deposition improvement after bariatric surgery. Sci Rep 2019;9:17315. [PMID: 31754142 DOI: 10.1038/s41598-019-53702-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
181 Björkström K, Stål P, Hultcrantz R, Hagström H. Histologic Scores for Fat and Fibrosis Associate With Development of Type 2 Diabetes in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2017;15:1461-8. [PMID: 28479500 DOI: 10.1016/j.cgh.2017.04.040] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
182 Li F, Ye J, Shao C, Zhong B. Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and Meta-analysis. Lipids Health Dis 2021;20:22. [PMID: 33637088 DOI: 10.1186/s12944-021-01440-w] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
183 Yin X, Liao W, Li Q, Zhang H, Liu Z, Zheng X, Zheng L, Feng X. Interactions between resveratrol and gut microbiota affect the development of hepatic steatosis: A fecal microbiota transplantation study in high-fat diet mice. Journal of Functional Foods 2020;67:103883. [DOI: 10.1016/j.jff.2020.103883] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
184 Toyoda Y, Takada T, Yamanashi Y, Suzuki H. Pathophysiological importance of bile cholesterol reabsorption: hepatic NPC1L1-exacerbated steatosis and decreasing VLDL-TG secretion in mice fed a high-fat diet. Lipids Health Dis 2019;18:234. [PMID: 31883528 DOI: 10.1186/s12944-019-1179-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
185 Ahn SY, Kim SB, Song IH. Clinical Patterns and Outcome of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Can J Gastroenterol Hepatol 2020;2020:4873875. [PMID: 32566546 DOI: 10.1155/2020/4873875] [Reference Citation Analysis]
186 Zhu S, Guan L, Tan X, Li G, Sun C, Gao M, Zhang B, Xu L. Hepatoprotective Effect and Molecular Mechanisms of Hengshun Aromatic Vinegar on Non-Alcoholic Fatty Liver Disease. Front Pharmacol 2020;11:585582. [PMID: 33343352 DOI: 10.3389/fphar.2020.585582] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
187 Hardy T, Wonders K, Younes R, Aithal GP, Aller R, Allison M, Bedossa P, Betsou F, Boursier J, Brosnan MJ, Burt A, Cobbold J, Cortez-Pinto H, Day CP, Dufour JF, Ekstedt M, Francque S, Harrison S, Miele L, Nasr P, Papatheodoridis G, Petta S, Tiniakos D, Torstenson R, Valenti L, Holleboom AG, Yki-Jarvinen H, Geier A, Romero-Gomez M, Ratziu V, Bugianesi E, Schattenberg JM, Anstee QM; LITMUS Consortium. The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. Contemp Clin Trials 2020;98:106175. [PMID: 33045403 DOI: 10.1016/j.cct.2020.106175] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
188 Shim P, Choi D, Park Y. Association of Blood Fatty Acid Composition and Dietary Pattern with the Risk of Non-Alcoholic Fatty Liver Disease in Patients Who Underwent Cholecystectomy. Ann Nutr Metab 2017;70:303-11. [PMID: 28595185 DOI: 10.1159/000475605] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
189 Alqahtani SA, Paik JM, Biswas R, Arshad T, Henry L, Younossi ZM. Poor Awareness of Liver Disease Among Adults With NAFLD in the United States. Hepatol Commun. [DOI: 10.1002/hep4.1765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
190 Deng Z, Gao S, An Y, Huang Y, Liu H, Zhu W, Lu W, He M, Xie W, Yu D, Li Y. Effects of earthworm extract on the lipid profile and fatty liver induced by a high-fat diet in guinea pigs. Ann Transl Med 2021;9:292. [PMID: 33708919 DOI: 10.21037/atm-20-5362] [Reference Citation Analysis]
191 Parker KJ, Ormachea J. The quantification of liver fat from wave speed and attenuation. Phys Med Biol 2021;66. [PMID: 34192672 DOI: 10.1088/1361-6560/ac1023] [Reference Citation Analysis]
192 Leong WL, Lai LL, Nik Mustapha NR, Vijayananthan A, Rahmat K, Mahadeva S, Chan WK. Comparing point shear wave elastography (ElastPQ) and transient elastography for diagnosis of fibrosis stage in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2020;35:135-41. [PMID: 31310032 DOI: 10.1111/jgh.14782] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
193 Zhang X, Wu M, Liu Z, Yuan H, Wu X, Shi T, Chen X, Zhang T. Increasing prevalence of NAFLD/NASH among children, adolescents and young adults from 1990 to 2017: a population-based observational study. BMJ Open 2021;11:e042843. [PMID: 33947727 DOI: 10.1136/bmjopen-2020-042843] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
194 Stefan N. Nonalcoholic Fatty Liver Disease and Mortality. Clin Gastroenterol Hepatol 2018;16:1043-5. [PMID: 29474973 DOI: 10.1016/j.cgh.2018.02.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
195 Wan X, Zhu X, Wang H, Feng Y, Zhou W, Liu P, Shen W, Zhang L, Liu L, Li T, Diao D, Yang F, Zhao Q, Chen L, Ren J, Yan S, Li J, Yu C, Ju Z. PGC1α protects against hepatic steatosis and insulin resistance via enhancing IL10-mediated anti-inflammatory response. FASEB J 2020;34:10751-61. [PMID: 32633848 DOI: 10.1096/fj.201902476R] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
196 Khan RS, Newsome PN. Novel insights into mechanisms of disease progression. Nat Rev Gastroenterol Hepatol 2018;15:71-2. [DOI: 10.1038/nrgastro.2017.181] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
197 Arman T, Lynch KD, Montonye ML, Goedken M, Clarke JD. Sub-Chronic Microcystin-LR Liver Toxicity in Preexisting Diet-Induced Nonalcoholic Steatohepatitis in Rats. Toxins (Basel) 2019;11:E398. [PMID: 31323923 DOI: 10.3390/toxins11070398] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
198 Boland ML, Oró D, Tølbøl KS, Thrane ST, Nielsen JC, Cohen TS, Tabor DE, Fernandes F, Tovchigrechko A, Veidal SS, Warrener P, Sellman BR, Jelsing J, Feigh M, Vrang N, Trevaskis JL, Hansen HH. Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source. World J Gastroenterol 2019; 25(33): 4904-4920 [PMID: 31543682 DOI: 10.3748/wjg.v25.i33.4904] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
199 Lai LL, Vethakkan SR, Nik Mustapha NR, Mahadeva S, Chan WK. Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus. Dig Dis Sci 2020;65:623-31. [PMID: 30684076 DOI: 10.1007/s10620-019-5477-1] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 16.0] [Reference Citation Analysis]
200 Svop Jensen V, Fledelius C, Max Wulff E, Lykkesfeldt J, Hvid H. Temporal Development of Dyslipidemia and Nonalcoholic Fatty Liver Disease (NAFLD) in Syrian Hamsters Fed a High-Fat, High-Fructose, High-Cholesterol Diet. Nutrients 2021;13:604. [PMID: 33673227 DOI: 10.3390/nu13020604] [Reference Citation Analysis]
201 Jayakumar S, Loomba R. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications. Aliment Pharmacol Ther 2019;50:144-58. [PMID: 31149745 DOI: 10.1111/apt.15314] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
202 Hu C, Zhang Y, Wang S, Lin L, Peng K, Du R, Qi H, Zhang J, Wang T, Zhao Z, Li M, Xu Y, Xu M, Li D, Bi Y, Wang W, Chen Y, Lu J. Association of bedtime with the risk of non‐alcoholic fatty liver disease among middle‐aged and elderly Chinese adults with pre‐diabetes and diabetes. Diabetes Metab Res Rev 2020;36. [DOI: 10.1002/dmrr.3322] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
203 Juanola O, Martínez-López S, Francés R, Gómez-Hurtado I. Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors. Int J Environ Res Public Health 2021;18:5227. [PMID: 34069012 DOI: 10.3390/ijerph18105227] [Reference Citation Analysis]
204 Moore JB. From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis. Proc Nutr Soc. 2019;78:290-304. [PMID: 30924429 DOI: 10.1017/s0029665119000570] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
205 Sato T, Tsuchiya A, Owaki T, Kumagai M, Motegi S, Iwasawa T, Nojiri S, Ogawa M, Takeuchi S, Watanabe Y, Kawata Y, Kamimura H, Terai S. Severe steatosis and mild colitis are important for the early occurrence of hepatocellular carcinoma. Biochem Biophys Res Commun 2021;566:36-44. [PMID: 34116355 DOI: 10.1016/j.bbrc.2021.05.097] [Reference Citation Analysis]
206 Su W, Mao Z, Liu Y, Zhang X, Zhang W, Gustafsson JA, Guan Y. Role of HSD17B13 in the liver physiology and pathophysiology. Mol Cell Endocrinol 2019;489:119-25. [PMID: 30365983 DOI: 10.1016/j.mce.2018.10.014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
207 Habig G, Smaltz C, Halegoua-DeMarzio D. Presence and Implications of Sarcopenia in Non-alcoholic Steatohepatitis. Metabolites 2021;11:242. [PMID: 33920751 DOI: 10.3390/metabo11040242] [Reference Citation Analysis]
208 Wargny M, Smati S, Pichelin M, Bigot-Corbel E, Authier C, Dierry V, Zaïr Y, Jacquin V, Hadjadj S, Boursier J, Cariou B. Fatty liver index is a strong predictor of changes in glycemic status in people with prediabetes: The IT-DIAB study. PLoS One 2019;14:e0221524. [PMID: 31465427 DOI: 10.1371/journal.pone.0221524] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
209 Xia SF, Qiu YY, Chen LM, Jiang YY, Huang W, Xie ZX, Tang X, Sun J. Myricetin alleviated hepatic steatosis by acting on microRNA-146b/thyroid hormone receptor b pathway in high-fat diet fed C57BL/6J mice. Food Funct 2019;10:1465-77. [PMID: 30776032 DOI: 10.1039/c8fo01452c] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
210 Wang J, Wu AH, Stanczyk FZ, Porcel J, Noureddin M, Terrault NA, Wilkens LR, Setiawan VW. Associations Between Reproductive and Hormone-Related Factors and Risk of Nonalcoholic Fatty Liver Disease in a Multiethnic Population. Clin Gastroenterol Hepatol 2021;19:1258-1266.e1. [PMID: 32801014 DOI: 10.1016/j.cgh.2020.08.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
211 Wong VW, Adams LA, de Lédinghen V, Wong GL, Sookoian S. Noninvasive biomarkers in NAFLD and NASH — current progress and future promise. Nat Rev Gastroenterol Hepatol 2018;15:461-78. [DOI: 10.1038/s41575-018-0014-9] [Cited by in Crossref: 153] [Cited by in F6Publishing: 144] [Article Influence: 38.3] [Reference Citation Analysis]
212 Tang G, Zhang L, Tao J, Wei Z. Effect of Nigella sativa in the treatment of nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. Phytother Res 2021;35:4183-93. [PMID: 33728708 DOI: 10.1002/ptr.7080] [Reference Citation Analysis]
213 Shang Y, Nasr P, Ekstedt M, Widman L, Stål P, Hultcrantz R, Kechagias S, Hagström H. Non-alcoholic fatty liver disease does not increase dementia risk although histology data might improve risk prediction. JHEP Rep 2021;3:100218. [PMID: 33554097 DOI: 10.1016/j.jhepr.2020.100218] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
214 Bi Y, Yin B, Fan G, Xia Y, Huang J, Li A, Lin Y. Effects of acupoint therapy on nonalcoholic fatty liver disease: A systematic review and meta-analysis. Complement Ther Clin Pract 2021;43:101376. [PMID: 33813176 DOI: 10.1016/j.ctcp.2021.101376] [Reference Citation Analysis]
215 Wong SW, Ting YW, Yong YK, Tan HY, Barathan M, Riazalhosseini B, Bee CJ, Tee KK, Larsson M, Velu V, Shankar EM, Mohamed R. Chronic inflammation involves CCL11 and IL-13 to facilitate the development of liver cirrhosis and fibrosis in chronic hepatitis B virus infection. Scand J Clin Lab Invest 2021;81:147-59. [PMID: 33528280 DOI: 10.1080/00365513.2021.1876245] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
216 Li Y, Yang Y, Li Y, Zhang P, Ge G, Jin J, Du T, Ma M, Na L, Ding L, Sheng H. Use of GP73 in the diagnosis of non-alcoholic steatohepatitis and the staging of hepatic fibrosis. J Int Med Res 2021;49:3000605211055378. [PMID: 34772312 DOI: 10.1177/03000605211055378] [Reference Citation Analysis]
217 Agbim U, Asrani SK. Non-invasive assessment of liver fibrosis and prognosis: an update on serum and elastography markers. Expert Review of Gastroenterology & Hepatology 2019;13:361-74. [DOI: 10.1080/17474124.2019.1579641] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 9.3] [Reference Citation Analysis]
218 Song M, Xia L, Liu Q, Sun M, Wang F, Yang C. Sarcopenia in Liver Disease: Current Evidence and Issues to Be sResolved. Adv Exp Med Biol 2018;1088:413-33. [PMID: 30390263 DOI: 10.1007/978-981-13-1435-3_19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
219 Schulze RJ, Drižytė K, Casey CA, McNiven MA. Hepatic Lipophagy: New Insights into Autophagic Catabolism of Lipid Droplets in the Liver. Hepatol Commun 2017;1:359-69. [PMID: 29109982 DOI: 10.1002/hep4.1056] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
220 Russo MF, Lembo E, Mari A, Angelini G, Verrastro O, Nanni G, Pompili M, Raffaelli M, Vecchio FM, Bornstein SR, Mingrone G. Insulin Resistance Is Central to Long-Term Reversal of Histologic Nonalcoholic Steatohepatitis After Metabolic Surgery. J Clin Endocrinol Metab 2021;106:750-61. [PMID: 33248441 DOI: 10.1210/clinem/dgaa892] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
221 Jun TW, Yeh ML, Yang JD, Chen VL, Nguyen P, Giama NH, Huang CF, Hsing AW, Dai CY, Huang JF, Chuang WL, Roberts LR, Yu ML, Nguyen MH. More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma. Liver Int 2018;38:895-902. [PMID: 29045023 DOI: 10.1111/liv.13613] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
222 Panda C, Varadharaj S, Voruganti VS. PUFA, genotypes and risk for cardiovascular disease. Prostaglandins Leukot Essent Fatty Acids 2021;176:102377. [PMID: 34915303 DOI: 10.1016/j.plefa.2021.102377] [Reference Citation Analysis]
223 Kang HH, Kim IK, Lee HI, Joo H, Lim JU, Lee J, Lee SH, Moon HS. Chronic intermittent hypoxia induces liver fibrosis in mice with diet-induced obesity via TLR4/MyD88/MAPK/NF-kB signaling pathways. Biochemical and Biophysical Research Communications 2017;490:349-55. [DOI: 10.1016/j.bbrc.2017.06.047] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 7.8] [Reference Citation Analysis]
224 Watanabe T, Tsuchiya A, Takeuchi S, Nojiri S, Yoshida T, Ogawa M, Itoh M, Takamura M, Suganami T, Ogawa Y, Terai S. Development of a non-alcoholic steatohepatitis model with rapid accumulation of fibrosis, and its treatment using mesenchymal stem cells and their small extracellular vesicles. Regen Ther 2020;14:252-61. [PMID: 32455155 DOI: 10.1016/j.reth.2020.03.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
225 Tardelli M, Bruschi FV, Fuchs CD, Claudel T, Auer N, Kunczer V, Ronda OAHO, Verkade HJ, Stojakovic T, Scharnagl H, Trauner M. Absence of Adiponutrin (PNPLA3) and Monoacylglycerol Lipase Synergistically Increases Weight Gain and Aggravates Steatohepatitis in Mice. Int J Mol Sci 2021;22:2126. [PMID: 33672787 DOI: 10.3390/ijms22042126] [Reference Citation Analysis]
226 Li YM, Zhao SY, Zhao HH, Wang BH, Li SM. Procyanidin B2 Alleviates Palmitic Acid-Induced Injury in HepG2 Cells via Endoplasmic Reticulum Stress Pathway. Evid Based Complement Alternat Med 2021;2021:8920757. [PMID: 34956386 DOI: 10.1155/2021/8920757] [Reference Citation Analysis]
227 Saitta C, Pollicino T, Raimondo G. Obesity and liver cancer. Ann Hepatol 2019;18:810-5. [PMID: 31543467 DOI: 10.1016/j.aohep.2019.07.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
228 Marinho PC, Vieira AB, Pereira PG, Rabelo K, Ciambarella BT, Nascimento ALR, Cortez E, Moura AS, Guimarães FV, Martins MA, Barquero G, Ferreira RN, de Carvalho JJ. Capybara Oil Improves Hepatic Mitochondrial Dysfunction, Steatosis, and Inflammation in a Murine Model of Nonalcoholic Fatty Liver Disease. Evid Based Complement Alternat Med 2018;2018:4956079. [PMID: 29853957 DOI: 10.1155/2018/4956079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
229 Enhörning S, Malan L. Copeptin relates to a fatty liver and measures of obesity in a South African population with mixed ethnicities. Endocrine 2019;65:304-11. [PMID: 31230225 DOI: 10.1007/s12020-019-01977-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
230 Zhang Q, Wang J, Huang F, Yao Y, Xu L. Leptin induces NAFLD progression through infiltrated CD8+ T lymphocytes mediating pyroptotic-like cell death of hepatocytes and macrophages. Dig Liver Dis 2021;53:598-605. [PMID: 33172809 DOI: 10.1016/j.dld.2020.10.025] [Reference Citation Analysis]
231 Chen J, Chen J, Huang J, Li Z, Gong Y, Zou B, Liu X, Ding L, Li P, Zhu Z, Zhang B, Guo H, Cai C, Li J. HIF-2α upregulation mediated by hypoxia promotes NAFLD-HCC progression by activating lipid synthesis via the PI3K-AKT-mTOR pathway. Aging (Albany NY) 2019;11:10839-60. [PMID: 31796646 DOI: 10.18632/aging.102488] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
232 Geidl-flueck B, Hochuli M, Németh Á, Eberl A, Derron N, Köfeler HC, Tappy L, Berneis K, Spinas GA, Gerber PA. Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial. Journal of Hepatology 2021;75:46-54. [DOI: 10.1016/j.jhep.2021.02.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
233 Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol 2021;19:55-71. [PMID: 32887946 DOI: 10.1038/s41579-020-0433-9] [Cited by in Crossref: 125] [Cited by in F6Publishing: 117] [Article Influence: 62.5] [Reference Citation Analysis]
234 Mouchiroud M, Camiré É, Aldow M, Caron A, Jubinville É, Turcotte L, Kaci I, Beaulieu MJ, Roy C, Labbé SM, Varin TV, Gélinas Y, Lamothe J, Trottier J, Mitchell PL, Guénard F, Festuccia WT, Joubert P, Rose CF, Karvellas CJ, Barbier O, Morissette MC, Marette A, Laplante M. The hepatokine Tsukushi is released in response to NAFLD and impacts cholesterol homeostasis. JCI Insight 2019;4:129492. [PMID: 31391339 DOI: 10.1172/jci.insight.129492] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
235 Jarvis H, Hanratty B. Detecting liver disease in primary care: are we ready for change? Br J Gen Pract 2017;67:202-3. [PMID: 28450323 DOI: 10.3399/bjgp17X690557] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
236 Reja M, Patel R, Pioppo L, Tawadros A, Bhurwal A, Marino D, Rustgi V. Renal Failure is Associated With Increased Mortality and Hospital Utilization in Patients Admitted With Nonalcoholic Steatohepatitis. J Clin Gastroenterol 2021;55:433-8. [PMID: 32740097 DOI: 10.1097/MCG.0000000000001389] [Reference Citation Analysis]
237 Syed-Abdul MM, Parks EJ, Gaballah AH, Bingham K, Hammoud GM, Kemble G, Buckley D, McCulloch W, Manrique-Acevedo C. Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities. Hepatology 2020;72:103-18. [PMID: 31630414 DOI: 10.1002/hep.31000] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 11.5] [Reference Citation Analysis]
238 Eng JM, Estall JL. Diet-Induced Models of Non-Alcoholic Fatty Liver Disease: Food for Thought on Sugar, Fat, and Cholesterol. Cells 2021;10:1805. [PMID: 34359974 DOI: 10.3390/cells10071805] [Reference Citation Analysis]
239 Baroiu L, Dumitru C, Iancu A, Leșe AC, Drăgănescu M, Baroiu N, Anghel L. COVID-19 impact on the liver. World J Clin Cases 2021; 9(16): 3814-3825 [PMID: 34141738 DOI: 10.12998/wjcc.v9.i16.3814] [Cited by in CrossRef: 2] [Article Influence: 2.0] [Reference Citation Analysis]
240 Yang YM, Noureddin M, Liu C, Ohashi K, Kim SY, Ramnath D, Powell EE, Sweet MJ, Roh YS, Hsin IF, Deng N, Liu Z, Liang J, Mena E, Shouhed D, Schwabe RF, Jiang D, Lu SC, Noble PW, Seki E. Hyaluronan synthase 2-mediated hyaluronan production mediates Notch1 activation and liver fibrosis. Sci Transl Med 2019;11:eaat9284. [PMID: 31189722 DOI: 10.1126/scitranslmed.aat9284] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 16.0] [Reference Citation Analysis]
241 Kessoku T, Kobayashi T, Tanaka K, Yamamoto A, Takahashi K, Iwaki M, Ozaki A, Kasai Y, Nogami A, Honda Y, Ogawa Y, Kato S, Imajo K, Higurashi T, Hosono K, Yoneda M, Usuda H, Wada K, Saito S, Nakajima A. The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target. Int J Mol Sci 2021;22:8161. [PMID: 34360923 DOI: 10.3390/ijms22158161] [Reference Citation Analysis]
242 Barata L, Feitosa MF, Bielak LF, Halligan B, Baldridge AS, Guo X, Yerges-Armstrong LM, Smith AV, Yao J, Palmer ND, VanWagner LB, Carr JJ, Chen YI, Allison M, Budoff MJ, Handelman SK, Kardia SLR, Mosley TH Jr, Ryan K, Harris TB, Launer LJ, Gudnason V, Rotter JI, Fornage M, Rasmussen-Torvik LJ, Borecki IB, O'Connell JR, Peyser PA, Speliotes EK, Province MA. Insulin Resistance Exacerbates Genetic Predisposition to Nonalcoholic Fatty Liver Disease in Individuals Without Diabetes. Hepatol Commun 2019;3:894-907. [PMID: 31334442 DOI: 10.1002/hep4.1353] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
243 Zeng F, Zhang Y, Han X, Zeng M, Gao Y, Weng J. Predicting Non-Alcoholic Fatty Liver Disease Progression and Immune Deregulations by Specific Gene Expression Patterns. Front Immunol 2020;11:609900. [PMID: 33574818 DOI: 10.3389/fimmu.2020.609900] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
244 Kogiso T, Hashimoto E. Are low triglyceride levels the cause or an outcome of advanced liver fibrosis in elderly patients with nonalcoholic fatty liver disease? Journal of Gastroenterology and Hepatology 2020;35:1459-60. [DOI: 10.1111/jgh.15226] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
245 Straś W, Małkowski P, Tronina O. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis - epidemiology, risk factors, clinical implications and treatment. Clin Exp Hepatol 2020;6:170-5. [PMID: 33145423 DOI: 10.5114/ceh.2020.99506] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
246 Javary J, Allain-courtois N, Benhamouche-trouillet S. La Reptine, nouvelle cible thérapeutique pour le syndrome métabolique et la stéatose hépatique. Med Sci (Paris) 2018;34:637-9. [DOI: 10.1051/medsci/20183408002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
247 Choung S, Kim JM, Joung KH, Lee ES, Kim HJ, Ku BJ. Epidermal growth factor receptor inhibition attenuates non-alcoholic fatty liver disease in diet-induced obese mice. PLoS One 2019;14:e0210828. [PMID: 30735525 DOI: 10.1371/journal.pone.0210828] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
248 Zhang L, Wang P, Shi M, Fang Z, Ji J, Liao X, Hu X, Chen F. The modulation of Luffa cylindrica (L.) Roem supplementation on gene expression and amino acid profiles in liver for alleviating hepatic steatosis via gut microbiota in high-fat diet-fed mice: insight from hepatic transcriptome analysis. The Journal of Nutritional Biochemistry 2020;80:108365. [DOI: 10.1016/j.jnutbio.2020.108365] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
249 Wu P, Zhang M, Webster NJG. Alternative RNA Splicing in Fatty Liver Disease. Front Endocrinol (Lausanne) 2021;12:613213. [PMID: 33716968 DOI: 10.3389/fendo.2021.613213] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
250 Le MH, Yeo YH, Henry L, Nguyen MH. Nonalcoholic Fatty Liver Disease and Renal Function Impairment: A Cross-Sectional Population-Based Study on Its Relationship From 1999 to 2016. Hepatol Commun 2019;3:1334-46. [PMID: 31592492 DOI: 10.1002/hep4.1408] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
251 Chang YH, Lin HC, Hwu DW, Chang DM, Lin KC, Lee YJ. Elevated serum cytokeratin-18 concentration in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease. Ann Clin Biochem 2019;56:141-7. [PMID: 30089409 DOI: 10.1177/0004563218796259] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
252 Fernández-Mincone T, Contreras-Briceño F, Espinosa-Ramírez M, García-Valdés P, López-Fuenzalida A, Riquelme A, Arab JP, Cabrera D, Arrese M, Barrera F. Nonalcoholic fatty liver disease and sarcopenia: pathophysiological connections and therapeutic implications. Expert Rev Gastroenterol Hepatol 2020;14:1141-57. [PMID: 32811209 DOI: 10.1080/17474124.2020.1810563] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
253 Golabi P, Fazel S, Otgonsuren M, Escheik C, Sayiner M, Younossi ZM. Association of Parity in Patients with Chronic Liver Disease. Annals of Hepatology 2018;17:1035-41. [DOI: 10.5604/01.3001.0012.7204] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
254 Mansour-Ghanaei R, Mansour-Ghanaei F, Naghipour M, Joukar F. The Lifestyle Characteristics in Non-Alcoholic Fatty Liver Disease in the PERSIAN Guilan Cohort Study. Open Access Maced J Med Sci 2019;7:3313-8. [PMID: 31949537 DOI: 10.3889/oamjms.2019.647] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
255 Kang SH, Cho KH, Do JY. Non-alcoholic fatty liver disease is associated with low-grade albuminuria in men without diabetes mellitus. Int J Med Sci 2019;16:285-91. [PMID: 30745809 DOI: 10.7150/ijms.28264] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
256 Lopez-Muñoz GA, Ortega MA, Ferret-Miñana A, De Chiara F, Ramón-Azcón J. Direct and Label-Free Monitoring of Albumin in 2D Fatty Liver Disease Model Using Plasmonic Nanogratings. Nanomaterials (Basel) 2020;10:E2520. [PMID: 33334062 DOI: 10.3390/nano10122520] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
257 Niu Y, Zhang W, Zhang H, Li X, Lin N, Su W, Gu H, Zhu L, Fan J, Qin L, Yang Z, Su Q. Serum creatinine levels and risk of nonalcohol fatty liver disease in a middle-aged and older Chinese population: A cross-sectional analysis. Diabetes Metab Res Rev 2021;:e3489. [PMID: 34344058 DOI: 10.1002/dmrr.3489] [Reference Citation Analysis]
258 van den Berg EH, Douwes RM, de Meijer VE, Schreuder TCMA, Blokzijl H. Liver transplantation for NASH cirrhosis is not performed at the expense of major post-operative morbidity. Dig Liver Dis. 2018;50:68-75. [PMID: 28935188 DOI: 10.1016/j.dld.2017.08.022] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
259 Preuss C, Jelenik T, Bódis K, Müssig K, Burkart V, Szendroedi J, Roden M, Markgraf DF. A New Targeted Lipidomics Approach Reveals Lipid Droplets in Liver, Muscle and Heart as a Repository for Diacylglycerol and Ceramide Species in Non-Alcoholic Fatty Liver. Cells 2019;8:E277. [PMID: 30909521 DOI: 10.3390/cells8030277] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
260 Lee JH, Lee HS, Ahn SB, Kwon YJ. Dairy protein intake is inversely related to development of non-alcoholic fatty liver disease. Clin Nutr 2021;40:5252-60. [PMID: 34534894 DOI: 10.1016/j.clnu.2021.08.012] [Reference Citation Analysis]
261 Zhu N, Huang S, Zhang Q, Zhao Z, Qu H, Ning M, Leng Y, Liu J. Metabolomic Study of High-Fat Diet-Induced Obese (DIO) and DIO Plus CCl4-Induced NASH Mice and the Effect of Obeticholic Acid. Metabolites 2021;11:374. [PMID: 34200685 DOI: 10.3390/metabo11060374] [Reference Citation Analysis]
262 Schumacher JD, Guo GL. Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis. Handb Exp Pharmacol 2019;256:325-57. [PMID: 31201553 DOI: 10.1007/164_2019_228] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
263 Gerges SH, Wahdan SA, Elsherbiny DA, El-Demerdash E. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. Life Sci 2021;271:119220. [PMID: 33592199 DOI: 10.1016/j.lfs.2021.119220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
264 Spahis S, Alvarez F, Ahmed N, Dubois J, Jalbout R, Paganelli M, Grzywacz K, Delvin E, Peretti N, Levy E. Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids. The Journal of Nutritional Biochemistry 2018;58:28-36. [DOI: 10.1016/j.jnutbio.2018.03.025] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
265 Guarino M, Kumar P, Felser A, Terracciano LM, Guixé-Muntet S, Humar B, Foti M, Nuoffer JM, St-Pierre MV, Dufour JF. Exercise Attenuates the Transition from Fatty Liver to Steatohepatitis and Reduces Tumor Formation in Mice. Cancers (Basel) 2020;12:E1407. [PMID: 32486073 DOI: 10.3390/cancers12061407] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
266 Magee N, Zou A, Ghosh P, Ahamed F, Delker D, Zhang Y. Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis. Journal of Biological Chemistry 2020;295:994-1008. [DOI: 10.1016/s0021-9258(17)49910-8] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
267 An SJ, Yang EJ, Oh S, Park KJ, Kim T, Hong YP, Yang YJ. The association between urinary bisphenol A levels and nonalcoholic fatty liver disease in Korean adults: Korean National Environmental Health Survey (KoNEHS) 2015-2017. Environ Health Prev Med 2021;26:91. [PMID: 34521354 DOI: 10.1186/s12199-021-01010-7] [Reference Citation Analysis]
268 Morrison MC, Kleemann R, van Koppen A, Hanemaaijer R, Verschuren L. Key Inflammatory Processes in Human NASH Are Reflected in Ldlr-/-.Leiden Mice: A Translational Gene Profiling Study. Front Physiol 2018;9:132. [PMID: 29527177 DOI: 10.3389/fphys.2018.00132] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
269 Hu W, Ma X, Zhou W, Li X, Sun T, Sun H. Preventive effect of Silibinin in combination with Pu-erh tea extract on non-alcoholic fatty liver disease in ob/ob mice. Food Funct 2017;8:1105-15. [DOI: 10.1039/c6fo01591c] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
270 Vidal-Cevallos P, Ordóñez-Vázquez AL, Procopio-Mosso O, Cardoso-Arias R, Uribe M, Chávez-Tapia NC. Cross-sectional pilot study to assess primary healthcare workers' knowledge of nonalcoholic fatty liver disease in a marginalized community in Mexico. Sci Rep 2021;11:12100. [PMID: 34103552 DOI: 10.1038/s41598-021-91199-y] [Reference Citation Analysis]
271 Yu E, Hsu HY, Huang CY, Hwang LC. Inflammatory Biomarkers and Risk of Atherosclerotic Cardiovascular Disease. Open Med (Wars) 2018;13:208-13. [PMID: 29845121 DOI: 10.1515/med-2018-0032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
272 Lin BZ, Lin TJ, Lin CL, Liao LY, Chang TA, Lu BJ, Chen KY. Differentiation of clinical patterns and survival outcomes of hepatocellular carcinoma on hepatitis B and nonalcoholic fatty liver disease. J Chin Med Assoc 2021;84:606-13. [PMID: 33871391 DOI: 10.1097/JCMA.0000000000000530] [Reference Citation Analysis]
273 Liu H, Zhan Q, Miao X, Xia X, Yang G, Peng X, Yan C. Punicalagin Prevents Hepatic Steatosis through Improving Lipid Homeostasis and Inflammation in Liver and Adipose Tissue and Modulating Gut Microbiota in Western Diet-Fed Mice. Mol Nutr Food Res 2021;65:e2001031. [PMID: 33369197 DOI: 10.1002/mnfr.202001031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
274 Bodai BI, Nakata TE. Breast Cancer: Lifestyle, the Human Gut Microbiota/Microbiome, and Survivorship. Perm J 2020;24. [PMID: 32589577 DOI: 10.7812/TPP/19.129] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
275 Lazarus JV, Cortez-Pinto H, Anstee QM. Reply to: "Caveats for the implementation of global strategies against non-alcoholic fatty liver disease". J Hepatol 2020;73:221-2. [PMID: 32280051 DOI: 10.1016/j.jhep.2020.03.017] [Reference Citation Analysis]
276 Pfeiffer RM, Rotman Y, O'Brien TR. Genetic Determinants of Cirrhosis and Hepatocellular Carcinoma Due to Fatty Liver Disease: What's the Score? Hepatology 2020;72:794-6. [PMID: 32506469 DOI: 10.1002/hep.31413] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
277 Paruk IM, Pirie FJ, Motala AA. Non-alcoholic fatty liver disease in Africa: A hidden danger. Glob Health Epidemiol Genom. 2019;4:e3. [PMID: 31019719 DOI: 10.1017/gheg.2019.2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
278 Elhence A, Shalimar. Treatment of non-alcoholic fatty liver disease - Current perspectives. Indian J Gastroenterol 2020;39:22-31. [PMID: 32152902 DOI: 10.1007/s12664-020-01021-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
279 Mitsinikos T, Mrowczynski-Hernandez P, Kohli R. Pediatric Nonalcoholic Fatty Liver Disease. Pediatr Clin North Am 2021;68:1309-20. [PMID: 34736591 DOI: 10.1016/j.pcl.2021.07.013] [Reference Citation Analysis]
280 Luci C, Bourinet M, Leclère PS, Anty R, Gual P. Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies. Front Endocrinol (Lausanne) 2020;11:597648. [PMID: 33384662 DOI: 10.3389/fendo.2020.597648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
281 Nastasa R, Stanciu C, Zenovia S, Singeap AM, Cojocariu C, Sfarti C, Girleanu I, Chiriac S, Cuciureanu T, Huiban L, Muzica CM, Trifan A. The Prevalence of Liver Steatosis and Fibrosis Assessed by Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter in Apparently Healthy Romanian Medical Students. Diagnostics (Basel) 2021;11:2341. [PMID: 34943578 DOI: 10.3390/diagnostics11122341] [Reference Citation Analysis]
282 Hu D, Yang W, Mao P, Cheng M. Combined Amelioration of Prebiotic Resveratrol and Probiotic Bifidobacteria on Obesity and Nonalcoholic Fatty Liver Disease. Nutr Cancer 2021;73:652-61. [PMID: 32436410 DOI: 10.1080/01635581.2020.1767166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
283 Yoshioka N, Tanaka M, Ochi K, Watanabe A, Ono K, Sawada M, Ogi T, Itoh M, Ito A, Shiraki Y, Enomoto A, Ishigami M, Fujishiro M, Ogawa Y, Suganami T. The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis-associated liver tumors in a novel murine model. Biomed Pharmacother 2021;140:111738. [PMID: 34029949 DOI: 10.1016/j.biopha.2021.111738] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
284 Simon TG, Roelstraete B, Khalili H, Hagström H, Ludvigsson JF. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut 2021;70:1375-82. [PMID: 33037056 DOI: 10.1136/gutjnl-2020-322786] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 7.5] [Reference Citation Analysis]
285 Higuera-de-la-Tijera F, Córdova-Gallardo J, Buganza-Torio E, Barranco-Fragoso B, Torre A, Parraguirre-Martínez S, Rojano-Rodríguez ME, Quintero-Bustos G, Castro-Narro G, Moctezuma-Velazquez C. Hepamet Fibrosis Score in Nonalcoholic Fatty Liver Disease Patients in Mexico: Lower than Expected Positive Predictive Value. Dig Dis Sci 2021. [PMID: 33428035 DOI: 10.1007/s10620-020-06821-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
286 Igarashi H, Shigiyama F, Wakui N, Nagai H, Shibuya K, Shiraga N, Hirose T, Kumashiro N. Whole hepatic lipid volume quantification and color mapping by multi-slice and multi-point magnetic resonance imaging. Hepatol Res 2019;49:1374-85. [PMID: 31313870 DOI: 10.1111/hepr.13408] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
287 Majumdar A, Tsochatzis EA. Changing trends of liver transplantation and mortality from non-alcoholic fatty liver disease. Metabolism 2020;111:154291. [DOI: 10.1016/j.metabol.2020.154291] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
288 De Roza MA, Goh GB. The increasing clinical burden of NAFLD in Asia. Lancet Gastroenterol Hepatol 2019;4:333-4. [PMID: 30902671 DOI: 10.1016/S2468-1253(19)30093-7] [Reference Citation Analysis]
289 Velarde-Ruiz Velasco JA, García-Jiménez ES, García-Zermeño KR, Morel-Cerda EC, Aldana-Ledesma JM, Castro-Narro GE, Cerpa-Cruz S, Tapia-Calderón DK, Mercado-Jauregui LA, Contreras-Omaña R. Extrahepatic complications of non-alcoholic fatty liver disease: Its impact beyond the liver. Rev Gastroenterol Mex (Engl Ed) 2019;84:472-81. [PMID: 31488310 DOI: 10.1016/j.rgmx.2019.05.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
290 Grimaudo S, Pipitone RM, Pennisi G, Celsa C, Cammà C, Di Marco V, Barcellona MR, Boemi R, Enea M, Giannetti A, Spatola F, Marchesini G, Craxì A, Petta S. Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2020;18:935-944.e3. [PMID: 31419571 DOI: 10.1016/j.cgh.2019.08.011] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 11.7] [Reference Citation Analysis]
291 Gastaldelli A. Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD? Clin Sci (Lond) 2017;131:2701-4. [PMID: 29109303 DOI: 10.1042/CS20170987] [Cited by in Crossref: 47] [Cited by in F6Publishing: 26] [Article Influence: 9.4] [Reference Citation Analysis]
292 Marciano S, Dirchwolf M, Torres MC, Allevato J, García Dans C, García B, Pollarsky F, Gaite L, Sirotinsky E, Rios B, Anselmo MN, Peche M, Hurtado E, Haddad L, Narvaez A, Mauro E, Martinez A, Bellizzi C, Ratusnu N, D Amico C, Arora S, Gadano A. Fibrosis assessment in patients with nonalcoholic fatty liver disease: Adherence to proposed algorithms and barriers to complying with them. Rev Gastroenterol Mex (Engl Ed) 2021:S0375-0906(21)00015-X. [PMID: 33773856 DOI: 10.1016/j.rgmx.2020.08.006] [Reference Citation Analysis]
293 Niriella MA, Kasturiratna A, Beddage T, Ediriweera DS, De Silva ST, Perera KR, Subasinghe CE, Kodisinghe SK, Piyaratna TC, Rishikesawan V, Dassanayaka AS, De Silva AP, Pathmeswaran A, Wickramasinghe AR, Kato N, Janaka de Silva H. Non-resolution of non-alcoholic fatty liver disease (NAFLD) among urban, adult Sri Lankans in the general population: A prospective, cohort follow-up study. PLoS One 2019;14:e0224474. [PMID: 31661524 DOI: 10.1371/journal.pone.0224474] [Reference Citation Analysis]
294 Petta S, Ciresi A, Bianco J, Geraci V, Boemi R, Galvano L, Magliozzo F, Merlino G, Craxì A, Giordano C. Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS. PLoS One 2017;12:e0186136. [PMID: 29161258 DOI: 10.1371/journal.pone.0186136] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
295 Zhang J, Feng W, Liu G, Ma Q, Li H, Gao X, Liu H, Piao G, Yuan H. Corosolic Acid Attenuates Hepatic Lipid Accumulation and Inflammatory Response via AMPK/SREBPs and NF-κB/MAPK Signaling Pathways. Am J Chin Med 2020;48:579-95. [DOI: 10.1142/s0192415x20500299] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
296 Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med. 2020;52:1898-1907. [PMID: 33268834 DOI: 10.1038/s12276-020-00527-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
297 Dai J, Yi J, Zhang S, Chen P, Jin H, Yu X, Zhang X. Serum 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid is associated with lipid profiles and might protect against non-alcoholic fatty liver disease in Chinese individuals. J Diabetes Investig 2019;10:793-800. [PMID: 30353682 DOI: 10.1111/jdi.12963] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
298 Liu Z, Wang J, Chen S, Xu C, Zhang Y. Associations of acrylamide with non-alcoholic fatty liver disease in American adults: a nationwide cross-sectional study. Environ Health 2021;20:98. [PMID: 34461916 DOI: 10.1186/s12940-021-00783-2] [Reference Citation Analysis]
299 Yoo J, Lee JM, Joo I, Lee DH, Yoon JH, Kang HJ, Ahn SJ. Reproducibility of ultrasound attenuation imaging for the noninvasive evaluation of hepatic steatosis. Ultrasonography 2020;39:121-9. [PMID: 31693842 DOI: 10.14366/usg.19034] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
300 Guo XF, Wang C, Yang T, Li S, Li KL, Li D. Vitamin D and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Food Funct 2020;11:7389-99. [PMID: 32966467 DOI: 10.1039/d0fo01095b] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
301 Sakane S, Hikita H, Shirai K, Myojin Y, Sasaki Y, Kudo S, Fukumoto K, Mizutani N, Tahata Y, Makino Y, Yamada R, Kodama T, Sakamori R, Tatsumi T, Takehara T. White Adipose Tissue Autophagy and Adipose-Liver Crosstalk Exacerbate Nonalcoholic Fatty Liver Disease in Mice. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00153-3. [PMID: 34303881 DOI: 10.1016/j.jcmgh.2021.07.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
302 Skubic C, Drakulić Ž, Rozman D. Personalized therapy when tackling nonalcoholic fatty liver disease: a focus on sex, genes, and drugs. Expert Opin Drug Metab Toxicol 2018;14:831-41. [PMID: 29969922 DOI: 10.1080/17425255.2018.1492552] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
303 Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, Kechagias S. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study. Hepatol Commun 2018;2:48-57. [PMID: 29404512 DOI: 10.1002/hep4.1124] [Cited by in Crossref: 80] [Cited by in F6Publishing: 79] [Article Influence: 16.0] [Reference Citation Analysis]
304 Imran M, Sergent O, Tête A, Gallais I, Chevanne M, Lagadic-Gossmann D, Podechard N. Membrane Remodeling as a Key Player of the Hepatotoxicity Induced by Co-Exposure to Benzo[a]pyrene and Ethanol of Obese Zebrafish Larvae. Biomolecules 2018;8:E26. [PMID: 29757947 DOI: 10.3390/biom8020026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
305 Yang M, Kimchi ET, Staveley-O'Carroll KF, Li G. Astaxanthin Prevents Diet-Induced NASH Progression by Shaping Intrahepatic Immunity. Int J Mol Sci 2021;22:11037. [PMID: 34681695 DOI: 10.3390/ijms222011037] [Reference Citation Analysis]
306 Hasan F, Daher HB. The Burden and Clinical Care Pathways of Nonalcoholic Steatohepatitis in the Middle East. Clin Liver Dis (Hoboken) 2019;14:207-11. [PMID: 32015870 DOI: 10.1002/cld.885] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
307 Yang J, Zhang X, Yi L, Yang L, Wang WE, Zeng C, Mi M, Chen X. Hepatic PKA inhibition accelerates the lipid accumulation in liver. Nutr Metab (Lond) 2019;16:69. [PMID: 31632452 DOI: 10.1186/s12986-019-0400-5] [Reference Citation Analysis]
308 Shaheen AA, Riazi K, Medellin A, Bhayana D, Kaplan GG, Jiang J, Park R, Schaufert W, Burak KW, Sargious M, Swain MG. Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study. CMAJ Open 2020;8:E370-6. [PMID: 32414883 DOI: 10.9778/cmajo.20200009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
309 Ji Y, Yin Y, Li Z, Zhang W. Gut Microbiota-Derived Components and Metabolites in the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients. 2019;11. [PMID: 31349604 DOI: 10.3390/nu11081712] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
310 Summart U, Thinkhamrop B, Chamadol N, Khuntikeo N, Songthamwat M, Kim CS. Gender differences in the prevalence of nonalcoholic fatty liver disease in the Northeast of Thailand: A population-based cross-sectional study. F1000Res. 2017;6:1630. [PMID: 29093809 DOI: 10.12688/f1000research.12417.2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
311 Sumida Y, Okanoue T, Nakajima A; Japan Study Group of NAFLD (JSG-NAFLD). Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis. Hepatol Res 2019;49:1256-62. [PMID: 31495973 DOI: 10.1111/hepr.13425] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 9.3] [Reference Citation Analysis]
312 Uhanova J, Minuk G, Lopez Ficher F, Chandok N. Nonalcoholic Fatty Liver Disease in Canadian First Nations and Non-First Nations Patients. Can J Gastroenterol Hepatol 2016;2016:6420408. [PMID: 27446857 DOI: 10.1155/2016/6420408] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
313 Makker J, Tariq H, Kumar K, Ravi M, Shaikh DH, Leung V, Hayat U, Hassan MT, Patel H, Nayudu S, Chilimuri S. Prevalence of advanced liver fibrosis and steatosis in type-2 diabetics with normal transaminases: A prospective cohort study. World J Gastroenterol 2021; 27(6): 523-533 [PMID: 33642826 DOI: 10.3748/wjg.v27.i6.523] [Reference Citation Analysis]
314 Pimpin L, Cortez-Pinto H, Negro F, Corbould E, Lazarus JV, Webber L, Sheron N; EASL HEPAHEALTH Steering Committee. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018;69:718-735. [PMID: 29777749 DOI: 10.1016/j.jhep.2018.05.011] [Cited by in Crossref: 211] [Cited by in F6Publishing: 190] [Article Influence: 52.8] [Reference Citation Analysis]
315 Adams LA, Roberts SK, Strasser SI, Mahady SE, Powell E, Estes C, Razavi H, George J. Nonalcoholic fatty liver disease burden: Australia, 2019-2030. J Gastroenterol Hepatol. 2020;35:1628-1635. [PMID: 32048317 DOI: 10.1111/jgh.15009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
316 Wijarnpreecha K, Panjawatanan P, Aby E, Ahmed A, Kim D. Nonalcoholic fatty liver disease in the over-60s: Impact of sarcopenia and obesity. Maturitas 2019;124:48-54. [PMID: 31097179 DOI: 10.1016/j.maturitas.2019.03.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
317 Ishiba H, Sumida Y, Seko Y, Tanaka S, Yoneda M, Hyogo H, Ono M, Fujii H, Eguchi Y, Suzuki Y, Yoneda M, Takahashi H, Nakahara T, Mori K, Kanemasa K, Shimada K, Imajo K, Yamaguchi K, Kawaguchi T, Nakajima A, Chayama K, Shima T, Fujimoto K, Okanoue T, Itoh Y; Japan Study Group of NAFLD. Type IV Collagen 7S Is the Most Accurate Test For Identifying Advanced Fibrosis in NAFLD With Type 2 Diabetes. Hepatol Commun 2021;5:559-72. [PMID: 33860115 DOI: 10.1002/hep4.1637] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
318 Tran BV, Ujita K, Taketomi-Takahashi A, Hirasawa H, Suto T, Tsushima Y. Reliability of ultrasound hepatorenal index and magnetic resonance imaging proton density fat fraction techniques in the diagnosis of hepatic steatosis, with magnetic resonance spectroscopy as the reference standard. PLoS One 2021;16:e0255768. [PMID: 34383812 DOI: 10.1371/journal.pone.0255768] [Reference Citation Analysis]
319 Wensink D, Coenen S, Wilson JHP, Wagenmakers MAEM, Langendonk JG. Liver involvement in patients with erythropoietic protoporphyria. Dig Liver Dis 2021:S1590-8658(21)00454-0. [PMID: 34475006 DOI: 10.1016/j.dld.2021.08.007] [Reference Citation Analysis]
320 Campbell PT, VanWagner LB, Colangelo LA, Lewis CE, Henkel A, Ajmera VH, Lloyd-Jones DM, Vaughan DE, Khan SS. Association between plasminogen activator inhibitor-1 in young adulthood and nonalcoholic fatty liver disease in midlife: CARDIA. Liver Int 2020;40:1111-20. [PMID: 32090434 DOI: 10.1111/liv.14417] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
321 Cadamuro M, Lasagni A, Sarcognato S, Guido M, Fabris R, Strazzabosco M, Strain AJ, Simioni P, Villa E, Fabris L. The Neglected Role of Bile Duct Epithelial Cells in NASH. Semin Liver Dis 2021. [PMID: 34794182 DOI: 10.1055/s-0041-1739455] [Reference Citation Analysis]
322 Chiang H, Lu HF, Chen JC, Chen YH, Sun HT, Huang HC, Tien HH, Huang C. Adlay Seed (Coix lacryma-jobi L.) Extracts Exhibit a Prophylactic Effect on Diet-Induced Metabolic Dysfunction and Nonalcoholic Fatty Liver Disease in Mice. Evid Based Complement Alternat Med 2020;2020:9519625. [PMID: 32595752 DOI: 10.1155/2020/9519625] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
323 Maeda S, Hikiba Y, Fujiwara H, Ikenoue T, Sue S, Sugimori M, Matsubayashi M, Kaneko H, Irie K, Sasaki T, Chuma M. NAFLD exacerbates cholangitis and promotes cholangiocellular carcinoma in mice. Cancer Sci 2021;112:1471-80. [PMID: 33506599 DOI: 10.1111/cas.14828] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
324 Olubamwo OO, Virtanen JK, Pihlajamaki J, Mantyselka P, Tuomainen TP. Fatty liver index as a predictor of increased risk of cardiometabolic disease: finding from the Kuopio Ischaemic Heart Disease Risk Factor Study Cohort. BMJ Open 2019;9:e031420. [PMID: 31492793 DOI: 10.1136/bmjopen-2019-031420] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
325 Lee YS, Kim SY, Ko E, Lee JH, Yi HS, Yoo YJ, Je J, Suh SJ, Jung YK, Kim JH, Seo YS, Yim HJ, Jeong WI, Yeon JE, Um SH, Byun KS. Exosomes derived from palmitic acid-treated hepatocytes induce fibrotic activation of hepatic stellate cells. Sci Rep. 2017;7:3710. [PMID: 28623272 DOI: 10.1038/s41598-017-03389-2] [Cited by in Crossref: 78] [Cited by in F6Publishing: 81] [Article Influence: 15.6] [Reference Citation Analysis]
326 Yoneda M, Honda Y, Nogami A, Imajo K, Nakajima A. Advances in ultrasound elastography for nonalcoholic fatty liver disease. J Med Ultrason (2001) 2020;47:521-33. [PMID: 32748075 DOI: 10.1007/s10396-020-01040-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
327 Patel S, Siddiqui MB, Roman JH, Zhang E, Lee E, Shen S, Faridnia M, Mintini RJ, Boyett S, Idowu MO, Sanyal AJ, Luketic VA, Siddiqui MS. Association Between Lipoprotein Particles and Atherosclerotic Events in Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31369-0. [PMID: 33007508 DOI: 10.1016/j.cgh.2020.09.039] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
328 Gong Z, Tas E, Yakar S, Muzumdar R. Hepatic lipid metabolism and non-alcoholic fatty liver disease in aging. Mol Cell Endocrinol. 2017;455:115-130. [PMID: 28017785 DOI: 10.1016/j.mce.2016.12.022] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 8.2] [Reference Citation Analysis]
329 Chen J, Liu J, Wang Y, Hu X, Zhou F, Hu Y, Yuan Y, Xu Y. Wogonin mitigates nonalcoholic fatty liver disease via enhancing PPARα/AdipoR2, in vivo and in vitro. Biomed Pharmacother 2017;91:621-31. [PMID: 28486193 DOI: 10.1016/j.biopha.2017.04.125] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
330 Khandelwal R, Dassanayake AS, Conjeevaram HS, Singh SP. Non-alcoholic fatty liver disease in diabetes: When to refer to the hepatologist? World J Diabetes 2021; 12(9): 1479-1493 [PMID: 34630901 DOI: 10.4239/wjd.v12.i9.1479] [Reference Citation Analysis]
331 Golabi P, Stepanova M, Pham HT, Cable R, Rafiq N, Bush H, Gogoll T, Younossi ZM. Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD). BMJ Open Gastroenterol 2018;5:e000198. [PMID: 29607054 DOI: 10.1136/bmjgast-2018-000198] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
332 Grgurevic I, Podrug K, Mikolasevic I, Kukla M, Madir A, Tsochatzis EA. Natural History of Nonalcoholic Fatty Liver Disease: Implications for Clinical Practice and an Individualized Approach. Can J Gastroenterol Hepatol 2020;2020:9181368. [PMID: 32051820 DOI: 10.1155/2020/9181368] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
333 Lonardo A, Suzuki A. Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research. J Clin Med 2020;9:E1278. [PMID: 32354182 DOI: 10.3390/jcm9051278] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 13.0] [Reference Citation Analysis]
334 Lonardo A, Leoni S, Alswat KA, Fouad Y. History of Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E5888. [PMID: 32824337 DOI: 10.3390/ijms21165888] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
335 Xin S, Zhan Q, Chen X, Xu J, Yu Y. Efficacy of serum miRNA test as a non-invasive method to diagnose nonalcoholic steatohepatitis: a systematic review and meta-analysis. BMC Gastroenterol 2020;20:186. [PMID: 32532204 DOI: 10.1186/s12876-020-01334-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
336 Doherty Lyons S, Blum JL, Hoffman-Budde C, Tijerina PB, Fiel MI, J Conklin D, Gany F, Odin JA, Zelikoff JT. Prenatal Exposure to Gutkha, a Globally Relevant Smokeless Tobacco Product, Induces Hepatic Changes in Adult Mice. Int J Environ Res Public Health 2020;17:E7895. [PMID: 33126512 DOI: 10.3390/ijerph17217895] [Reference Citation Analysis]
337 Houttu V, Csader S, Nieuwdorp M, Holleboom AG, Schwab U. Dietary Interventions in Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Front Nutr 2021;8:716783. [PMID: 34368214 DOI: 10.3389/fnut.2021.716783] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
338 Deng J, Zhang Y, Bu L, Shi H, Tang H, Wang S, Wang Q, Dang S, Li M, Han Z, Lu X. The Prevalence, Popular Trends, and Associated and Predictive Factors of Non-Obese Fatty Liver Disease. Front Endocrinol (Lausanne) 2021;12:744710. [PMID: 34603215 DOI: 10.3389/fendo.2021.744710] [Reference Citation Analysis]
339 van Kleef LA, Ayada I, Alferink LJM, Pan Q, de Knegt RJ. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study. Hepatology 2021. [PMID: 34453359 DOI: 10.1002/hep.32131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
340 Saiman Y, Hooks R, Carr RM. High-Risk Groups for Non-alcoholic Fatty Liver and Non-alcoholic Steatohepatitis Development and Progression. Curr Hepatology Rep 2020;19:412-9. [DOI: 10.1007/s11901-020-00539-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
341 Gao Y, Tian R, Liu H, Xue H, Zhang R, Han S, Ji L, Huang W, Zhan J, You Y. Research progress on intervention effect and mechanism of protocatechuic acid on nonalcoholic fatty liver disease. Crit Rev Food Sci Nutr 2021;:1-23. [PMID: 34142875 DOI: 10.1080/10408398.2021.1939265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
342 Mantovani A, Mingolla L, Rigolon R, Pichiri I, Cavalieri V, Zoppini G, Lippi G, Bonora E, Targher G. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular disease in adult patients with type 1 diabetes. Int J Cardiol 2016;225:387-91. [PMID: 27768965 DOI: 10.1016/j.ijcard.2016.10.040] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
343 Zhou J, Li H, Cai Y, Ma L, Mathews D, Lu B, Zhu B, Chen Y, Qian X, Xiao X, Li Q, Guo S, Huo Y, Zhao L, Tian Y, Li Q, Wu C. Mice lacking adenosine 2A receptor reveal increased severity of MCD-induced NASH. J Endocrinol 2019:JOE-19-0198. [PMID: 31505462 DOI: 10.1530/JOE-19-0198] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
344 Takada S, Matsubara T, Fujii H, Sato-Matsubara M, Daikoku A, Odagiri N, Amano-Teranishi Y, Kawada N, Ikeda K. Stress can attenuate hepatic lipid accumulation via elevation of hepatic β-muricholic acid levels in mice with nonalcoholic steatohepatitis. Lab Invest 2021;101:193-203. [PMID: 33303970 DOI: 10.1038/s41374-020-00509-x] [Reference Citation Analysis]
345 Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Sundby Palle M, Vogl T, Loomba R, Plum-Mörschel L. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2021;54:1150-61. [PMID: 34570916 DOI: 10.1111/apt.16608] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
346 Semmler G, Wernly S, Bachmayer S, Leitner I, Wernly B, Egger M, Schwenoha L, Datz L, Balcar L, Semmler M, Stickel F, Niederseer D, Aigner E, Datz C. Metabolic dysfunction-associated fatty liver disease (MAFLD) - rather a bystander than a driver of mortality. J Clin Endocrinol Metab 2021:dgab339. [PMID: 33982065 DOI: 10.1210/clinem/dgab339] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
347 Abdelmalek MF, Charles ED, Sanyal AJ, Harrison SA, Neuschwander-Tetri BA, Goodman Z, Ehman RA, Karsdal M, Nakajima A, Du S, Tirucherai GS, Klinger GH, Mora J, Yamaguchi M, Shevell DE, Loomba R. The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. Contemp Clin Trials 2021;104:106335. [PMID: 33657443 DOI: 10.1016/j.cct.2021.106335] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
348 Dongiovanni P, Meroni M, Petta S, Longo M, Alisi A, Soardo G, Valenti L, Miele L, Grimaudo S, Pennisi G, Antonio G, Consonni D, Fargion S, Fracanzani AL. Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD. Biochim Biophys Acta Mol Cell Biol Lipids 2020;1865:158765. [PMID: 32663609 DOI: 10.1016/j.bbalip.2020.158765] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
349 Fernandez ML. Lifestyle Factors and Genetic Variants Associated to Health Disparities in the Hispanic Population. Nutrients 2021;13:2189. [PMID: 34202120 DOI: 10.3390/nu13072189] [Reference Citation Analysis]
350 Jung J, Loomba RR, Imajo K, Madamba E, Gandhi S, Bettencourt R, Singh S, Hernandez C, Valasek MA, Behling C, Richards L, Fowler K, Sirlin CB, Nakajima A, Loomba R. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. Gut 2021;70:1946-53. [PMID: 33214165 DOI: 10.1136/gutjnl-2020-322976] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
351 Pennisi G, Celsa C, Giammanco A, Spatola F, Petta S. The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives. Int J Mol Sci 2019;20:E5613. [PMID: 31717576 DOI: 10.3390/ijms20225613] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
352 Saltzman ET, Palacios T, Thomsen M, Vitetta L. Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease. Front Microbiol 2018;9:61. [PMID: 29441049 DOI: 10.3389/fmicb.2018.00061] [Cited by in Crossref: 64] [Cited by in F6Publishing: 68] [Article Influence: 16.0] [Reference Citation Analysis]
353 Duseja A, Acharya SK, Mehta M, Chhabra S, Rana S, Das A, Dattagupta S, Dhiman RK, Chawla YK; Shalimar. High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study. BMJ Open Gastroenterol 2019;6:e000315. [PMID: 31423319 DOI: 10.1136/bmjgast-2019-000315] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
354 Mukthinuthalapati VVPK, Attar BM, Abu Omar Y, Nath V, Czapar C, Gandhi SR. Thin Patient, Fatty Liver. Cureus 2019;11:e4139. [PMID: 31058022 DOI: 10.7759/cureus.4139] [Reference Citation Analysis]
355 Zhong GC, Liu S, Wu YL, Xia M, Zhu JX, Hao FB, Wan L. ABO blood group and risk of newly diagnosed nonalcoholic fatty liver disease: A case-control study in Han Chinese population. PLoS One 2019;14:e0225792. [PMID: 31800606 DOI: 10.1371/journal.pone.0225792] [Reference Citation Analysis]
356 Negi CK, Babica P, Bajard L, Bienertova-Vasku J, Tarantino G. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism 2021;126:154925. [PMID: 34740573 DOI: 10.1016/j.metabol.2021.154925] [Reference Citation Analysis]
357 Murphree CR, Nguyen NN, Raghunathan V, Olson SR, DeLoughery T, Shatzel JJ. Diagnosis and management of hereditary haemochromatosis. Vox Sang 2020;115:255-62. [PMID: 32080859 DOI: 10.1111/vox.12896] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
358 Shaheen AA, Swain MG. Editorial: choosing an appropriate risk stratification tool for nonalcoholic fatty liver disease-one size does not fit all. Aliment Pharmacol Ther 2020;51:661-2. [PMID: 32100347 DOI: 10.1111/apt.15640] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
359 Wu M, Xu H, Liu J, Tan X, Wan S, Guo M, Long Y, Xu Y. Metformin and Fibrosis: A Review of Existing Evidence and Mechanisms. J Diabetes Res 2021;2021:6673525. [PMID: 34007848 DOI: 10.1155/2021/6673525] [Reference Citation Analysis]
360 Lee YS, Yoo YJ, Jung YK, Kim JH, Seo YS, Yim HJ, Kim IH, Lee SY, Kim BH, Kim JW, Lee CH, Yeon JE, Kwon SY, Um SH, Byun KS. Multiparametric MR Is a Valuable Modality for Evaluating Disease Severity of Nonalcoholic Fatty Liver Disease. Clin Transl Gastroenterol 2020;11:e00157. [PMID: 32251018 DOI: 10.14309/ctg.0000000000000157] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
361 Zhang YN, Fowler KJ, Hamilton G, Cui JY, Sy EZ, Balanay M, Hooker JC, Szeverenyi N, Sirlin CB. Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging. Br J Radiol. 2018;91:20170959. [PMID: 29722568 DOI: 10.1259/bjr.20170959] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 10.3] [Reference Citation Analysis]
362 Hu Q, Wei S, Wen J, Zhang W, Jiang Y, Qu C, Xiang J, Zhao Y, Peng X, Ma X. Network pharmacology reveals the multiple mechanisms of Xiaochaihu decoction in the treatment of non-alcoholic fatty liver disease. BioData Min 2020;13:11. [PMID: 32863886 DOI: 10.1186/s13040-020-00224-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
363 Wong RJ, Kachru N, Martinez DJ, Moynihan M, Ozbay AB, Gordon SC. Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases. J Clin Gastroenterol 2021;55:891-902. [PMID: 32815873 DOI: 10.1097/MCG.0000000000001409] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
364 Min HK, Maruyama H, Jang BK, Shimada M, Mirshahi F, Ren S, Oh Y, Puri P, Sanyal AJ. Suppression of IGF binding protein-3 by palmitate promotes hepatic inflammatory responses. FASEB J 2016;30:4071-82. [PMID: 27553225 DOI: 10.1096/fj.201600427R] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
365 Alvarez CS, Florio AA, Butt J, Rivera-Andrade A, Kroker-Lobos MF, Waterboer T, Camargo MC, Freedman ND, Graubard BI, Lazo M, Guallar E, Groopman JD, Ramírez-Zea M, McGlynn KA. Associations between Helicobacter pylori with nonalcoholic fatty liver disease and other metabolic conditions in Guatemala. Helicobacter 2020;25:e12756. [PMID: 33006810 DOI: 10.1111/hel.12756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
366 Lin M, Zeng H, Deng G, Lei J, Li J. Vitamin E in paediatric non-alcoholic fatty liver disease: a meta-analysis. Clin Res Hepatol Gastroenterol 2021;45:101530. [PMID: 33272889 DOI: 10.1016/j.clinre.2020.08.008] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
367 Wang X, Chen X, Zhang H, Pang J, Lin J, Xu X, Yang L, Ma J, Ling W, Chen Y. Circulating retinol-binding protein 4 is associated with the development and regression of non-alcoholic fatty liver disease. Diabetes & Metabolism 2020;46:119-28. [DOI: 10.1016/j.diabet.2019.04.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
368 Hong J, Huang J, Shen L, Zhu S, Gao W, Wu J, Huang O, He J, Zhu L, Chen W, Li Y, Chen X, Shen K. A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis. BMC Cancer 2020;20:663. [PMID: 32677982 DOI: 10.1186/s12885-020-07156-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
369 Han J, Guo X, Meng XJ, Zhang J, Yamaguchi R, Motoo Y, Yamada S. Acupuncture improved lipid metabolism by regulating intestinal absorption in mice. World J Gastroenterol 2020; 26(34): 5118-5129 [PMID: 32982113 DOI: 10.3748/wjg.v26.i34.5118] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
370 Lam B, Kurzke K, Younossi Z. The Clinical and Economic Burden of Nonalcoholic Steatohepatitis. Curr Hepatology Rep 2018;17:345-9. [DOI: 10.1007/s11901-018-0423-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
371 Cocker F, Chien Yee K, Palmer AJ, de Graaff B. Increasing incidence and mortality related to liver cancer in Australia: time to turn the tide. Aust N Z J Public Health 2019;43:267-73. [PMID: 30958629 DOI: 10.1111/1753-6405.12889] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
372 Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab 2020;42:101092. [PMID: 33010471 DOI: 10.1016/j.molmet.2020.101092] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
373 Marciano S, Dirchwolf M, Torres MC, Allevato J, García Dans C, García B, Pollarsky F, Gaite L, Sirotinsky E, Rios B, Anselmo MN, Peche M, Hurtado E, Haddad L, Narvaez A, Mauro E, Martinez A, Bellizzi C, Ratusnu N, D'Amico C, Arora S, Gadano A. Fibrosis assessment in patients with nonalcoholic fatty liver disease: Adherence to proposed algorithms and barriers to complying with them. Rev Gastroenterol Mex (Engl Ed) 2021:S2255-534X(21)00103-1. [PMID: 34690105 DOI: 10.1016/j.rgmxen.2021.09.002] [Reference Citation Analysis]
374 Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123-133. [PMID: 28802062 DOI: 10.1002/hep.29466] [Cited by in Crossref: 594] [Cited by in F6Publishing: 568] [Article Influence: 118.8] [Reference Citation Analysis]
375 Pollack BL, Batmanghelich K, Cai SS, Gordon E, Wallace S, Catania R, Morillo-Hernandez C, Furlan A, Borhani AA. Deep Learning Prediction of Voxel-Level Liver Stiffness in Patients with Nonalcoholic Fatty Liver Disease. Radiol Artif Intell 2021;3:e200274. [PMID: 34870213 DOI: 10.1148/ryai.2021200274] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
376 Valenzuela R, Videla LA. Crosstalk mechanisms in hepatoprotection: Thyroid hormone-docosahexaenoic acid (DHA) and DHA-extra virgin olive oil combined protocols. Pharmacological Research 2018;132:168-75. [DOI: 10.1016/j.phrs.2017.12.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
377 Kosick HM, Keyrouz A, Adeyi O, Sebastiani G, Patel K. A Stepwise Algorithmic Approach and External Validation Study for Noninvasive Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2021. [PMID: 33389416 DOI: 10.1007/s10620-020-06748-8] [Reference Citation Analysis]
378 Sauvé MF, Feldman F, Koudoufio M, Ould-Chikh NE, Ahmarani L, Sane A, N'Timbane T, El-Jalbout R, Patey N, Spahis S, Stintzi A, Delvin E, Levy E. Glycomacropeptide for Management of Insulin Resistance and Liver Metabolic Perturbations. Biomedicines 2021;9:1140. [PMID: 34572325 DOI: 10.3390/biomedicines9091140] [Reference Citation Analysis]
379 Kandeil MA, Hashem RM, Mahmoud MO, Hetta MH, Tohamy MA. Zingiber officinale extract and omega-3 fatty acids ameliorate endoplasmic reticulum stress in a nonalcoholic fatty liver rat model. J Food Biochem 2019;43:e13076. [PMID: 31608477 DOI: 10.1111/jfbc.13076] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
380 Liu S, Wang J, Wu S, Niu J, Zheng R, Bie L, Xin Z, Wang S, Lin H, Zhao Z, Wang T, Xu M, Lu J, Chen Y, Xu Y, Wang W, Ning G, Bi Y, Li M, Xu Y. The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis. Metabolism 2021;120:154779. [PMID: 33895182 DOI: 10.1016/j.metabol.2021.154779] [Reference Citation Analysis]
381 Antraco VJ, Hirata BKS, de Jesus Simão J, Cruz MM, da Silva VS, da Cunha de Sá RDC, Abdala FM, Armelin-Correa L, Alonso-Vale MIC. Omega-3 Polyunsaturated Fatty Acids Prevent Nonalcoholic Steatohepatitis (NASH) and Stimulate Adipogenesis. Nutrients 2021;13:622. [PMID: 33671850 DOI: 10.3390/nu13020622] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
382 Kuwashiro T, Takahashi H, Hyogo H, Ogawa Y, Imajo K, Yoneda M, Nakahara T, Oeda S, Tanaka K, Amano Y, Ogawa S, Kawaguchi A, Aishima S, Kage M, Chayama K, Nakajima A, Eguchi Y. Discordant pathological diagnosis of non-alcoholic fatty liver disease: A prospective multicenter study. JGH Open 2020;4:497-502. [PMID: 32514460 DOI: 10.1002/jgh3.12289] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
383 Wu B, Zheng X, Li X, Wang C, Li L, Tang Z, Cui H, Li Z, Chen L, Ma X. Design, synthesis and activity evaluation of prodrug form JBP485 and Vitamin E for alleviation of NASH. Bioorg Med Chem Lett 2022;56:128464. [PMID: 34808388 DOI: 10.1016/j.bmcl.2021.128464] [Reference Citation Analysis]
384 Meritsi A, Manesis E, Koussis P, Rapti S, Latsou D, Tsitsopoulos E, Moshoyianni H, Manolakopoulos S, Pektasides D, Thanopoulou A. PNPLA3 rs 738409 and Other Nongenetic Factors Associated with Hepatic Steatosis Estimated by Magnetic Resonance Imaging Proton Density Fat Fraction in Adult Greek Subjects with Type 2 Diabetes Mellitus. Metab Syndr Relat Disord 2021. [PMID: 34962148 DOI: 10.1089/met.2021.0098] [Reference Citation Analysis]
385 Salva-Pastor N, López-Sánchez GN, Chávez-Tapia NC, Audifred-Salomón JR, Niebla-Cárdenas D, Topete-Estrada R, Pereznuñez-Zamora H, Vidaltamayo-Ramírez R, Báez-Arellano ME, Uribe M, Nuño-Lámbarri N. Polycystic ovary syndrome with feasible equivalence to overweight as a risk factor for non-alcoholic fatty liver disease development and severity in Mexican population. Ann Hepatol 2020;19:251-7. [PMID: 32111488 DOI: 10.1016/j.aohep.2020.01.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
386 Canivet CM, Bonnafous S, Rousseau D, Leclere PS, Lacas-Gervais S, Patouraux S, Sans A, Luci C, Bailly-Maitre B, Iannelli A, Tran A, Anty R, Gual P. Hepatic FNDC5 is a potential local protective factor against Non-Alcoholic Fatty Liver. Biochim Biophys Acta Mol Basis Dis 2020;1866:165705. [PMID: 32001301 DOI: 10.1016/j.bbadis.2020.165705] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
387 De Munck TJI, Xu P, Vanderfeesten BLJ, Elizalde M, Masclee AAM, Nevens F, Cassiman D, Schaap FG, Jonkers DMAE, Verbeek J. The Role of Brown Adipose Tissue in the Development and Treatment of Nonalcoholic Steatohepatitis: An Exploratory Gene Expression Study in Mice. Horm Metab Res 2020;52:869-76. [PMID: 33260239 DOI: 10.1055/a-1301-2378] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
388 Nishio T, Taura K, Nakamura N, Seo S, Yasuchika K, Kaido T, Okajima H, Hatano E, Uemoto S. Impact of statin use on the prognosis of patients with hepatocellular carcinoma undergoing liver resection: a subgroup analysis of patients without chronic hepatitis viral infection. Surgery 2018;163:264-9. [PMID: 29167018 DOI: 10.1016/j.surg.2017.09.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
389 Lazarus JV, Palayew A, Carrieri P, Ekstedt M, Marchesini G, Novak K, Ratziu V, Romero-Gómez M, Tacke F, Zelber-Sagi S, Cortez-Pinto H, Anstee QM. European 'NAFLD Preparedness Index' - Is Europe ready to meet the challenge of fatty liver disease? JHEP Rep 2021;3:100234. [PMID: 33733078 DOI: 10.1016/j.jhepr.2021.100234] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
390 Zhang Y, Li J, Ni Y, Wang Y, Liu H. Correlational study on the levels of 25-hydroxyvitamin D and non-alcoholic fatty liver disease in type 2 diabetic patients. BMC Endocr Disord 2021;21:100. [PMID: 34006273 DOI: 10.1186/s12902-021-00762-1] [Reference Citation Analysis]
391 Li D, Liu F, Wang X, Li X. Apple Polyphenol Extract Alleviates High-Fat-Diet-Induced Hepatic Steatosis in Male C57BL/6 Mice by Targeting LKB1/AMPK Pathway. J Agric Food Chem 2019;67:12208-18. [DOI: 10.1021/acs.jafc.9b05495] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
392 Kozaczek M, Bottje W, Albataineh D, Hakkak R. Effects of Short- and Long-Term Soy Protein Feeding on Hepatic Cytochrome P450 Expression in Obese Nonalcoholic Fatty Liver Disease Rat Model. Front Nutr 2021;8:699620. [PMID: 34262928 DOI: 10.3389/fnut.2021.699620] [Reference Citation Analysis]
393 Popa A, Bende F, Șirli R, Popescu A, Bâldea V, Lupușoru R, Cotrău R, Fofiu R, Foncea C, Sporea I. Quantification of Liver Fibrosis, Steatosis, and Viscosity Using Multiparametric Ultrasound in Patients with Non-Alcoholic Liver Disease: A "Real-Life" Cohort Study. Diagnostics (Basel) 2021;11:783. [PMID: 33926073 DOI: 10.3390/diagnostics11050783] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
394 Zhou J, Zhou F, Wang W, Zhang XJ, Ji YX, Zhang P, She ZG, Zhu L, Cai J, Li H. Epidemiological Features of NAFLD From 1999 to 2018 in China. Hepatology. 2020;71:1851-1864. [PMID: 32012320 DOI: 10.1002/hep.31150] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 46.0] [Reference Citation Analysis]
395 Kubihal S, Gupta Y, Shalimar, Kandasamy D, Goyal A, Kalaivani M, Goyal A, Kedia S, Kachhawa G, Ambekar S, Bhatia D, Garg V, Gupta N, Tandon N. Prevalence of non-alcoholic fatty liver disease and factors associated with it in Indian women with a history of gestational diabetes mellitus. J Diabetes Investig 2021;12:877-85. [PMID: 32961610 DOI: 10.1111/jdi.13411] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
396 Baselli GA, Dongiovanni P, Rametta R, Meroni M, Pelusi S, Maggioni M, Badiali S, Pingitore P, Maurotti S, Montalcini T, Taliento AE, Prati D, Rossi G, Fracanzani AL, Mancina RM, Romeo S, Valenti L. Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker. Gut 2020;69:1855-66. [PMID: 32001554 DOI: 10.1136/gutjnl-2019-319226] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
397 Fabrellas N, Hernández R, Graupera I, Solà E, Ramos P, Martín N, Sáez G, Simón C, Pérez A, Graell T, Larrañaga A, Garcia M, de la Arada A, Juanola A, Coiduras A, Duaso I, Casado A, Martin J, Ginès M, Moreno N, Gema Perez A, Marti L, Bernat M, Sola M, Olivé C, Solé C, Ginès P. Prevalence of hepatic steatosis as assessed by controlled attenuation parameter (CAP) in subjects with metabolic risk factors in primary care. A population-based study. PLoS One 2018;13:e0200656. [PMID: 30226889 DOI: 10.1371/journal.pone.0200656] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
398 Zeng F, Luo J, Han H, Xie W, Wang L, Han R, Chen H, Cai Y, Huang H, Xia Z. Allopurinol ameliorates liver injury in type 1 diabetic rats through activating Nrf2. Int J Immunopathol Pharmacol 2021;35:20587384211031417. [PMID: 34240649 DOI: 10.1177/20587384211031417] [Reference Citation Analysis]
399 Rother A, Niemann U, Hielscher T, Völzke H, Ittermann T, Spiliopoulou M. Assessing the difficulty of annotating medical data in crowdworking with help of experiments. PLoS One 2021;16:e0254764. [PMID: 34324540 DOI: 10.1371/journal.pone.0254764] [Reference Citation Analysis]
400 Patel V, Joharapurkar A, Kshirsagar S, Patel M, Sutariya B, Patel H, Pandey D, Patel D, Ranvir R, Kadam S, Bahekar R, Jain M. Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates nonalcoholic fatty liver disease. Can J Physiol Pharmacol. 2018;96:587-596. [PMID: 29406832 DOI: 10.1139/cjpp-2017-0683] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
401 Huang KT, Chen KD, Hsu LW, Kung CP, Li SR, Chen CC, Chiu KW, Goto S, Chen CL. Decreased PEDF Promotes Hepatic Fatty Acid Uptake and Lipid Droplet Formation in the Pathogenesis of NAFLD. Nutrients 2020;12:E270. [PMID: 31968655 DOI: 10.3390/nu12010270] [Reference Citation Analysis]
402 Oh S, Son M, Byun KA, Jang JT, Choi CH, Son KH, Byun K. Attenuating Effects of Dieckol on High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease by Decreasing the NLRP3 Inflammasome and Pyroptosis. Mar Drugs 2021;19:318. [PMID: 34070893 DOI: 10.3390/md19060318] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
403 Liu Y, Zhong GC, Tan HY, Hao FB, Hu JJ. Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis. Sci Rep 2019;9:11124. [PMID: 31366982 DOI: 10.1038/s41598-019-47687-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
404 Lange N, Dufour JF. Changing Epidemiology of HCC: How to Screen and Identify Patients at Risk? Dig Dis Sci 2019;64:903-9. [PMID: 30863952 DOI: 10.1007/s10620-019-05515-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
405 Nguyen MH, Lim JK, Burak Ozbay A, Fraysse J, Liou I, Meyer N, Dusheiko G, Gordon SC. Advancing Age and Comorbidity in a US Insured Population-Based Cohort of Patients With Chronic Hepatitis B. Hepatology. 2019;69:959-973. [PMID: 30175482 DOI: 10.1002/hep.30246] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 9.3] [Reference Citation Analysis]
406 Vali Y, Lee J, Boursier J, Spijker R, Verheij J, Brosnan MJ, Anstee QM, Bossuyt PM, Zafarmand MH, On Behalf Of The Litmus Systematic Review Team. FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis. J Clin Med 2021;10:2415. [PMID: 34072480 DOI: 10.3390/jcm10112415] [Reference Citation Analysis]
407 Wang S, Yang FJ, Shang LC, Zhang YH, Zhou Y, Shi XL. Puerarin protects against high-fat high-sucrose diet-induced non-alcoholic fatty liver disease by modulating PARP-1/PI3K/AKT signaling pathway and facilitating mitochondrial homeostasis. Phytother Res 2019;33:2347-59. [PMID: 31273855 DOI: 10.1002/ptr.6417] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
408 Lin WT, Yang KC, Chen YT, Huang KC, Yang WS. Elevated serum S14 levels are associated with more severe liver steatosis by ultrasonography. Sci Rep 2021;11:24181. [PMID: 34921174 DOI: 10.1038/s41598-021-03279-8] [Reference Citation Analysis]
409 Newsome P, Francque S, Harrison S, Ratziu V, Van Gaal L, Calanna S, Hansen M, Linder M, Sanyal A. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. Aliment Pharmacol Ther 2019;50:193-203. [PMID: 31246368 DOI: 10.1111/apt.15316] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 13.3] [Reference Citation Analysis]
410 Raza S, Rajak S, Upadhyay A, Tewari A, Anthony Sinha R. Current treatment paradigms and emerging therapies for NAFLD/NASH. Front Biosci (Landmark Ed) 2021;26:206-37. [PMID: 33049668 DOI: 10.2741/4892] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
411 Mohamed IN, Li L, Ismael S, Ishrat T, El-Remessy AB. Thioredoxin interacting protein, a key molecular switch between oxidative stress and sterile inflammation in cellular response. World J Diabetes 2021; 12(12): 1979-1999 [DOI: 10.4239/wjd.v12.i12.1979] [Reference Citation Analysis]
412 Rodríguez de Lope C, Reig M, Matilla A, Ferrer MT, Dueñas E, Mínguez B, F Castroagudín J, Ortiz I, Pascual S, Lledó JL, Gallego A, Arenas JI, Aracil C, Forne M, Muñoz C, Pons F, Sala M, Iñarrairaegui M, Martin-Llahi M, Andreu V, Garre C, Rendón P, Fuentes J, Crespo J, Rodríguez M, Bruix J, Varela M; en representación del Grupo de Estudio de Cáncer Hepático (GECH). Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers. Med Clin (Barc) 2017;149:61-71. [PMID: 28279536 DOI: 10.1016/j.medcli.2016.12.048] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
413 Sugimoto K, Moriyasu F, Oshiro H, Takeuchi H, Abe M, Yoshimasu Y, Kasai Y, Sakamaki K, Hara T, Itoi T. The Role of Multiparametric US of the Liver for the Evaluation of Nonalcoholic Steatohepatitis. Radiology 2020;296:532-40. [PMID: 32573385 DOI: 10.1148/radiol.2020192665] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 14.0] [Reference Citation Analysis]
414 Li H, Wang Q, Chen P, Zhou C, Zhang X, Chen L. Ursodeoxycholic Acid Treatment Restores Gut Microbiota and Alleviates Liver Inflammation in Non-Alcoholic Steatohepatitic Mouse Model. Front Pharmacol 2021;12:788558. [PMID: 34938193 DOI: 10.3389/fphar.2021.788558] [Reference Citation Analysis]
415 Trojan J, Zangos S, Schnitzbauer AA. Diagnostics and Treatment of Hepatocellular Carcinoma in 2016: Standards and Developments. Visc Med. 2016;32:116-120. [PMID: 27413729 DOI: 10.1159/000445730] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
416 Hamid H, Zhang JY, Li WX, Liu C, Li ML, Zhao LH, Ji C, Ma QG. Interactions between the cecal microbiota and non-alcoholic steatohepatitis using laying hens as the model. Poult Sci 2019;98:2509-21. [PMID: 30690636 DOI: 10.3382/ps/pey596] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
417 Chow MD, Lee YH, Guo GL. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mol Aspects Med. 2017;56:34-44. [PMID: 28442273 DOI: 10.1016/j.mam.2017.04.004] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 10.6] [Reference Citation Analysis]
418 Van Dijk AM, Vali Y, Mak AL, Lee J, Tushuizen ME, Zafarmand MH, Anstee QM, Brosnan MJ, Nieuwdorp M, Bossuyt PM, Holleboom AG. Systematic Review with Meta-Analyses: Diagnostic Accuracy of FibroMeter Tests in Patients with Non-Alcoholic Fatty Liver Disease. J Clin Med 2021;10:2910. [PMID: 34209858 DOI: 10.3390/jcm10132910] [Reference Citation Analysis]
419 Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908-922. [PMID: 29967350 DOI: 10.1038/s41591-018-0104-9] [Cited by in Crossref: 777] [Cited by in F6Publishing: 742] [Article Influence: 194.3] [Reference Citation Analysis]
420 Canbay A, Sowa JP. L-Ornithine L-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease. Drugs 2019;79:39-44. [PMID: 30706422 DOI: 10.1007/s40265-018-1020-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
421 Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism 2019;92:82-97. [DOI: 10.1016/j.metabol.2018.11.014] [Cited by in Crossref: 165] [Cited by in F6Publishing: 164] [Article Influence: 55.0] [Reference Citation Analysis]
422 Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol 2017; 23(47): 8263-8276 [PMID: 29307986 DOI: 10.3748/wjg.v23.i47.8263] [Cited by in CrossRef: 252] [Cited by in F6Publishing: 225] [Article Influence: 50.4] [Reference Citation Analysis]
423 Zou Y, Lan J, Zhong Y, Yang S, Zhang H, Xie G. Association of remnant cholesterol with nonalcoholic fatty liver disease: a general population-based study. Lipids Health Dis 2021;20:139. [PMID: 34657611 DOI: 10.1186/s12944-021-01573-y] [Reference Citation Analysis]
424 Masarone M, Rosato V, Aglitti A, Bucci T, Caruso R, Salvatore T, Sasso FC, Tripodi MF, Persico M. Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage. PLoS One 2017;12:e0178473. [PMID: 28570615 DOI: 10.1371/journal.pone.0178473] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
425 Hyun J, Jung Y. DNA Methylation in Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E8138. [PMID: 33143364 DOI: 10.3390/ijms21218138] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
426 Patikorn C, Veettil SK, Phisalprapa P, Pham T, Kowdley KV, Chaiyakunapruk N. Horizon scanning of therapeutic modalities for nonalcoholic steatohepatitis. Ann Hepatol 2021;24:100315. [PMID: 33515800 DOI: 10.1016/j.aohep.2021.100315] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
427 Wang N, Wang Y, Zhang W, Chen Y, Chen X, Wang C, Li Q, Chen C, Jiang B, Lu Y. C-peptide is associated with NAFLD inflammatory and fibrotic progression in type 2 diabetes. Diabetes Metab Res Rev 2020;36:e3210. [PMID: 31351021 DOI: 10.1002/dmrr.3210] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
428 Aller R, Fernández-Rodríguez C, Lo Iacono O, Bañares R, Abad J, Carrión JA, García-Monzón C, Caballería J, Berenguer M, Rodríguez-Perálvarez M, Miranda JL, Vilar-Gómez E, Crespo J, García-Cortés M, Reig M, Navarro JM, Gallego R, Genescà J, Arias-Loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-Guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-Gómez M. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. Gastroenterol Hepatol 2018;41:328-49. [PMID: 29631866 DOI: 10.1016/j.gastrohep.2017.12.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
429 Alamri H, Patterson NH, Yang E, Zoroquiain P, Lazaris A, Chaurand P, Metrakos P. Mapping the triglyceride distribution in NAFLD human liver by MALDI imaging mass spectrometry reveals molecular differences in micro and macro steatosis. Anal Bioanal Chem 2019;411:885-94. [PMID: 30515538 DOI: 10.1007/s00216-018-1506-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
430 Johansen P, Howard D, Bishop R, Moreno SI, Buchholtz K. Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements. Pharmacoeconomics 2020;38:485-97. [PMID: 31919793 DOI: 10.1007/s40273-019-00881-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
431 Bianco C, Casirati E, Malvestiti F, Valenti L. Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets. JHEP Rep 2021;3:100284. [PMID: 34027340 DOI: 10.1016/j.jhepr.2021.100284] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
432 Shili-Masmoudi S, Wong GL, Hiriart JB, Liu K, Chermak F, Shu SS, Foucher J, Tse YK, Bernard PH, Yip TC, Merrouche W, Chan HL, Wong VW, de Lédinghen V. Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease. Liver Int 2020;40:581-9. [PMID: 31749300 DOI: 10.1111/liv.14301] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
433 Kumar A, Acharya SK, Singh SP, Arora A, Dhiman RK, Aggarwal R, Anand AC, Bhangui P, Chawla YK, Datta Gupta S, Dixit VK, Duseja A, Kalra N, Kar P, Kulkarni SS, Kumar R, Kumar M, Madhavan R, Mohan Prasad VG, Mukund A, Nagral A, Panda D, Paul SB, Rao PN, Rela M, Sahu MK, Saraswat VA, Shah SR, Shalimar, Sharma P, Taneja S, Wadhawan M; INASL Task-Force on Hepatocellular Carcinoma. 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. J Clin Exp Hepatol 2020;10:43-80. [PMID: 32025166 DOI: 10.1016/j.jceh.2019.09.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
434 Rheinwalt KP, Drebber U, Schierwagen R, Klein S, Neumann UP, Ulmer TF, Plamper A, Kroh A, Schipper S, Odenthal M, Uschner FE, Lingohr P, Trebicka J, Brol MJ. Baseline Presence of NAFLD Predicts Weight Loss after Gastric Bypass Surgery for Morbid Obesity. J Clin Med 2020;9:E3430. [PMID: 33114543 DOI: 10.3390/jcm9113430] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
435 Pereira ENGDS, Silvares RR, Flores EEI, Rodrigues KL, Daliry A. Pyridoxamine improves metabolic and microcirculatory complications associated with nonalcoholic fatty liver disease. Microcirculation. 2020;27:e12603. [PMID: 31876010 DOI: 10.1111/micc.12603] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
436 Ching-Yeung Yu B, Kwok D, Wong VW. Magnitude of Nonalcoholic Fatty Liver Disease: Eastern Perspective. J Clin Exp Hepatol 2019;9:491-6. [PMID: 31516265 DOI: 10.1016/j.jceh.2019.01.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
437 Takahashi S, Tanaka M, Furuhashi M, Moniwa N, Koyama M, Higashiura Y, Osanami A, Gocho Y, Ohnishi H, Numata K, Hisasue T, Hanawa N, Miura T. Fatty liver index is independently associated with deterioration of renal function during a 10-year period in healthy subjects. Sci Rep 2021;11:8606. [PMID: 33883636 DOI: 10.1038/s41598-021-88025-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
438 Dioguardi Burgio M, Ronot M, Reizine E, Rautou P, Castera L, Paradis V, Garteiser P, Van Beers B, Vilgrain V. Quantification of hepatic steatosis with ultrasound: promising role of attenuation imaging coefficient in a biopsy-proven cohort. Eur Radiol 2020;30:2293-301. [DOI: 10.1007/s00330-019-06480-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
439 Kim BJ, Kim HS, Kang JG, Kim BS, Kang JH. Association of epicardial fat volume and nonalcoholic fatty liver disease with metabolic syndrome: From the CAESAR study. Journal of Clinical Lipidology 2016;10:1423-1430.e1. [DOI: 10.1016/j.jacl.2016.09.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
440 Coilly A, Desterke C, Guettier C, Samuel D, Chiappini F. FABP4 and MMP9 levels identified as predictive factors for poor prognosis in patients with nonalcoholic fatty liver using data mining approaches and gene expression analysis. Sci Rep 2019;9:19785. [PMID: 31874999 DOI: 10.1038/s41598-019-56235-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
441 Chen S, Guo H, Xie M, Zhou C, Zheng M. Neutrophil: An emerging player in the occurrence and progression of metabolic associated fatty liver disease. Int Immunopharmacol 2021;97:107609. [PMID: 33887577 DOI: 10.1016/j.intimp.2021.107609] [Reference Citation Analysis]
442 Li J, Le MH, Barakat MT, Cheung RC, Nguyen MH. The Changing Epidemiology of Liver Disease Among US Children and Adolescents From 1999 to 2016. Am J Gastroenterol 2021. [PMID: 34328446 DOI: 10.14309/ajg.0000000000001386] [Reference Citation Analysis]
443 Baik M, Kim SU, Nam HS, Heo JH, Kim YD. The Paradoxical Protective Effect of Liver Steatosis on Severity and Functional Outcome of Ischemic Stroke. Front Neurol 2019;10:375. [PMID: 31031700 DOI: 10.3389/fneur.2019.00375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
444 Choi DH, Jung CH, Mok JO, Kim CH, Kang SK, Kim BY. Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease. Endocrinol Metab (Seoul) 2018;33:387-94. [PMID: 30229578 DOI: 10.3803/EnM.2018.33.3.387] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
445 Feng Y, Chen Y, Yang B, Lan Q, Wang T, Cui G, Ren Z, Choi IC, Leung GP, Yan F, Chen D, Yu HH, Lee SMY. Hepatoprotective Effect of Jianpi Huoxue Formula on Nonalcoholic Fatty Liver Disease Induced by Methionine-Choline-Deficient Diet in Rat. Biomed Res Int 2019;2019:7465272. [PMID: 31355279 DOI: 10.1155/2019/7465272] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
446 Fu S, Yu M, Tan Y, Liu D. Role of histone deacetylase on nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2021;15:353-61. [PMID: 33213187 DOI: 10.1080/17474124.2021.1854089] [Reference Citation Analysis]
447 Lonardo A, Byrne CD, Caldwell SH, Cortez-Pinto H, Targher G. Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:1388-9. [PMID: 27038241 DOI: 10.1002/hep.28584] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 7.2] [Reference Citation Analysis]
448 Zhang K, Meng J, Li X, Tang X, Ma S, Lv Y, Yang S. Noni (Morinda citrifolia L.) wine prevents the oxidative stress and obesity in mice induced by high-fat diet. J Food Biochem 2020;44:e13460. [PMID: 32902870 DOI: 10.1111/jfbc.13460] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
449 Maciejewska-Markiewicz D, Stachowska E, Hawryłkowicz V, Stachowska L, Prowans P. The Role of Resolvins, Protectins and Marensins in Non-Alcoholic Fatty Liver Disease (NAFLD). Biomolecules 2021;11:937. [PMID: 34202667 DOI: 10.3390/biom11070937] [Reference Citation Analysis]
450 Yi HW, Zhu XX, Huang XL, Lai YZ, Tang Y. Selenium-enriched Bifidobacterium longum protected alcohol and high fat diet induced hepatic injury in mice. Chin J Nat Med 2020;18:169-77. [PMID: 32245586 DOI: 10.1016/S1875-5364(20)30018-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
451 Aitharaju V, De Silvestri A, Barr RG. Assessment of chronic liver disease by multiparametric ultrasound: results from a private practice outpatient facility. Abdom Radiol (NY) 2021. [PMID: 34304291 DOI: 10.1007/s00261-021-03225-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
452 Zhou M, Yang N, Xing X, Chang D, Li J, Deng J, Chen Y, Hu C, Zhang R, Lu X, Zhao Y, He Y. Obesity interacts with hyperuricemia on the severity of non-alcoholic fatty liver disease. BMC Gastroenterol 2021;21:43. [PMID: 33509116 DOI: 10.1186/s12876-021-01615-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
453 Pan YJ, Ren X, Zhang YY, Lv J, Zeng QL, Zhang HY, Yu ZJ. IL-17A-mediated ERK1/2/p65 signaling pathway is associated with cell apoptosis after non-alcoholic steatohepatitis. IUBMB Life 2019;71:302-9. [PMID: 30481403 DOI: 10.1002/iub.1960] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
454 Yoneda M, Imajo K, Takahashi H, Ogawa Y, Eguchi Y, Sumida Y, Yoneda M, Kawanaka M, Saito S, Tokushige K, Nakajima A. Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods. J Gastroenterol 2018;53:181-96. [PMID: 29177681 DOI: 10.1007/s00535-017-1414-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 7.6] [Reference Citation Analysis]
455 Li H, Toth E, Cherrington NJ. Asking the Right Questions With Animal Models: Methionine- and Choline-Deficient Model in Predicting Adverse Drug Reactions in Human NASH. Toxicol Sci 2018;161:23-33. [PMID: 29145614 DOI: 10.1093/toxsci/kfx253] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
456 Xiao J, Wang F, Wong NK, He J, Zhang R, Sun R, Xu Y, Liu Y, Li W, Koike K, He W, You H, Miao Y, Liu X, Meng M, Gao B, Wang H, Li C. Global liver disease burdens and research trends: Analysis from a Chinese perspective. J Hepatol. 2019;71:212-221. [PMID: 30871980 DOI: 10.1016/j.jhep.2019.03.004] [Cited by in Crossref: 90] [Cited by in F6Publishing: 85] [Article Influence: 30.0] [Reference Citation Analysis]
457 Serfaty L. Management of patients with non-alcoholic steatohepatitis (NASH) in real life. Liver Int 2018;38 Suppl 1:52-5. [PMID: 29427486 DOI: 10.1111/liv.13637] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
458 de Freitas Diniz TB, de Jesus RN, Jimenez LS, Pareja JC, Chaim EA, Cazzo E. Non-Alcoholic Fatty Liver Disease Is Associated with Impairment of Ejection Fraction Among Individuals with Obesity Undergoing Bariatric Surgery: Results of a Cross-Sectional Study. Obes Surg 2020;30:456-60. [PMID: 31529394 DOI: 10.1007/s11695-019-04179-7] [Reference Citation Analysis]
459 Lv X, Dong Y, Hu L, Lu F, Zhou C, Qin S. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review. Endocrinol Diabetes Metab 2020;3:e00163. [PMID: 32704576 DOI: 10.1002/edm2.163] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
460 Hatton G, Alterio T, Nobili V, Mann JP. Unmet needs in pediatric NAFLD research: what do we need to prioritize for the future? Expert Review of Gastroenterology & Hepatology 2018;12:961-7. [DOI: 10.1080/17474124.2018.1512853] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
461 Miller E, Schmidberger J, Kratzer W. Focal fatty sparing as an indicator of higher-grade fatty liver assessed by attenuation imaging: a prospective clinical study in NAFLD population. Z Gastroenterol 2021. [PMID: 34905800 DOI: 10.1055/a-1695-3637] [Reference Citation Analysis]
462 Xiao L, Liang S, Ge L, Qiu S, Wan H, Wu S, Fei J, Peng S, Zeng X. Si-Wei-Qing-Gan-Tang Improves Non-Alcoholic Steatohepatitis by Modulating the Nuclear Factor-κB Signal Pathway and Autophagy in Methionine and Choline Deficient Diet-Fed Rats. Front Pharmacol 2020;11:530. [PMID: 32425782 DOI: 10.3389/fphar.2020.00530] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
463 Hutton C, Gyngell ML, Milanesi M, Bagur A, Brady M. Validation of a standardized MRI method for liver fat and T2* quantification. PLoS One 2018;13:e0204175. [PMID: 30235288 DOI: 10.1371/journal.pone.0204175] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
464 Demir M, Lang S, Martin A, Farowski F, Wisplinghoff H, Vehreschild MJGT, Krawczyk M, Nowag A, Scholz CJ, Kretzschmar A, Roderburg C, Lammert F, Goeser T, Kasper P, Steffen HM. Phenotyping non-alcoholic fatty liver disease by the gut microbiota: Ready for prime time? J Gastroenterol Hepatol 2020;35:1969-77. [PMID: 32267559 DOI: 10.1111/jgh.15071] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
465 Mori J, Umemura A, Satake W, Cha PC, Suzuki Y, Itoh K, Chiyonobu T. TUBB3 E410K syndrome with childhood-onset non-alcoholic steatohepatitis. J Clin Endocrinol Metab 2021:dgab628. [PMID: 34435630 DOI: 10.1210/clinem/dgab628] [Reference Citation Analysis]
466 Petrov PD, García-Mediavilla MV, Guzmán C, Porras D, Nistal E, Martínez-Flórez S, Castell JV, González-Gallego J, Sánchez-Campos S, Jover R. A Network Involving Gut Microbiota, Circulating Bile Acids, and Hepatic Metabolism Genes That Protects Against Non-Alcoholic Fatty Liver Disease. Mol Nutr Food Res 2019;63:e1900487. [PMID: 31322321 DOI: 10.1002/mnfr.201900487] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
467 Ke F, Xue G, Jiang X, Li F, Lai X, Zhang M, Shen Y, Gao L. Combination of asprosin and adiponectin as a novel marker for diagnosing non-alcoholic fatty liver disease. Cytokine 2020;134:155184. [PMID: 32645536 DOI: 10.1016/j.cyto.2020.155184] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
468 Wong C, Yaow CYL, Ng CH, Chin YH, Low YF, Lim AYL, Muthiah MD, Khoo CM. Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis. Front Endocrinol (Lausanne) 2020;11:609135. [PMID: 33643221 DOI: 10.3389/fendo.2020.609135] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
469 Zhuge B, Li G. MiR-150 deficiency ameliorated hepatosteatosis and insulin resistance in nonalcoholic fatty liver disease via targeting CASP8 and FADD-like apoptosis regulator. Biochemical and Biophysical Research Communications 2017;494:687-92. [DOI: 10.1016/j.bbrc.2017.10.149] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
470 van Cooten VV, de Jong DJ, Wessels FJ, de Jong PA, Kok M. Liver Enhancement on Computed Tomography Is Suboptimal in Patients with Liver Steatosis. J Pers Med 2021;11:1255. [PMID: 34945727 DOI: 10.3390/jpm11121255] [Reference Citation Analysis]
471 Baltieri L, Chaim EA, Chaim FDM, Utrini MP, Gestic MA, Cazzo E. CORRELATION BETWEEN NONALCOHOLIC FATTY LIVER DISEASE FEATURES AND LEVELS OF ADIPOKINES AND INFLAMMATORY CYTOKINES AMONG MORBIDLY OBESE INDIVIDUALS. Arq Gastroenterol 2018;55:247-51. [DOI: 10.1590/s0004-2803.201800000-62] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
472 Luci C, Vieira E, Bourinet M, Rousseau D, Bonnafous S, Patouraux S, Lefevre L, Larbret F, Prod'homme V, Iannelli A, Tran A, Anty R, Bailly-Maitre B, Deckert M, Gual P. SYK-3BP2 Pathway Activity in Parenchymal and Myeloid Cells Is a Key Pathogenic Factor in Metabolic Steatohepatitis. Cell Mol Gastroenterol Hepatol 2021;13:173-91. [PMID: 34411785 DOI: 10.1016/j.jcmgh.2021.08.004] [Reference Citation Analysis]
473 Chen L, Kan J, Zheng N, Li B, Hong Y, Yan J, Tao X, Wu G, Ma J, Zhu W, Sheng L, Chen L, Li B, Zhong J, Du J, Li H. A botanical dietary supplement from white peony and licorice attenuates nonalcoholic fatty liver disease by modulating gut microbiota and reducing inflammation. Phytomedicine 2021;91:153693. [PMID: 34403877 DOI: 10.1016/j.phymed.2021.153693] [Reference Citation Analysis]
474 Bahrami M, Cheraghpour M, Jafarirad S, Alavinejad P, Asadi F, Hekmatdoost A, Mohammadi M, Yari Z. The effect of melatonin on treatment of patients with non-alcoholic fatty liver disease: a randomized double blind clinical trial. Complement Ther Med 2020;52:102452. [PMID: 32951715 DOI: 10.1016/j.ctim.2020.102452] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
475 Koo DJ, Lee MY, Jung I, Moon SJ, Kwon H, Park SE, Rhee EJ, Lee WY. Changes in Insulin Resistance Index and the Risk of Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease without Diabetes: Kangbuk Samsung Health Study. Endocrinol Metab (Seoul) 2021;36:1016-28. [PMID: 34674510 DOI: 10.3803/EnM.2021.1110] [Reference Citation Analysis]
476 Danford CJ, Iriana S, Shen C, Curry MP, Lai M. Evidence of bias during liver transplant evaluation of non-alcoholic steatohepatitis cirrhosis patients. Liver Int 2019;39:1165-73. [PMID: 30809932 DOI: 10.1111/liv.14080] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
477 Kanwal F, Shubrook JH, Younossi Z, Natarajan Y, Bugianesi E, Rinella ME, Harrison SA, Mantzoros C, Pfotenhauer K, Klein S, Eckel RH, Kruger D, El-Serag H, Cusi K. Preparing for the NASH epidemic: A call to action. Metabolism 2021;122:154822. [PMID: 34289945 DOI: 10.1016/j.metabol.2021.154822] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
478 Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, Imajo K, Takahashi H, Eguchi Y, Ono M, Nozaki Y, Hyogo H, Koseki M, Yoshida Y, Kawaguchi T, Kamada Y, Okanoue T, Nakajima A, Jsg-Nafld JSGON. Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. Int J Mol Sci 2020;21:E1907. [PMID: 32168769 DOI: 10.3390/ijms21061907] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
479 Moh Moh MA, Jung C, Lee B, Choi D, Kim B, Kim C, Kang S, Mok J. Association of glucagon-to-insulin ratio and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Diabetes and Vascular Disease Research 2019;16:186-95. [DOI: 10.1177/1479164118810691] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
480 Koletzko L, Mahli A, Hellerbrand C. Development of an in vitro model to study hepatitis C virus effects on hepatocellular lipotoxicity and lipid metabolism. Pathol Res Pract 2018;214:1700-6. [PMID: 30201523 DOI: 10.1016/j.prp.2018.08.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
481 Tripathi DM, Rohilla S, Kaur I, Siddiqui H, Rawal P, Juneja P, Kumar V, Kumari A, Naidu VGM, Ramakrishna S, Banerjee S, Puria R, Sarin SK, Kaur S. Immunonano-Lipocarrier-Mediated Liver Sinusoidal Endothelial Cell-Specific RUNX1 Inhibition Impedes Immune Cell Infiltration and Hepatic Inflammation in Murine Model of NASH. Int J Mol Sci 2021;22:8489. [PMID: 34445195 DOI: 10.3390/ijms22168489] [Reference Citation Analysis]
482 Alves-Bezerra M, Furey N, Johnson CG, Bissig KD. Using CRISPR/Cas9 to model human liver disease. JHEP Rep 2019;1:392-402. [PMID: 32039390 DOI: 10.1016/j.jhepr.2019.09.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
483 Wu Y, Li X, Tan F, Zhou X, Mu J, Zhao X. Lactobacillus fermentum CQPC07 attenuates obesity, inflammation and dyslipidemia by modulating the antioxidant capacity and lipid metabolism in high-fat diet induced obese mice. J Inflamm (Lond) 2021;18:5. [PMID: 33531053 DOI: 10.1186/s12950-021-00272-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
484 Kucukoglu O, Sowa JP, Mazzolini GD, Syn WK, Canbay A. Hepatokines and adipokines in NASH-related hepatocellular carcinoma. J Hepatol. 2021;74:442-457. [PMID: 33161047 DOI: 10.1016/j.jhep.2020.10.030] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
485 Pan L, Huang P, Xie X, Xu J, Guo D, Jiang Y. Reply to "Does MAFLD really increase the severity of COVID-19?". Dig Liver Dis 2021;53:168. [PMID: 33187919 DOI: 10.1016/j.dld.2020.10.034] [Reference Citation Analysis]
486 Han TS, Hur K, Cho HS, Ban HS. Epigenetic Associations between lncRNA/circRNA and miRNA in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E2622. [PMID: 32937886 DOI: 10.3390/cancers12092622] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
487 Chandrasekharan K, Alazawi W. Genetics of Non-Alcoholic Fatty Liver and Cardiovascular Disease: Implications for Therapy? Front Pharmacol 2019;10:1413. [PMID: 31969816 DOI: 10.3389/fphar.2019.01413] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
488 Wongtrakul W, Niltwat S, Charatcharoenwitthaya P. The Effects of Modest Alcohol Consumption on Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 2021;8:744713. [PMID: 34513896 DOI: 10.3389/fmed.2021.744713] [Reference Citation Analysis]
489 Noureddin M, Vipani A, Bresee C, Todo T, Kim IK, Alkhouri N, Setiawan VW, Tran T, Ayoub WS, Lu SC, Klein AS, Sundaram V, Nissen NN. NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances. Am J Gastroenterol. 2018;113:1649-1659. [PMID: 29880964 DOI: 10.1038/s41395-018-0088-6] [Cited by in Crossref: 181] [Cited by in F6Publishing: 167] [Article Influence: 45.3] [Reference Citation Analysis]
490 Mole DJ, Fallowfield JA, Kendall TJ, Welsh F, Semple SI, Bachtiar V, Kelly M, Wigmore SJ, James Garden O, Wilman HR, Banerjee R, Rees M, Brady M. Study protocol: HepaT1ca - an observational clinical cohort study to quantify liver health in surgical candidates for liver malignancies. BMC Cancer 2018;18:890. [PMID: 30208871 DOI: 10.1186/s12885-018-4737-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
491 Kozlitina J. Genetic Risk Factors and Disease Modifiers of Nonalcoholic Steatohepatitis. Gastroenterol Clin North Am 2020;49:25-44. [PMID: 32033763 DOI: 10.1016/j.gtc.2019.09.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
492 Birerdinc A, Younossi ZM. Epigenome-Wide Association Studies Provide Insight into the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. Ann Hepatol 2018;17:11-3. [PMID: 29311407 DOI: 10.5604/01.3001.0010.7530] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
493 Younossi ZM, Stepanova M, Anstee QM, Lawitz EJ, Wai-sun Wong V, Romero-gomez M, Kersey K, Li G, Subramanian GM, Myers RP, Djedjos CS, Okanoue T, Trauner M, Goodman Z, Harrison SA. Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology 2019;17:2552-2560.e10. [DOI: 10.1016/j.cgh.2019.02.024] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
494 Koo DJ, Lee MY, Jung I, Moon SJ, Kwon H, Park SE, Rhee EJ, Lee WY. Baseline homeostasis model assessment of insulin resistance associated with fibrosis progression in patients with nonalcoholic fatty liver disease without diabetes: A cohort study. PLoS One 2021;16:e0255535. [PMID: 34432804 DOI: 10.1371/journal.pone.0255535] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
495 Wang N, Chen C, Zhao L, Chen Y, Han B, Xia F, Cheng J, Li Q, Lu Y. Vitamin D and Nonalcoholic Fatty Liver Disease: Bi-directional Mendelian Randomization Analysis. EBioMedicine 2018;28:187-93. [PMID: 29339098 DOI: 10.1016/j.ebiom.2017.12.027] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
496 McCarron S, Bathon B, Conlon DM, Abbey D, Rader DJ, Gawronski K, Brown CD, Olthoff KM, Shaked A, Raabe TD. Functional Characterization of Organoids Derived From Irreversibly Damaged Liver of Patients With NASH. Hepatology 2021. [PMID: 33901295 DOI: 10.1002/hep.31857] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
497 Bertasso IM, Pietrobon CB, Ribeiro RA, Soares GM, Oliveira JC, Alegre-Maller ACP, Boschero AC, Araújo ACF, Guimarães ATB, Bonfleur ML, Balbo SL. Pregnancy and lactation after Roux-en-Y gastric bypass worsen nonalcoholic fatty liver disease in obese rats and lead to differential programming of hepatic de novo lipogenesis in offspring. J Dev Orig Health Dis 2021;:1-11. [PMID: 33998431 DOI: 10.1017/S2040174421000271] [Reference Citation Analysis]
498 Wang C, Ren L, Chen S, Zheng H, Yang Y, Gu T, Li Y, Wang C. Longdan Xiegan Tang attenuates liver injury and hepatic insulin resistance by regulating the angiotensin-converting enzyme 2/Ang (1-7)/Mas axis-mediated anti-inflammatory pathway in rats. J Ethnopharmacol 2021;274:114072. [PMID: 33781876 DOI: 10.1016/j.jep.2021.114072] [Reference Citation Analysis]
499 Umano GR, Grandone A, Di Sessa A, Cozzolino D, Pedullà M, Marzuillo P, Del Giudice EM. Pediatric obesity-related non-alcoholic fatty liver disease: waist-to-height ratio best anthropometrical predictor. Pediatr Res 2021;90:166-70. [PMID: 33038873 DOI: 10.1038/s41390-020-01192-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
500 Dai W, Zhang Z, Zhao S. The Risk of Type 2 Diabetes and Coronary Artery Disease in Non-obese Patients With Non-alcoholic Fatty Liver Disease: A Cohort Study. Front Cardiovasc Med 2021;8:680664. [PMID: 34490362 DOI: 10.3389/fcvm.2021.680664] [Reference Citation Analysis]
501 Zou Y, Zhong L, Hu C, Sheng G. Association between the alanine aminotransferase/aspartate aminotransferase ratio and new-onset non-alcoholic fatty liver disease in a nonobese Chinese population: a population-based longitudinal study. Lipids Health Dis 2020;19:245. [PMID: 33239040 DOI: 10.1186/s12944-020-01419-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
502 Pan CS, Stanley TL. Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review. Front Endocrinol (Lausanne) 2020;11:70. [PMID: 32153507 DOI: 10.3389/fendo.2020.00070] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
503 Longo M, Zatterale F, Naderi J, Parrillo L, Formisano P, Raciti GA, Beguinot F, Miele C. Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications. Int J Mol Sci 2019;20:E2358. [PMID: 31085992 DOI: 10.3390/ijms20092358] [Cited by in Crossref: 215] [Cited by in F6Publishing: 200] [Article Influence: 71.7] [Reference Citation Analysis]
504 Sasson A, Kristoferson E, Batista R, McClung JA, Abraham NG, Peterson SJ. The pivotal role of heme Oxygenase-1 in reversing the pathophysiology and systemic complications of NAFLD. Arch Biochem Biophys 2021;697:108679. [PMID: 33248947 DOI: 10.1016/j.abb.2020.108679] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
505 Gao Y, Lu J, Liu X, Liu J, Ma Q, Shi Y, Su H. Effect of Long-Term Exercise on Liver Lipid Metabolism in Chinese Patients With NAFLD: A Systematic Review and Meta-Analysis. Front Physiol 2021;12:748517. [PMID: 34880774 DOI: 10.3389/fphys.2021.748517] [Reference Citation Analysis]
506 Kim MJ. Non-alcoholic Fatty Liver Disease, Cardio-metabolic Syndrome and Hypertension: One Concept Fits Multi-systemic Presentations. Korean Circ J 2020;50:706-8. [PMID: 32725977 DOI: 10.4070/kcj.2020.0217] [Reference Citation Analysis]
507 Alqahtani SA, Schattenberg JM. NAFLD in the Elderly. Clin Interv Aging 2021;16:1633-49. [PMID: 34548787 DOI: 10.2147/CIA.S295524] [Reference Citation Analysis]
508 Xanthakos SA. Nonalcoholic steatohepatitis in children with severe obesity: A global concern. Surg Obes Relat Dis 2017;13:1609-11. [PMID: 28935179 DOI: 10.1016/j.soard.2017.06.003] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
509 Cuthbertson DJ, Koskinen J, Brown E, Magnussen CG, Hutri-Kähönen N, Sabin M, Tossavainen P, Jokinen E, Laitinen T, Viikari J, Raitakari OT, Juonala M. Fatty liver index predicts incident risk of prediabetes, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). Ann Med 2021;53:1256-64. [PMID: 34309471 DOI: 10.1080/07853890.2021.1956685] [Reference Citation Analysis]
510 Wong VW, Chan WK, Chitturi S, Chawla Y, Dan YY, Duseja A, Fan J, Goh KL, Hamaguchi M, Hashimoto E, Kim SU, Lesmana LA, Lin YC, Liu CJ, Ni YH, Sollano J, Wong SK, Wong GL, Chan HL, Farrell G. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33:70-85. [PMID: 28670712 DOI: 10.1111/jgh.13857] [Cited by in Crossref: 165] [Cited by in F6Publishing: 154] [Article Influence: 55.0] [Reference Citation Analysis]
511 Cariello M, Piccinin E, Moschetta A. Transcriptional Regulation of Metabolic Pathways via Lipid-Sensing Nuclear Receptors PPARs, FXR, and LXR in NASH. Cell Mol Gastroenterol Hepatol 2021;11:1519-39. [PMID: 33545430 DOI: 10.1016/j.jcmgh.2021.01.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
512 Liu J, Guan L, Zhao M, Li Q, Song A, Gao L, Lin H, Zhao J. Association Between the Triglyceride-Glucose Index and Outcomes of Nonalcoholic Fatty Liver Disease: A Large-Scale Health Management Cohort Study. Diabetes Metab Syndr Obes 2021;14:2829-39. [PMID: 34188506 DOI: 10.2147/DMSO.S316864] [Reference Citation Analysis]
513 Torres-Peña JD, Martín-Piedra L, Fuentes-Jiménez F. Statins in Non-alcoholic Steatohepatitis. Front Cardiovasc Med 2021;8:777131. [PMID: 34901236 DOI: 10.3389/fcvm.2021.777131] [Reference Citation Analysis]
514 Liu Y, Zhang D, Liu G, Chen Q, Lu Z. Ameliorative effect of dieckol-enriched extraction from Laminaria japonica on hepatic steatosis induced by a high-fat diet via β-oxidation pathway in ICR mice. Journal of Functional Foods 2019;58:44-55. [DOI: 10.1016/j.jff.2019.04.051] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
515 Kessoku T, Kobayashi T, Imajo K, Tanaka K, Yamamoto A, Takahashi K, Kasai Y, Ozaki A, Iwaki M, Nogami A, Honda Y, Ogawa Y, Kato S, Higurashi T, Hosono K, Yoneda M, Okamoto T, Usuda H, Wada K, Kobayashi N, Saito S, Nakajima A. Endotoxins and Non-Alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne) 2021;12:770986. [PMID: 34777261 DOI: 10.3389/fendo.2021.770986] [Reference Citation Analysis]
516 Tobari M, Hashimoto E, Taniai M, Ikarashi Y, Kodama K, Kogiso T, Tokushige K, Takayoshi N, Hashimoto N. Characteristics of non-alcoholic steatohepatitis among lean patients in Japan: Not uncommon and not always benign. J Gastroenterol Hepatol. 2019;34:1404-1410. [PMID: 30590868 DOI: 10.1111/jgh.14585] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
517 Ghoshal UC, Goel A, Quigley EMM. Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: An emerging paradigm. Indian J Gastroenterol 2020;39:9-21. [PMID: 32291578 DOI: 10.1007/s12664-020-01027-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
518 Biberci Keskin E, Coban G. Evaluation of Liver Biopsy Findings and Comparison with Noninvasive Fibrosis Scores in Patients with Non-Alcoholic Steatohepatitis. Medeni Med J 2019;34:354-9. [PMID: 32821461 DOI: 10.5222/MMJ.2019.48640] [Reference Citation Analysis]
519 Okamoto K, Koda M, Okamoto T, Onoyama T, Miyoshi K, Kishina M, Matono T, Kato J, Tokunaga S, Sugihara T, Hiramatsu A, Hyogo H, Tobita H, Sato S, Kawanaka M, Hara Y, Hino K, Chayama K, Murawaki Y, Isomoto H. Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease. PLoS One 2020;15:e0219412. [PMID: 32106257 DOI: 10.1371/journal.pone.0219412] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
520 Pedroso JAB, Camporez JP, Belpiede LT, Pinto RS, Cipolla-Neto J, Donato J Jr. Evaluation of Hepatic Steatosis in Rodents by Time-Domain Nuclear Magnetic Resonance. Diagnostics (Basel) 2019;9:E198. [PMID: 31756971 DOI: 10.3390/diagnostics9040198] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
521 Liu K, Xu W, Wong VW. Serum biomarkers for nonalcoholic fatty liver disease: Are we there yet? Hepatology 2017;65:8-11. [PMID: 27639247 DOI: 10.1002/hep.28840] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
522 Zamani-garmsiri F, Hashemnia SMR, Shabani M, Bagherieh M, Emamgholipour S, Meshkani R. Combination of metformin and genistein alleviates non-alcoholic fatty liver disease in high-fat diet-fed mice. The Journal of Nutritional Biochemistry 2021;87:108505. [DOI: 10.1016/j.jnutbio.2020.108505] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
523 Stroffolini T, Sagnelli E, Sagnelli C, Morisco F, Babudieri S, Furlan C, Pirisi M, Russello M, Smedile A, Pisaturo M, Almasio PL. Decreasing role of HCV and HBV infections as aetiological factors of hepatocellular carcinoma in Italy. Infection. 2019;. [PMID: 31028627 DOI: 10.1007/s15010-019-01308-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
524 Lee M, Kim KJ, Chung TH, Bae J, Lee YH, Lee BW, Cha BS, Yun M, Kang ES. Nonalcoholic fatty liver disease, diastolic dysfunction, and impaired myocardial glucose uptake in patients with type 2 diabetes. Diabetes Obes Metab 2021;23:1041-51. [PMID: 33394549 DOI: 10.1111/dom.14310] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
525 Schuppan D, Surabattula R, Wang XY. Determinants of fibrosis progression and regression in NASH. J Hepatol. 2018;68:238-250. [PMID: 29154966 DOI: 10.1016/j.jhep.2017.11.012] [Cited by in Crossref: 160] [Cited by in F6Publishing: 151] [Article Influence: 32.0] [Reference Citation Analysis]
526 VanWagner LB, Armstrong MJ. Lean NAFLD: A not so benign condition? Hepatol Commun 2018;2:5-8. [PMID: 29404505 DOI: 10.1002/hep4.1143] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
527 Liang Y, Zhang Y, Deng Y, Liang S, He Y, Chen Y, Liu C, Lin C, Han L, Tu G, Yang Q. Chaihu-Shugan-San Decoction Modulates Intestinal Microbe Dysbiosis and Alleviates Chronic Metabolic Inflammation in NAFLD Rats via the NLRP3 Inflammasome Pathway. Evid Based Complement Alternat Med 2018;2018:9390786. [PMID: 30105078 DOI: 10.1155/2018/9390786] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
528 Viglino D, Jullian-desayes I, Minoves M, Aron-wisnewsky J, Leroy V, Zarski J, Tamisier R, Joyeux-faure M, Pépin J. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease. Eur Respir J 2017;49:1601923. [DOI: 10.1183/13993003.01923-2016] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
529 Zhai M, Liu Z, Long J, Zhou Q, Yang L, Zhou Q, Liu S, Dai Y. The incidence trends of liver cirrhosis caused by nonalcoholic steatohepatitis via the GBD study 2017. Sci Rep 2021;11:5195. [PMID: 33664363 DOI: 10.1038/s41598-021-84577-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
530 Zhou D, Pan Q, Xin FZ, Zhang RN, He CX, Chen GY, Liu C, Chen YW, Fan JG. Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier. World J Gastroenterol 2017; 23(1): 60-75 [PMID: 28104981 DOI: 10.3748/wjg.v23.i1.60] [Cited by in CrossRef: 127] [Cited by in F6Publishing: 113] [Article Influence: 25.4] [Reference Citation Analysis]
531 Zhao J, Nishiumi S, Tagawa R, Yano Y, Inoue J, Hoshi N, Yoshida M, Kodama Y. Adrenic acid induces oxidative stress in hepatocytes. Biochem Biophys Res Commun 2020;532:620-5. [PMID: 32900489 DOI: 10.1016/j.bbrc.2020.08.102] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
532 Li L, Xie P, Lin W, Liu J, Chen J, Guo Z, Bin C, An W, Zhang C, Zhan Y. CKIP-1 augments autophagy in steatotic hepatocytes by inhibiting Akt/mTOR signal pathway. Exp Cell Res 2020;397:112341. [PMID: 33191205 DOI: 10.1016/j.yexcr.2020.112341] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
533 Assimakopoulos K, Karaivazoglou K, Tsermpini EE, Diamantopoulou G, Triantos C. Quality of life in patients with nonalcoholic fatty liver disease: A systematic review. J Psychosom Res 2018;112:73-80. [PMID: 30097139 DOI: 10.1016/j.jpsychores.2018.07.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
534 Galarregui C, Marin-Alejandre BA, Perez-Diaz-Del-Campo N, Cantero I, Monreal JI, Elorz M, Benito-Boillos A, Herrero JI, Tur JA, Martínez JA, Zulet MA, Abete I. Predictive Value of Serum Ferritin in Combination with Alanine Aminotransferase and Glucose Levels for Noninvasive Assessment of NAFLD: Fatty Liver in Obesity (FLiO) Study. Diagnostics (Basel) 2020;10:E917. [PMID: 33171699 DOI: 10.3390/diagnostics10110917] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
535 Ma K, Tang D, Yu C, Zhao L. Progress in research on the roles of TGR5 receptor in liver diseases. Scand J Gastroenterol 2021;56:717-26. [PMID: 33771073 DOI: 10.1080/00365521.2021.1903547] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
536 Younossi ZM, Stepanova M, Younossi Y, Golabi P, Mishra A, Rafiq N, Henry L. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut 2020;69:564-8. [DOI: 10.1136/gutjnl-2019-318813] [Cited by in Crossref: 83] [Cited by in F6Publishing: 69] [Article Influence: 27.7] [Reference Citation Analysis]
537 Park H, Lee SJ. Working hours and nonalcoholic fatty liver disease according to sleep duration. Chronobiol Int 2019;36:1671-80. [PMID: 31581841 DOI: 10.1080/07420528.2019.1670671] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
538 Bergram M, Nasr P, Iredahl F, Kechagias S, Rådholm K, Ekstedt M. Low awareness of non-alcoholic fatty liver disease in patients with type 2 diabetes in Swedish Primary Health Care. Scand J Gastroenterol 2021;:1-10. [PMID: 34618619 DOI: 10.1080/00365521.2021.1984572] [Reference Citation Analysis]
539 França LM, Dos Santos PC, Barroso WA, Gondim RSD, Coêlho CFF, Flister KFT, Paes AMA. Post-weaning exposure to high-sucrose diet induces early non-alcoholic fatty liver disease onset and progression in male mice: role of dysfunctional white adipose tissue. J Dev Orig Health Dis 2020;11:509-20. [PMID: 32594969 DOI: 10.1017/S2040174420000598] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
540 Gamede M, Mabuza L, Ngubane P, Khathi A. Plant-derived oleanolic acid ameliorates markers associated with non-alcoholic fatty liver disease in a diet-induced pre-diabetes rat model. Diabetes Metab Syndr Obes 2019;12:1953-62. [PMID: 31632109 DOI: 10.2147/DMSO.S218626] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
541 Brunner KT, Pedley A, Massaro JM, Hoffmann U, Benjamin EJ, Long MT. Increasing liver fat is associated with progression of cardiovascular risk factors. Liver Int 2020;40:1339-43. [PMID: 32301571 DOI: 10.1111/liv.14472] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
542 Hu D, Xu Y, Xie J, Sun C, Zheng X, Chen W. Systematic evaluation of phenolic compounds and protective capacity of a new mulberry cultivar J33 against palmitic acid-induced lipotoxicity using a simulated digestion method. Food Chemistry 2018;258:43-50. [DOI: 10.1016/j.foodchem.2018.03.049] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 13.3] [Reference Citation Analysis]
543 Lim JJ, Dutta M, Dempsey JL, Lehmler HJ, MacDonald J, Bammler T, Walker C, Kavanagh TJ, Gu H, Mani S, Cui JY. Neonatal Exposure to BPA, BDE-99, and PCB Produces Persistent Changes in Hepatic Transcriptome Associated With Gut Dysbiosis in Adult Mouse Livers. Toxicol Sci 2021;184:83-103. [PMID: 34453844 DOI: 10.1093/toxsci/kfab104] [Reference Citation Analysis]
544 Gajos A, Tapper EB. The Role of Advanced Practice Providers in the Care of Nonalcoholic Fatty Liver Disease. Clin Ther 2021;43:518-23. [PMID: 33388173 DOI: 10.1016/j.clinthera.2020.12.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
545 Wong S, Chan W. Epidemiology of non-alcoholic fatty liver disease in Asia. Indian J Gastroenterol 2020;39:1-8. [DOI: 10.1007/s12664-020-01018-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
546 Lu H, Yuan X, Zhang Y, Han M, Liu S, Han K, Liang P, Cheng J. HCBP6 deficiency exacerbates glucose and lipid metabolism disorders in non-alcoholic fatty liver mice. Biomed Pharmacother 2020;129:110347. [PMID: 32535386 DOI: 10.1016/j.biopha.2020.110347] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
547 Lee YN, Chowdhury TA. Diabetes: an Overview for Clinical Oncologists. Clin Oncol (R Coll Radiol) 2020;32:579-90. [PMID: 32299722 DOI: 10.1016/j.clon.2020.03.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
548 Huang Z, Wang M, Liu L, Peng J, Guo C, Chen X, Huang L, Tan J, Yang G. Transcriptional Repression of CYP3A4 by Increased miR-200a-3p and miR-150-5p Promotes Steatosis in vitro. Front Genet 2019;10:484. [PMID: 31191607 DOI: 10.3389/fgene.2019.00484] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
549 Takahashi H, Kotani K, Tanaka K, Egucih Y, Anzai K. Therapeutic Approaches to Nonalcoholic Fatty Liver Disease: Exercise Intervention and Related Mechanisms. Front Endocrinol (Lausanne). 2018;9:588. [PMID: 30374329 DOI: 10.3389/fendo.2018.00588] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
550 Hrncir T, Hrncirova L, Kverka M, Hromadka R, Machova V, Trckova E, Kostovcikova K, Kralickova P, Krejsek J, Tlaskalova-Hogenova H. Gut Microbiota and NAFLD: Pathogenetic Mechanisms, Microbiota Signatures, and Therapeutic Interventions. Microorganisms 2021;9:957. [PMID: 33946843 DOI: 10.3390/microorganisms9050957] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
551 Kamimura H, Kimura A, Terai S. Potential Effect of a Selective Peroxisome Proliferator-activated Receptor Alpha Modulator on Metabolic Dysfunction-associated Fatty Liver Disease. Intern Med 2021;60:2165-6. [PMID: 33612688 DOI: 10.2169/internalmedicine.6906-20] [Reference Citation Analysis]
552 Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol 2018;14:99-114. [DOI: 10.1038/nrendo.2017.173] [Cited by in Crossref: 142] [Cited by in F6Publishing: 122] [Article Influence: 28.4] [Reference Citation Analysis]
553 Ahadi M, Molooghi K, Masoudifar N, Namdar AB, Vossoughinia H, Farzanehfar M. A review of non-alcoholic fatty liver disease in non-obese and lean individuals. J Gastroenterol Hepatol 2021;36:1497-507. [PMID: 33217052 DOI: 10.1111/jgh.15353] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
554 Zhang C, Wang P, Li Y, Huang C, Ni W, Chen Y, Shi J, Chen G, Hu X, Ye M, Duan S, Wang K. Role of MicroRNAs in the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Anat Rec (Hoboken) 2019;302:193-200. [PMID: 30312023 DOI: 10.1002/ar.23954] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
555 Mori S, Arima N, Ito M, Fujiyama S, Kamo Y, Ueki Y. Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment. PLoS One 2018;13:e0203084. [PMID: 30142184 DOI: 10.1371/journal.pone.0203084] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
556 Wu Y, Li H, Guo X, Yoshida EM, Mendez-Sanchez N, Levi Sandri GB, Teschke R, Romeiro FG, Shukla A, Qi X. Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis. Hepatol Int. 2020;14:621-637. [PMID: 32710250 DOI: 10.1007/s12072-020-10074-6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 18.5] [Reference Citation Analysis]
557 Li B, Chen PY, Tan YF, Huang H, Jiang M, Wu ZR, Jiang CH, Zheng DF, He D, Shi YJ, Luo Y, Yang JY. Standard liver weight model in adult deceased donors with fatty liver: A prospective cohort study. World J Gastroenterol 2021; 27(39): 6701-6714 [PMID: 34754162 DOI: 10.3748/wjg.v27.i39.6701] [Reference Citation Analysis]
558 Foerster F, Gairing SJ, Müller L, Galle PR. NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. J Hepatol 2021:S0168-8278(21)02037-7. [PMID: 34555422 DOI: 10.1016/j.jhep.2021.09.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
559 Jeong SW. Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming. Diabetes Metab J. 2020;44:640-657. [PMID: 33115209 DOI: 10.4093/dmj.2020.0115] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
560 Altay O, Nielsen J, Uhlen M, Boren J, Mardinoglu A. Systems biology perspective for studying the gut microbiota in human physiology and liver diseases. EBioMedicine 2019;49:364-73. [PMID: 31636011 DOI: 10.1016/j.ebiom.2019.09.057] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
561 Han E, Kim MK, Jang BK, Kim HS. Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. Diabetes Metab J 2021;45:698-707. [PMID: 33517613 DOI: 10.4093/dmj.2020.0118] [Reference Citation Analysis]
562 Li Y, He F, He Y, Pan X, Wu Y, Hu Z, Lin X, Xu S, Peng XE. Dose-response association between physical activity and non-alcoholic fatty liver disease: a case-control study in a Chinese population. BMJ Open 2019;9:e026854. [PMID: 30928957 DOI: 10.1136/bmjopen-2018-026854] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
563 Li G, Zhou F, Chen Y, Zhang W, Wang N. Kukoamine A attenuates insulin resistance and fatty liver through downregulation of Srebp-1c. Biomed Pharmacother. 2017;89:536-543. [PMID: 28254666 DOI: 10.1016/j.biopha.2017.02.024] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
564 Blériot C, Barreby E, Dunsmore G, Ballaire R, Chakarov S, Ficht X, De Simone G, Andreata F, Fumagalli V, Guo W, Wan G, Gessain G, Khalilnezhad A, Zhang XM, Ang N, Chen P, Morgantini C, Azzimato V, Kong WT, Liu Z, Pai R, Lum J, Shihui F, Low I, Xu C, Malleret B, Kairi MFM, Balachander A, Cexus O, Larbi A, Lee B, Newell EW, Ng LG, Phoo WW, Sobota RM, Sharma A, Howland SW, Chen J, Bajenoff M, Yvan-Charvet L, Venteclef N, Iannacone M, Aouadi M, Ginhoux F. A subset of Kupffer cells regulates metabolism through the expression of CD36. Immunity 2021;54:2101-2116.e6. [PMID: 34469775 DOI: 10.1016/j.immuni.2021.08.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
565 Gutiérrez-Cuevas J, Santos A, Armendariz-Borunda J. Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases. Int J Mol Sci 2021;22:11629. [PMID: 34769060 DOI: 10.3390/ijms222111629] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
566 Li L, Zheng W, Wang C, Qi J, Li H. Mogroside V Protects against Hepatic Steatosis in Mice on a High-Fat Diet and LO2 Cells Treated with Free Fatty Acids via AMPK Activation. Evid Based Complement Alternat Med 2020;2020:7826874. [PMID: 32419825 DOI: 10.1155/2020/7826874] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
567 Godin O, Leboyer M, Belzeaux R, Bellivier F, Loftus J, Courtet P, Dubertret C, Gard S, Henry C, Llorca PM, Schwan R, Passerieux C, Polosan M, Samalin L, Olié E, Etain B; FondaMental Advanced Centers of Expertise in Bipolar Disorders (FACE-BD) Collaborators. Non-alcoholic fatty liver disease in a sample of individuals with bipolar disorders: results from the FACE-BD cohort. Acta Psychiatr Scand 2021;143:82-91. [PMID: 33011976 DOI: 10.1111/acps.13239] [Reference Citation Analysis]
568 Park E, Jeong JJ, Won SM, Sharma SP, Gebru YA, Ganesan R, Gupta H, Suk KT, Kim DJ. Gut Microbiota-Related Cellular and Molecular Mechanisms in the Progression of Nonalcoholic Fatty Liver Disease. Cells 2021;10:2634. [PMID: 34685614 DOI: 10.3390/cells10102634] [Reference Citation Analysis]
569 Ekstedt M, Nasr P, Kechagias S. Natural History of NAFLD/NASH. Curr Hepatol Rep. 2017;16:391-397. [PMID: 29984130 DOI: 10.1007/s11901-017-0378-2] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 10.2] [Reference Citation Analysis]
570 Maurice JB, Garvey L, Tsochatzis EA, Wiltshire M, Cooke G, Guppy N, McDonald J, Marchesi J, Nelson M, Kelleher P, Goldin R, Thursz M, Lemoine M. Monocyte-macrophage activation is associated with nonalcoholic fatty liver disease and liver fibrosis in HIV monoinfection independently of the gut microbiome and bacterial translocation. AIDS 2019;33:805-14. [PMID: 30882489 DOI: 10.1097/QAD.0000000000002133] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
571 Marlicz W, Skonieczna-Żydecka K, Dabos KJ, Łoniewski I, Koulaouzidis A. Emerging concepts in non-invasive monitoring of Crohn's disease. Therap Adv Gastroenterol 2018;11:1756284818769076. [PMID: 29707039 DOI: 10.1177/1756284818769076] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
572 Beier JI, Banales JM. Pyroptosis: An inflammatory link between NAFLD and NASH with potential therapeutic implications. J Hepatol. 2018;68:643-645. [PMID: 29408544 DOI: 10.1016/j.jhep.2018.01.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 6.5] [Reference Citation Analysis]
573 Liu WY, Eslam M, Zheng KI, Ma HL, Rios RS, Lv MZ, Li G, Tang LJ, Zhu PW, Wang XD, Byrne CD, Targher G, George J, Zheng MH. Associations of Hydroxysteroid 17-beta Dehydrogenase 13 Variants with Liver Histology in Chinese Patients with Metabolic-associated Fatty Liver Disease. J Clin Transl Hepatol 2021;9:194-202. [PMID: 34007801 DOI: 10.14218/JCTH.2020.00151] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
574 Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet 2021;398:1359-76. [PMID: 34543610 DOI: 10.1016/S0140-6736(21)01374-X] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
575 Cheng HS, Rademaker M. Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: utility of transient elastography. Psoriasis (Auckl) 2018;8:21-9. [PMID: 29785393 DOI: 10.2147/PTT.S141629] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
576 Idilman IS, Low HM, Gidener T, Philbrick K, Mounajjed T, Li J, Allen AM, Yin M, Venkatesh SK. Association between Visceral Adipose Tissue and Non-Alcoholic Steatohepatitis Histology in Patients with Known or Suspected Non-Alcoholic Fatty Liver Disease. J Clin Med 2021;10:2565. [PMID: 34200525 DOI: 10.3390/jcm10122565] [Reference Citation Analysis]
577 Safari Z, Gérard P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol Life Sci 2019;76:1541-58. [PMID: 30683985 DOI: 10.1007/s00018-019-03011-w] [Cited by in Crossref: 101] [Cited by in F6Publishing: 91] [Article Influence: 33.7] [Reference Citation Analysis]
578 Guillaume M, Moal V, Delabaudiere C, Zuberbuhler F, Robic MA, Lannes A, Metivier S, Oberti F, Gourdy P, Fouchard-Hubert I, Selves J, Michalak S, Peron JM, Cales P, Bureau C, Boursier J. Direct comparison of the specialised blood fibrosis tests FibroMeterV2G and Enhanced Liver Fibrosis score in patients with non-alcoholic fatty liver disease from tertiary care centres. Aliment Pharmacol Ther 2019;50:1214-22. [PMID: 31617224 DOI: 10.1111/apt.15529] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
579 Younossi ZM, Stepanova M, Ong J, Yilmaz Y, Duseja A, Eguchi Y, El Kassas M, Castellanos-fernandez M, George J, Jacobson IM, Bugianesi E, Wong VW, Arrese M, de Ledinghen V, Romero-gomez M, Mendez-sanchez N, Ahmed A, Wong R, Papatheodoridis G, Serfaty L, Younossi I, Nader F, Ziayee M, Afendy A. Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. Clinical Gastroenterology and Hepatology 2019;17:1625-1633.e1. [DOI: 10.1016/j.cgh.2018.11.033] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 14.7] [Reference Citation Analysis]
580 Schwenger KJP, Kiu A, AlAli M, Alhanaee A, Fischer SE, Allard JP. Comparison of bioelectrical impedance analysis, mass index, and waist circumference in assessing risk for non-alcoholic steatohepatitis. Nutrition 2021;93:111491. [PMID: 34739937 DOI: 10.1016/j.nut.2021.111491] [Reference Citation Analysis]
581 Ok DP, Ko K, Bae JY. Exercise without dietary changes alleviates nonalcoholic fatty liver disease without weight loss benefits. Lipids Health Dis 2018;17:207. [PMID: 30172252 DOI: 10.1186/s12944-018-0852-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
582 Bruinstroop E, Zhou J, Tripathi M, Yau WW, Boelen A, Singh BK, Yen PM. Early induction of hepatic deiodinase type 1 inhibits hepatosteatosis during NAFLD progression. Mol Metab 2021;53:101266. [PMID: 34098145 DOI: 10.1016/j.molmet.2021.101266] [Reference Citation Analysis]
583 Oka A, Ishimura N, Ishihara S. A New Dawn for the Use of Artificial Intelligence in Gastroenterology, Hepatology and Pancreatology. Diagnostics (Basel) 2021;11:1719. [PMID: 34574060 DOI: 10.3390/diagnostics11091719] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
584 Reza MI, Syed AA, Singh P, Husain A, Gayen JR. Pancreastatin induces hepatic steatosis in type 2 diabetes by impeding mitochondrial functioning. Life Sci 2021;284:119905. [PMID: 34453940 DOI: 10.1016/j.lfs.2021.119905] [Reference Citation Analysis]
585 Zou Y, Zhong L, Hu C, Zhong M, Peng N, Sheng G. LDL/HDL cholesterol ratio is associated with new-onset NAFLD in Chinese non-obese people with normal lipids: a 5-year longitudinal cohort study. Lipids Health Dis 2021;20:28. [PMID: 33766067 DOI: 10.1186/s12944-021-01457-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
586 Lonardo A, Ballestri S, Targher G. “ Not all forms of NAFLD were created equal ”. Do metabolic syndrome-related NAFLD and PNPLA3 -related NAFLD exert a variable impact on the risk of early carotid atherosclerosis? Atherosclerosis 2017;257:253-5. [DOI: 10.1016/j.atherosclerosis.2017.01.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
587 Liu J, Ayada I, Zhang X, Wang L, Li Y, Wen T, Ma Z, Bruno MJ, de Knegt RJ, Cao W, Peppelenbosch MP, Ghanbari M, Li Z, Pan Q. Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00208-1. [PMID: 33618024 DOI: 10.1016/j.cgh.2021.02.030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
588 Taneja S, Roy A. Nonalcoholic steatohepatitis recurrence after liver transplant. Transl Gastroenterol Hepatol 2020;5:24. [PMID: 32258528 DOI: 10.21037/tgh.2019.10.12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
589 Haaker MW, Kruitwagen HS, Vaandrager AB, Houweling M, Penning LC, Molenaar MR, van Wolferen ME, Oosterhoff LA, Spee B, Helms JB. Identification of potential drugs for treatment of hepatic lipidosis in cats using an in vitro feline liver organoid system. J Vet Intern Med 2020;34:132-8. [PMID: 31830357 DOI: 10.1111/jvim.15670] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
590 Liu Z, Suo C, Shi O, Lin C, Zhao R, Yuan H, Jin L, Zhang T, Chen X. The Health Impact of MAFLD, a Novel Disease Cluster of NAFLD, Is Amplified by the Integrated Effect of Fatty Liver Disease–Related Genetic Variants. Clinical Gastroenterology and Hepatology 2020. [DOI: 10.1016/j.cgh.2020.12.033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
591 de Mello VD, Matte A, Perfilyev A, Männistö V, Rönn T, Nilsson E, Käkelä P, Ling C, Pihlajamäki J. Human liver epigenetic alterations in non-alcoholic steatohepatitis are related to insulin action. Epigenetics 2017;12:287-95. [PMID: 28277977 DOI: 10.1080/15592294.2017.1294305] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
592 Cebola I. Liver gene regulatory networks: Contributing factors to nonalcoholic fatty liver disease. Wiley Interdiscip Rev Syst Biol Med 2020;12:e1480. [PMID: 32020788 DOI: 10.1002/wsbm.1480] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
593 Jin S, Jiang S, Hu A. Association between obstructive sleep apnea and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Sleep Breath. 2018;22:841-851. [PMID: 29335916 DOI: 10.1007/s11325-018-1625-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
594 Huang YZ, Yang GY, Wang C, Chen XY, Zhang LL. Effectiveness of drug interventions in nonalcoholic fatty liver disease: A network meta-analysis. World J Diabetes 2021; 12(9): 1576-1586 [PMID: 34630909 DOI: 10.4239/wjd.v12.i9.1576] [Reference Citation Analysis]
595 Lin C, Kao J. Review article: the prevention of hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 2018;48:5-14. [DOI: 10.1111/apt.14683] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
596 Sun YD, Zhang H, Chen YQ, Wu CX, Chen ML, Xu HR, Wang S, Liu JZ, Han JJ. Overweight with HBV infection limited the efficacy of TACE in hepatocellular carcinoma by inhibiting the upregulated HMGB1. BMC Cancer 2021;21:1063. [PMID: 34583662 DOI: 10.1186/s12885-021-08783-8] [Reference Citation Analysis]
597 Wu K, Zhai MZ, Weltzien EK, Cespedes Feliciano EM, Meyerhardt JA, Giovannucci E, Caan BJ. Non-alcoholic fatty liver disease and colorectal cancer survival. Cancer Causes Control 2019;30:165-8. [PMID: 30443695 DOI: 10.1007/s10552-018-1095-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
598 Tapper EB, Chhatwal J. We are Not Meeting the Needs of Pharmacoeconomic Models of Nonalcoholic Steatohepatitis, But We Can. Pharmacoeconomics 2020;38:427-9. [PMID: 32086769 DOI: 10.1007/s40273-020-00892-9] [Reference Citation Analysis]
599 Su Z, Guo Y, Huang X, Feng B, Tang L, Zheng G, Zhu Y. Phytochemicals: Targeting Mitophagy to Treat Metabolic Disorders. Front Cell Dev Biol 2021;9:686820. [PMID: 34414181 DOI: 10.3389/fcell.2021.686820] [Reference Citation Analysis]
600 Chinnadurai R, Ritchie J, Green D, Kalra PA. Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease. Nephrology Dialysis Transplantation 2019;34:449-57. [DOI: 10.1093/ndt/gfx381] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
601 Durand M, Coué M, Croyal M, Moyon T, Tesse A, Atger F, Ouguerram K, Jacobi D. Changes in Key Mitochondrial Lipids Accompany Mitochondrial Dysfunction and Oxidative Stress in NAFLD. Oxid Med Cell Longev 2021;2021:9986299. [PMID: 34257827 DOI: 10.1155/2021/9986299] [Reference Citation Analysis]
602 Wu J, Zeng C, Yang Z, Li X, Lei G, Xie D, Wang Y, Wei J, Yang T. Association Between Dietary Selenium Intake and the Prevalence of Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study.J Am Coll Nutr. 2020;39:103-111. [PMID: 31157605 DOI: 10.1080/07315724.2019.1613271] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
603 Zhang J, Li K, Pan L, Teng F, Zhang P, Lin B, Yuan Y, Wei X, Li W, Zhang H. Association of circulating adipsin with nonalcoholic fatty liver disease in obese adults: a cross-sectional study. BMC Gastroenterol 2021;21:131. [PMID: 33743586 DOI: 10.1186/s12876-021-01721-9] [Reference Citation Analysis]
604 Senussi NH, McCarthy DM. Simultaneous Metabolic and Alcohol-associated Fatty Liver Disease (SMAFLD) and Simultaneous Metabolic and Alcohol-associated Steatohepatitis (SMASH). Ann Hepatol 2021;24:100526. [PMID: 34509272 DOI: 10.1016/j.aohep.2021.100526] [Reference Citation Analysis]
605 Zhou R, Llorente C, Cao J, Zaramela LS, Zeng S, Gao B, Li SZ, Welch RD, Huang FQ, Qi LW, Pan C, Huang Y, Zhou P, Beussen I, Zhang Y, Bryam G, Fiehn O, Wang L, Liu EH, Yu RT, Downes M, Evans RM, Goglin K, Fouts DE, Brenner DA, Bode L, Fan X, Zengler K, Schnabl B. Intestinal α1-2-Fucosylation Contributes to Obesity and Steatohepatitis in Mice. Cell Mol Gastroenterol Hepatol 2021;12:293-320. [PMID: 33631374 DOI: 10.1016/j.jcmgh.2021.02.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
606 Aragonès G, Auguet T, Armengol S, Berlanga A, Guiu-Jurado E, Aguilar C, Martínez S, Sabench F, Porras JA, Ruiz MD, Hernández M, Sirvent JJ, Del Castillo D, Richart C. PNPLA3 Expression Is Related to Liver Steatosis in Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2016;17:E630. [PMID: 27128907 DOI: 10.3390/ijms17050630] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
607 Bayliss J, Ooi GJ, De Nardo W, Shah YJH, Montgomery MK, McLean C, Kemp W, Roberts SK, Brown WA, Burton PR, Watt MJ. Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes. Front Endocrinol (Lausanne) 2021;12:642432. [PMID: 33746906 DOI: 10.3389/fendo.2021.642432] [Reference Citation Analysis]
608 Chang J, Koseki M, Saga A, Kanno K, Higo T, Okuzaki D, Okada T, Inui H, Tanaka K, Asaji M, Zhu Y, Kamada Y, Ono M, Saibara T, Ichi I, Ohama T, Nishida M, Yamashita S, Sakata Y. Dietary Oxysterol, 7-Ketocholesterol Accelerates Hepatic Lipid Accumulation and Macrophage Infiltration in Obese Mice. Front Endocrinol (Lausanne) 2020;11:614692. [PMID: 33776901 DOI: 10.3389/fendo.2020.614692] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
609 Narayanasamy K, Karthick R, Panneerselvam P, Mohan N, Ramachandran A, Prakash R, Rajaram M. Association of metabolic syndrome and patatin-like phospholipase 3 - rs738409 gene variant in non-alcoholic fatty liver disease among a Chennai-based south Indian population. J Gene Med 2020;22:e3160. [PMID: 31945251 DOI: 10.1002/jgm.3160] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
610 Wang RR, Zhang LF, Chen LP, Wang JY, Zhang L, Xu YS, Yang PL, Ji G, Liu BC. Structural and Functional Modulation of Gut Microbiota by Jiangzhi Granules during the Amelioration of Nonalcoholic Fatty Liver Disease. Oxid Med Cell Longev 2021;2021:2234695. [PMID: 34966475 DOI: 10.1155/2021/2234695] [Reference Citation Analysis]
611 Cho YK. Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone? Clin Mol Hepatol 2018;24:299-301. [PMID: 30196651 DOI: 10.3350/cmh.2018.1006] [Reference Citation Analysis]
612 Bellanti F, Vendemiale G. Coronavirus disease 2019 and non-alcoholic fatty liver disease. World J Hepatol 2021; 13(9): 969-978 [PMID: 34630869 DOI: 10.4254/wjh.v13.i9.969] [Reference Citation Analysis]
613 Orabi D, Berger NA, Brown JM. Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention. Cancers (Basel) 2021;13:3473. [PMID: 34298687 DOI: 10.3390/cancers13143473] [Reference Citation Analysis]
614 Chen L, Du S, Lu L, Lin Z, Jin W, Hu D, Jiang X, Xin Y, Xuan S. The additive effects of the TM6SF2 E167K and PNPLA3 I148M polymorphisms on lipid metabolism. Oncotarget 2017;8:74209-16. [PMID: 29088779 DOI: 10.18632/oncotarget.18474] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
615 Ismaiel A, Jaaouani A, Leucuta DC, Popa SL, Dumitrascu DL. The Visceral Adiposity Index in Non-Alcoholic Fatty Liver Disease and Liver Fibrosis-Systematic Review and Meta-Analysis. Biomedicines 2021;9:1890. [PMID: 34944706 DOI: 10.3390/biomedicines9121890] [Reference Citation Analysis]
616 Shao C, Ye J, Li F, Feng S, Wang W, Zhong B. Different predictors of steatosis and fibrosis severity among lean, overweight and obese patients with nonalcoholic fatty liver disease. Digestive and Liver Disease 2019;51:1392-9. [DOI: 10.1016/j.dld.2019.02.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
617 Mantovani A, Dalbeni A. Treatments for NAFLD: State of Art. Int J Mol Sci 2021;22:2350. [PMID: 33652942 DOI: 10.3390/ijms22052350] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
618 Faris M, Jahrami H, Abdelrahim D, Bragazzi N, BaHammam A. The effects of Ramadan intermittent fasting on liver function in healthy adults: A systematic review, meta-analysis, and meta-regression. Diabetes Res Clin Pract 2021;178:108951. [PMID: 34273453 DOI: 10.1016/j.diabres.2021.108951] [Reference Citation Analysis]
619 Saberi B, Dadabhai AS, Nanavati J, Wang L, Shinohara RT, Mullin GE. Vitamin D levels do not predict the stage of hepatic fibrosis in patients with non-alcoholic fatty liver disease: A PRISMA compliant systematic review and meta-analysis of pooled data. World J Hepatol 2018; 10(1): 142-154 [PMID: 29399288 DOI: 10.4254/wjh.v10.i1.142] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
620 Ballestri S, Capitelli M, Fontana MC, Arioli D, Romagnoli E, Graziosi C, Lonardo A, Marietta M, Dentali F, Cioni G. Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative Review. Adv Ther 2020;37:1910-32. [PMID: 32285340 DOI: 10.1007/s12325-020-01307-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
621 Raoul JL, Raimbourg J, Hiret S, Adhoute X, Senellart H. [Hepatocellular carcinoma: Increase in incidence or future plague?]. Bull Cancer 2018;105:502-7. [PMID: 29567280 DOI: 10.1016/j.bulcan.2018.02.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
622 Lockhart ME. NASH Diagnosis Made Better but Maybe Not Yet Easier. Radiology 2021;301:635-6. [PMID: 34519579 DOI: 10.1148/radiol.2021212104] [Reference Citation Analysis]
623 Vandel J, Dubois-Chevalier J, Gheeraert C, Derudas B, Raverdy V, Thuillier D, Gaal L, Francque S, Pattou F, Staels B, Eeckhoute J, Lefebvre P. Hepatic Molecular Signatures Highlight the Sexual Dimorphism of Nonalcoholic Steatohepatitis (NASH). Hepatology 2021;73:920-36. [PMID: 32394476 DOI: 10.1002/hep.31312] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
624 Kang SY, Kim YJ, Park HS. Trends in the Prevalence of Non-Alcoholic Fatty Liver Disease and Its Future Predictions in Korean Men, 1998-2035. J Clin Med 2020;9:E2626. [PMID: 32823604 DOI: 10.3390/jcm9082626] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
625 Su B, Zhang X, Luo G. Homeobox B5 suppression attenuates proliferation and elevates apoptosis in hepatoma cell lines through ERK/MDM2 signalling. Clin Exp Pharmacol Physiol 2020;47:1058-66. [PMID: 32037602 DOI: 10.1111/1440-1681.13278] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
626 Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, Sebastiani G, Ekstedt M, Hagstrom H, Nasr P, Stal P, Wong VW, Kechagias S, Hultcrantz R, Loomba R. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017;65:1557-1565. [PMID: 28130788 DOI: 10.1002/hep.29085] [Cited by in Crossref: 673] [Cited by in F6Publishing: 620] [Article Influence: 134.6] [Reference Citation Analysis]
627 Myers S, Neyroud-Caspar I, Spahr L, Gkouvatsos K, Fournier E, Giostra E, Magini G, Frossard JL, Bascaron ME, Vernaz N, Zampaglione L, Negro F, Goossens N. NAFLD and MAFLD as emerging causes of HCC: A populational study. JHEP Rep 2021;3:100231. [PMID: 33748726 DOI: 10.1016/j.jhepr.2021.100231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
628 Dietrich CF, Shi L, Löwe A, Dong Y, Potthoff A, Sparchez Z, Teufel A, Guth S, Koch J, Barr RG, Cui XW. Conventional ultrasound for diagnosis of hepatic steatosis is better than believed. Z Gastroenterol 2021. [PMID: 34171931 DOI: 10.1055/a-1491-1771] [Reference Citation Analysis]
629 Spinosa M, Stine JG. Nonalcoholic Fatty Liver Disease-Evidence for a Thrombophilic State? Curr Pharm Des 2020;26:1036-44. [PMID: 32003679 DOI: 10.2174/1381612826666200131101553] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
630 Spahis S, Delvin E, Borys JM, Levy E. Oxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis. Antioxid Redox Signal. 2017;26:519-541. [PMID: 27452109 DOI: 10.1089/ars.2016.6776] [Cited by in Crossref: 173] [Cited by in F6Publishing: 163] [Article Influence: 28.8] [Reference Citation Analysis]
631 Fallatah HI, Al-Dabbagh A, Hiejazi MT, Hanbazazah SAA, Hussein AO, Al-Sahafi MA, Akbar HO. Prevalence and Clinical Characteristics of NAFLD in Chronic Liver Disease Patients from King Abdulaziz University Hospital, Jeddah. Saudi J Med Med Sci 2020;8:118-24. [PMID: 32587493 DOI: 10.4103/sjmms.sjmms_272_19] [Reference Citation Analysis]
632 Tanajewski L, Harris R, Harman DJ, Aithal GP, Card TR, Gkountouras G, Berdunov V, Guha IN, Elliott RA. Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study. BMJ Open. 2017;7:e015659. [PMID: 28679676 DOI: 10.1136/bmjopen-2016-015659] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
633 Ma X, Zheng X, Liu S, Zhuang L, Wang M, Wang Y, Xin Y, Xuan S. Relationship of circulating total bilirubin, UDP-glucuronosyltransferases 1A1 and the development of non-alcoholic fatty liver disease: a cross-sectional study. BMC Gastroenterol 2022;22:6. [PMID: 34986792 DOI: 10.1186/s12876-021-02088-7] [Reference Citation Analysis]
634 Koutoukidis DA, Jebb SA, Tomlinson JW, Cobbold JF, Aveyard P. Association of Weight Changes With Changes in Histological Features and Blood Markers in Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology 2021. [DOI: 10.1016/j.cgh.2021.03.047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
635 Kirkegaard-Klitbo DM, Fuchs A, Stender S, Sigvardsen PE, Kühl JT, Kofoed KF, Køber L, Nordestgaard BG, Bendtsen F, Mocroft A, Lundgren J, Nielsen SD, Benfield T. Prevalence and Risk Factors of Moderate-to-Severe Hepatic Steatosis in Human Immunodeficiency Virus Infection: The Copenhagen Co-morbidity Liver Study. J Infect Dis 2020;222:1353-62. [PMID: 32417886 DOI: 10.1093/infdis/jiaa246] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
636 Gawrieh S, Wilson LA, Cummings OW, Clark JM, Loomba R, Hameed B, Abdelmalek MF, Dasarathy S, Neuschwander-Tetri BA, Kowdley K, Kleiner D, Doo E, Tonascia J, Sanyal A, Chalasani N; NASH Clinical Research Network. Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. Am J Gastroenterol 2019;114:1626-35. [PMID: 31517638 DOI: 10.14309/ajg.0000000000000388] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 14.0] [Reference Citation Analysis]
637 Li M, Cao D, Liu Y, Jin L, Zeng N, Wang L, Zhao K, Lv H, Zhang M, Zhang P, Yang Z, Zhang Z. Alterations in the Liver Fat Fraction Features Examined by Magnetic Resonance Imaging Following Bariatric Surgery: a Self-Controlled Observational Study. OBES SURG 2020;30:1917-28. [DOI: 10.1007/s11695-020-04415-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
638 Giammarino AM, Qiu H, Bulsara K, Khan S, Jiang Y, Da BL, Bernstein DE, Satapathy SK. Community Socioeconomic Deprivation Predicts Nonalcoholic Steatohepatitis. Hepatol Commun 2021. [PMID: 34668658 DOI: 10.1002/hep4.1831] [Reference Citation Analysis]
639 Yan JX, Pan BJ, Zhao PP, Wang LT, Liu JF, Fu SB. Serum ferritin is correlated with non-alcoholic fatty liver disease in middle-aged and older patients with type 2 diabetes. Endocr Connect 2021;10:1560-9. [PMID: 34738917 DOI: 10.1530/EC-21-0367] [Reference Citation Analysis]
640 Mahmoudi A, Butler AE, Jamialahmadi T, Sahebkar A. Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis. Biomed Res Int 2021;2021:3654660. [PMID: 34988225 DOI: 10.1155/2021/3654660] [Reference Citation Analysis]
641 Liu F, Zhao J, Rao H, Yu W, Zhang W, Theise ND, Wee A, Wei L. Second Harmonic Generation Reveals Subtle Fibrosis Differences in Adult and Pediatric Nonalcoholic Fatty Liver Disease. American Journal of Clinical Pathology 2017;148:502-12. [DOI: 10.1093/ajcp/aqx104] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
642 Ribeiro RA, Bonfleur ML, Batista TM, Borck PC, Carneiro EM. Regulation of glucose and lipid metabolism by the pancreatic and extra-pancreatic actions of taurine. Amino Acids 2018;50:1511-24. [PMID: 30206707 DOI: 10.1007/s00726-018-2650-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
643 Abshagen K, Mense L, Fischer F, Liebig M, Schaeper U, Navarro G, Glass Ä, Frank M, Klöting N, Vollmar B. Repin1 deficiency in liver tissue alleviates NAFLD progression in mice. J Adv Res 2019;16:99-111. [PMID: 30899593 DOI: 10.1016/j.jare.2018.11.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
644 Dorairaj V, Sulaiman SA, Abu N, Abdul Murad NA. Extracellular Vesicles in the Development of the Non-Alcoholic Fatty Liver Disease: An Update. Biomolecules 2020;10:E1494. [PMID: 33143043 DOI: 10.3390/biom10111494] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
645 Zhang MH, Li J, Zhu XY, Zhang YQ, Ye ST, Leng YR, Yang T, Zhang H, Kong LY. Physalin B ameliorates nonalcoholic steatohepatitis by stimulating autophagy and NRF2 activation mediated improvement in oxidative stress. Free Radic Biol Med 2021;164:1-12. [PMID: 33388433 DOI: 10.1016/j.freeradbiomed.2020.12.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
646 Wegermann K, Howe C, Henao R, Wang Y, Guy CD, Abdelmalek MF, Diehl AM, Moylan CA. Serum Bile Acid, Vitamin E, and Serotonin Metabolites Are Associated With Future Liver-Related Events in Nonalcoholic Fatty Liver Disease. Hepatol Commun 2021;5:608-17. [PMID: 33860119 DOI: 10.1002/hep4.1665] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
647 Zhang R, Cheng K, Xu S, Li S, Zhou Y, Zhou S, Kong R, Li L, Li J, Feng J, Wu L, Liu T, Xia Y, Lu J, Guo C, Zhou Y. Metformin and Diammonium Glycyrrhizinate Enteric-Coated Capsule versus Metformin Alone versus Diammonium Glycyrrhizinate Enteric-Coated Capsule Alone in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Gastroenterol Res Pract 2017;2017:8491742. [PMID: 28133479 DOI: 10.1155/2017/8491742] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
648 Kahl S, Pützer J, Roden M. Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis. Semin Liver Dis 2021. [PMID: 34289506 DOI: 10.1055/s-0041-1732354] [Reference Citation Analysis]
649 Lee M, Shin E, Bae J, Cho Y, Lee JY, Lee YH, Lee BW, Kang ES, Cha BS. Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression. Sci Rep 2020;10:19429. [PMID: 33173107 DOI: 10.1038/s41598-020-75288-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
650 Ramírez-Mejía MM, Díaz-Orozco LE, Barranco-Fragoso B, Méndez-Sánchez N. A Review of the Increasing Prevalence of Metabolic-Associated Fatty Liver Disease (MAFLD) in Children and Adolescents Worldwide and in Mexico and the Implications for Public Health. Med Sci Monit 2021;27:e934134. [PMID: 34456329 DOI: 10.12659/MSM.934134] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
651 Dai G, Tan Y, Liu J, Yuan B, Song Q, Liu J, He S. The significance of IL-28B and CK-18 M30 levels in the diagnosis of non-alcoholic steatohepatitis in SD rats. Pathol Res Pract 2020;216:152901. [PMID: 32143904 DOI: 10.1016/j.prp.2020.152901] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
652 Alemany-Pagès M, Moura-Ramos M, Araújo S, Macedo MP, Ribeiro RT, do Ó D, Ramalho-Santos J, Azul AM. Insights from qualitative research on NAFLD awareness with a cohort of T2DM patients: time to go public with insulin resistance? BMC Public Health 2020;20:1142. [PMID: 32690054 DOI: 10.1186/s12889-020-09249-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
653 Colca JR, McDonald WG, Adams WJ. MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis. Expert Opin Investig Drugs. 2018;27:631-636. [PMID: 29950116 DOI: 10.1080/13543784.2018.1494153] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
654 Chen G, Ni Y, Nagata N, Xu L, Ota T. Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease. Int J Mol Sci. 2016;17:1379. [PMID: 27563875 DOI: 10.3390/ijms17091379] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
655 Cigrovski Berkovic M, Virovic-Jukic L, Bilic-Curcic I, Mrzljak A. Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management. World J Gastroenterol 2020; 26(21): 2740-2757 [PMID: 32550751 DOI: 10.3748/wjg.v26.i21.2740] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
656 Tincopa MA. Diagnostic and interventional circulating biomarkers in nonalcoholic steatohepatitis. Endocrinol Diabetes Metab 2020;3:e00177. [PMID: 33102798 DOI: 10.1002/edm2.177] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
657 Zhang S, Fu J, Zhang Q, Liu L, Meng G, Yao Z, Wu H, Bao X, Gu Y, Lu M, Sun S, Wang X, Zhou M, Jia Q, Song K, Xiang H, Wu Y, Niu K. Association between nut consumption and non-alcoholic fatty liver disease in adults. Liver Int 2019;39:1732-41. [PMID: 31162803 DOI: 10.1111/liv.14164] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
658 Lee PCH, Gu Y, Yeung MY, Fong CHY, Woo YC, Chow WS, Tan K, Lam KSL. Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study. Diabetes Ther. 2018;9:285-295. [PMID: 29322486 DOI: 10.1007/s13300-017-0355-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
659 Munsterman ID, van Erp M, Weijers G, Bronkhorst C, de Korte CL, Drenth JPH, van der Laak JAWM, Tjwa ETTL. A Novel Automatic Digital Algorithm that Accurately Quantifies Steatosis in NAFLD on Histopathological Whole-Slide Images. Cytometry B Clin Cytom 2019;96:521-8. [PMID: 31173462 DOI: 10.1002/cyto.b.21790] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
660 Preguiça I, Alves A, Nunes S, Fernandes R, Gomes P, Viana SD, Reis F. Diet-induced rodent models of obesity-related metabolic disorders-A guide to a translational perspective. Obes Rev 2020;21:e13081. [PMID: 32691524 DOI: 10.1111/obr.13081] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
661 Liu B, Deng X, Jiang Q, Li G, Zhang J, Zhang N, Xin S, Xu K. Scoparone improves hepatic inflammation and autophagy in mice with nonalcoholic steatohepatitis by regulating the ROS/P38/Nrf2 axis and PI3K/AKT/mTOR pathway in macrophages.Biomed Pharmacother. 2020;125:109895. [PMID: 32000066 DOI: 10.1016/j.biopha.2020.109895] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
662 Araz M, Kilinc F, Kerimoglu U, Keskin M, Kucukkartallar T. Irinotecan-induced NASH and liver failure. Clin Res Hepatol Gastroenterol 2021;45:101606. [PMID: 33446474 DOI: 10.1016/j.clinre.2020.101606] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
663 Xavier A, Zacconi F, Gainza C, Cabrera D, Arrese M, Uribe S, Sing-long C, Andia ME. Intrahepatic fatty acids composition as a biomarker of NAFLD progression from steatosis to NASH by using 1 H-MRS. RSC Adv 2019;9:42132-9. [DOI: 10.1039/c9ra08914d] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
664 Livzan MA, Gaus OV, Nikolaev NA, Krolevetz TS. NAFLD: comorbidity and associated diseases. jour 2020;1:57-65. [DOI: 10.31146/1682-8658-ecg-170-10-57-65] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
665 Jiménez-Cortegana C, García-Galey A, Tami M, Del Pino P, Carmona I, López S, Alba G, Sánchez-Margalet V. Role of Leptin in Non-Alcoholic Fatty Liver Disease. Biomedicines 2021;9:762. [PMID: 34209386 DOI: 10.3390/biomedicines9070762] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
666 Brandt A, Jin CJ, Nolte K, Sellmann C, Engstler AJ, Bergheim I. Short-Term Intake of a Fructose-, Fat- and Cholesterol-Rich Diet Causes Hepatic Steatosis in Mice: Effect of Antibiotic Treatment. Nutrients 2017;9:E1013. [PMID: 28906444 DOI: 10.3390/nu9091013] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
667 Zhang Q, Ye L, Xin F, Zhou J, Cao B, Dong Y, Qian L. Milk Fat Globule Membrane Supplementation During Suckling Ameliorates Maternal High Fat Diet-Induced Hepatic Steatosis in Adult Male Offspring of Mice. J Nutr 2021;151:1487-96. [PMID: 33693864 DOI: 10.1093/jn/nxab026] [Reference Citation Analysis]
668 Gao B, Sakaguchi K, Ogawa T, Kagawa Y, Kubo H, Shimizu T. Functional Analysis of Induced Human Ballooned Hepatocytes in a Cell Sheet-Based Three Dimensional Model. Tissue Eng Regen Med 2021;18:217-24. [PMID: 33517537 DOI: 10.1007/s13770-020-00297-x] [Reference Citation Analysis]
669 Soleimani D, Paknahad Z, Rouhani MH. Therapeutic Effects of Garlic on Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Patients: A Randomized Clinical Trial. Diabetes Metab Syndr Obes 2020;13:2389-97. [PMID: 32753923 DOI: 10.2147/DMSO.S254555] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
670 Yari Z, Cheraghpour M, Aghamohammadi V, Alipour M, Ghanei N, Hekmatdoost A. Energy-dense nutrient-poor snacks and risk of non-alcoholic fattyliver disease: a case-control study in Iran. BMC Res Notes 2020;13:221. [PMID: 32299509 DOI: 10.1186/s13104-020-05063-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
671 Wilman HR, Kelly M, Garratt S, Matthews PM, Milanesi M, Herlihy A, Gyngell M, Neubauer S, Bell JD, Banerjee R, Thomas EL. Characterisation of liver fat in the UK Biobank cohort. PLoS One. 2017;12:e0172921. [PMID: 28241076 DOI: 10.1371/journal.pone.0172921] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 8.4] [Reference Citation Analysis]
672 Figge A, Jähnert A, Canbay A. [The harmfulness of simple steatosis]. Dtsch Med Wochenschr 2021;146:146-51. [PMID: 33513646 DOI: 10.1055/a-1156-0875] [Reference Citation Analysis]
673 Hasturk B, Yilmaz Y, Eren F. Potential clinical variants detected in mitochondrial DNA D-loop hypervariable region I of patients with non-alcoholic steatohepatitis. Hormones (Athens) 2019;18:463-75. [PMID: 31656024 DOI: 10.1007/s42000-019-00137-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
674 Mantovani A, Targher G. Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease. Ann Transl Med. 2017;5:270. [PMID: 28758096 DOI: 10.21037/atm.2017.04.41] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 9.6] [Reference Citation Analysis]
675 Li X, Yuan B, Lu M, Wang Y, Ding N, Liu C, Gao M, Yao Z, Zhang S, Zhao Y, Xie L, Chen Z. The methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression. Nat Commun 2021;12:7213. [PMID: 34893641 DOI: 10.1038/s41467-021-27539-3] [Reference Citation Analysis]
676 Lazarus JV, Mark HE, Colombo M, Demaio S, Dillon JF, George J, Hagström H, Hocking S, Lee N, Nieuwenhuijsen MJ, Rinella ME, Romero-Gomez M, Soriano JB, Schattenberg JM, Tacke F, Tsochatzis EA, Valenti L, Zelber-Sagi S, Ashworth Dirac M, Huang TT. A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. Aliment Pharmacol Ther 2021. [PMID: 34866201 DOI: 10.1111/apt.16720] [Reference Citation Analysis]
677 Jung I, Koo DJ, Lee MY, Moon SJ, Kwon H, Park SE, Rhee EJ, Lee WY. Increased Risk of Nonalcoholic Fatty Liver Disease in Individuals with High Weight Variability. Endocrinol Metab (Seoul) 2021;36:845-54. [PMID: 34474519 DOI: 10.3803/EnM.2021.1098] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
678 Whang E, Liu Y, Kageyama S, Woo SL, Yang J, Lee R, Li Z, Ji H, Chen Y, Kupiec-Weglinski JW. Vertical Sleeve Gastrectomy Attenuates the Progression of Non-Alcoholic Steatohepatitis in Mice on a High-Fat High-Cholesterol Diet. Obes Surg 2019;29:2420-9. [PMID: 30982168 DOI: 10.1007/s11695-019-03860-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
679 Sheng D, Zhao S, Gao L, Zheng H, Liu W, Hou J, Jin Y, Ye F, Zhao Q, Li R, Zhao N, Zhang L, Han Z, Wei L. BabaoDan attenuates high-fat diet-induced non-alcoholic fatty liver disease via activation of AMPK signaling. Cell Biosci 2019;9:77. [PMID: 31548878 DOI: 10.1186/s13578-019-0339-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
680 Wu Y, Wang M, Yang T, Qin L, Hu Y, Zhao D, Wu L, Liu T. Cinnamic Acid Ameliorates Nonalcoholic Fatty Liver Disease by Suppressing Hepatic Lipogenesis and Promoting Fatty Acid Oxidation. Evid Based Complement Alternat Med 2021;2021:9561613. [PMID: 34512784 DOI: 10.1155/2021/9561613] [Reference Citation Analysis]
681 Mazzotti A, Caletti MT, Brodosi L, Di Domizio S, Forchielli ML, Petta S, Bugianesi E, Bianchi G, Marchesini G. An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers. J Hepatol. 2018;69:1155-1163. [PMID: 30290973 DOI: 10.1016/j.jhep.2018.07.013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
682 Tan CH, Al-Kalifah N, Ser KH, Lee YC, Chen JC, Lee WJ. Long-term effect of bariatric surgery on resolution of nonalcoholic steatohepatitis (NASH): An external validation and application of a clinical NASH score. Surg Obes Relat Dis 2018;14:1600-6. [PMID: 30077664 DOI: 10.1016/j.soard.2018.05.024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
683 Villela-Nogueira CA, Leite NC, Cardoso CR, Salles GF. NAFLD and Increased Aortic Stiffness: Parallel or Common Physiopathological Mechanisms? Int J Mol Sci 2016;17:E460. [PMID: 27104526 DOI: 10.3390/ijms17040460] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
684 Alves CC, Waitzberg DL, de Andrade LS, Dos Santos Aguiar L, Reis MB, Guanabara CC, Júnior OA, Ribeiro DA, Sala P. Prebiotic and Synbiotic Modifications of Beta Oxidation and Lipogenic Gene Expression after Experimental Hypercholesterolemia in Rat Liver. Front Microbiol 2017;8:2010. [PMID: 29089934 DOI: 10.3389/fmicb.2017.02010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
685 Caussy C, Alquiraish MH, Nguyen P, Hernandez C, Cepin S, Fortney LE, Ajmera V, Bettencourt R, Collier S, Hooker J, Sy E, Rizo E, Richards L, Sirlin CB, Loomba R. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. Hepatology. 2018;67:1348-1359. [PMID: 29108123 DOI: 10.1002/hep.29639] [Cited by in Crossref: 108] [Cited by in F6Publishing: 102] [Article Influence: 27.0] [Reference Citation Analysis]
686 Borges-Canha M, Neves JS, Libânio D, Von-Hafe M, Vale C, Araújo-Martins M, Leite AR, Pimentel-Nunes P, Carvalho D, Leite-Moreira A. Association between nonalcoholic fatty liver disease and cardiac function and structure-a meta-analysis. Endocrine 2019;66:467-76. [PMID: 31482382 DOI: 10.1007/s12020-019-02070-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
687 Rao A, Kosters A, Mells JE, Zhang W, Setchell KD, Amanso AM, Wynn GM, Xu T, Keller BT, Yin H, Banton S, Jones DP, Wu H, Dawson PA, Karpen SJ. Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice. Sci Transl Med 2016;8:357ra122. [PMID: 27655848 DOI: 10.1126/scitranslmed.aaf4823] [Cited by in Crossref: 86] [Cited by in F6Publishing: 85] [Article Influence: 17.2] [Reference Citation Analysis]
688 Ma J, Tan X, Kwon Y, Delgado ER, Zarnegar A, DeFrances MC, Duncan AW, Zarnegar R. A Novel Humanized Model of NASH and Its Treatment With META4, A Potent Agonist of MET. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00221-6. [PMID: 34756982 DOI: 10.1016/j.jcmgh.2021.10.007] [Reference Citation Analysis]
689 Gong F, Gao L, Ding T. IDH2 protects against nonalcoholic steatohepatitis by alleviating dyslipidemia regulated by oxidative stress. Biochemical and Biophysical Research Communications 2019;514:593-600. [DOI: 10.1016/j.bbrc.2019.04.069] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
690 Xu XF, Yang XK, Song Y, Chen BJ, Yu X, Xu T, Chen ZL. Dysregulation of Non-coding RNAs mediates Cisplatin Resistance in Hepatocellular Carcinoma and therapeutic strategies. Pharmacol Res 2021;:105906. [PMID: 34543740 DOI: 10.1016/j.phrs.2021.105906] [Reference Citation Analysis]
691 Coelho CFF, França LM, Nascimento JR, Dos Santos AM, Azevedo-Santos APS, Nascimento FRF, Paes AMA. Early onset and progression of non-alcoholic fatty liver disease in young monosodium l-glutamate-induced obese mice. J Dev Orig Health Dis 2019;10:188-95. [PMID: 29855396 DOI: 10.1017/S2040174418000284] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
692 Swain MG, Ramji A, Patel K, Sebastiani G, Shaheen AA, Tam E, Marotta P, Elkhashab M, Bajaj HS, Estes C, Razavi H. Burden of nonalcoholic fatty liver disease in Canada, 2019-2030: a modelling study. CMAJ Open 2020;8:E429-36. [PMID: 32518095 DOI: 10.9778/cmajo.20190212] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
693 Wang C, Ma C, Gong L, Dai S, Li Y. Preventive and therapeutic role of betaine in liver disease: A review on molecular mechanisms. Eur J Pharmacol 2021;912:174604. [PMID: 34743980 DOI: 10.1016/j.ejphar.2021.174604] [Reference Citation Analysis]
694 Robeva R, Mladenović D, Vesković M, Hrnčić D, Bjekić-Macut J, Stanojlović O, Livadas S, Yildiz BO, Macut D. The interplay between metabolic dysregulations and non-alcoholic fatty liver disease in women after menopause. Maturitas 2021;151:22-30. [PMID: 34446275 DOI: 10.1016/j.maturitas.2021.06.012] [Reference Citation Analysis]
695 Li Y, De Stefano V, Li H, Zheng K, Bai Z, Guo X, Qi X. Epidemiology of Budd-Chiari syndrome: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2019;43:468-74. [PMID: 30528513 DOI: 10.1016/j.clinre.2018.10.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
696 Banini BA, Sanyal AJ. NAFLD-related HCC. Adv Cancer Res 2021;149:143-69. [PMID: 33579423 DOI: 10.1016/bs.acr.2020.11.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
697 Sheridan DA, Aithal G, Alazawi W, Allison M, Anstee Q, Cobbold J, Khan S, Fowell A, McPherson S, Newsome PN, Oben J, Tomlinson J, Tsochatzis E. Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey. Frontline Gastroenterol 2017;8:252-9. [PMID: 29067150 DOI: 10.1136/flgastro-2017-100806] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
698 Jirapinyo P, Mccarty TR, Dolan RD, Shah R, Thompson CC. Effect of Endoscopic Bariatric and Metabolic Therapies on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2021. [DOI: 10.1016/j.cgh.2021.03.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
699 Diniz AB, Antunes MM, Lacerda VAS, Nakagaki BN, Freitas Lopes MA, Castro-Oliveira HM, Mattos MS, Mafra K, de Miranda CDM, de Oliveira Costa KM, Lopes ME, Alvarenga DM, Carvalho-Gontijo R, Marchesi SC, Lacerda DR, de Araújo AM, de Carvalho É, David BA, Santos MM, Lima CX, Silva Gomes JA, Minto Fontes Cal TC, de Souza BR, Couto CA, Faria LC, Teixeira Vidigal PV, Matos Ferreira AV, Radhakrishnnan S, Ricci M, Oliveira AG, Rezende RM, Menezes GB. Imaging and immunometabolic phenotyping uncover changes in the hepatic immune response in the early phases of NAFLD. JHEP Rep 2020;2:100117. [PMID: 32695965 DOI: 10.1016/j.jhepr.2020.100117] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
700 Donaldson J, Ngema M, Nkomozepi P, Erlwanger K. Quercetin administration post‐weaning attenuates high‐fructose, high‐cholesterol diet‐induced hepatic steatosis in growing, female, Sprague Dawley rat pups. J Sci Food Agric 2019;99:6954-61. [DOI: 10.1002/jsfa.9984] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
701 Dokmak A, Lizaola-Mayo B, Trivedi HD. The Impact of Nonalcoholic Fatty Liver Disease in Primary Care: A Population Health Perspective. Am J Med 2021;134:23-9. [PMID: 32931760 DOI: 10.1016/j.amjmed.2020.08.010] [Reference Citation Analysis]
702 Simon TG, Corey KE, Chung RT, Giugliano R. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe. Dig Dis Sci 2016;61:3425-35. [DOI: 10.1007/s10620-016-4330-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
703 Mertens J, Van Gaal LF, Francque SM, De Block C. NAFLD in type 1 diabetes: overrated or underappreciated? Ther Adv Endocrinol Metab 2021;12:20420188211055557. [PMID: 34840719 DOI: 10.1177/20420188211055557] [Reference Citation Analysis]
704 Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases.Transl Gastroenterol Hepatol. 2020;5:16. [PMID: 32258520 DOI: 10.21037/tgh.2019.09.08] [Cited by in Crossref: 61] [Cited by in F6Publishing: 49] [Article Influence: 30.5] [Reference Citation Analysis]
705 Akdis CA. Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? Nat Rev Immunol 2021. [PMID: 33846604 DOI: 10.1038/s41577-021-00538-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 21] [Article Influence: 14.0] [Reference Citation Analysis]
706 Higashiura Y, Furuhashi M, Tanaka M, Takahashi S, Mori K, Miyamori D, Koyama M, Ohnishi H, Moniwa N, Numata K, Hisasue T, Hanawa N, Miura T. Elevated Fatty Liver Index Is Independently Associated With New Onset of Hypertension During a 10-Year Period in Both Male and Female Subjects. J Am Heart Assoc 2021;10:e021430. [PMID: 34259033 DOI: 10.1161/JAHA.121.021430] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
707 Wong RJ, Tran T, Kaufman H, Niles J, Gish R. Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis. PLoS One 2019;14:e0220612. [PMID: 31369606 DOI: 10.1371/journal.pone.0220612] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
708 Jiang T, Guo XJ, Tu LP, Lu Z, Cui J, Ma XX, Hu XJ, Yao XH, Cui LT, Li YZ, Huang JB, Xu JT. Application of computer tongue image analysis technology in the diagnosis of NAFLD. Comput Biol Med 2021;135:104622. [PMID: 34242868 DOI: 10.1016/j.compbiomed.2021.104622] [Reference Citation Analysis]
709 Kriss M, Golden-Mason L, Kaplan J, Mirshahi F, Setiawan VW, Sanyal AJ, Rosen HR. Increased hepatic and circulating chemokine and osteopontin expression occurs early in human NAFLD development. PLoS One 2020;15:e0236353. [PMID: 32730345 DOI: 10.1371/journal.pone.0236353] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
710 Castillo-Castro C, Martagón-Rosado AJ, Ortiz-Lopez R, Garrido-Treviño LF, Villegas-Albo M, Bosques-Padilla FJ. Promising diagnostic biomarkers of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: From clinical proteomics to microbiome. World J Hepatol 2021; 13(11): 1494-1511 [PMID: 34904026 DOI: 10.4254/wjh.v13.i11.1494] [Reference Citation Analysis]
711 Hardesty JE, Wahlang B, Falkner KC, Shi H, Jin J, Zhou Y, Wilkey DW, Merchant ML, Watson CT, Feng W, Morris AJ, Hennig B, Prough RA, Cave MC. Proteomic Analysis Reveals Novel Mechanisms by Which Polychlorinated Biphenyls Compromise the Liver Promoting Diet-Induced Steatohepatitis. J Proteome Res 2019;18:1582-94. [PMID: 30807179 DOI: 10.1021/acs.jproteome.8b00886] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
712 Yuan X, Sun Y, Cheng Q, Hu K, Ye J, Zhao Y, Wu J, Shao X, Fang L, Ding Y, Sun X, Shi X, Xue B. Proteomic analysis to identify differentially expressed proteins between subjects with metabolic healthy obesity and non-alcoholic fatty liver disease. J Proteomics 2020;221:103683. [PMID: 32058041 DOI: 10.1016/j.jprot.2020.103683] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
713 Ferrari A, Longo R, Silva R, Mitro N, Caruso D, De Fabiani E, Crestani M. Epigenome modifiers and metabolic rewiring: New frontiers in therapeutics. Pharmacology & Therapeutics 2019;193:178-93. [DOI: 10.1016/j.pharmthera.2018.08.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
714 Yang A, Yan X, Fan X, Shi Y, Huang T, Li W, Chen W, Jia J, You H. Hepatic stellate cells-specific LOXL1 deficiency abrogates hepatic inflammation, fibrosis, and corrects lipid metabolic abnormalities in non-obese NASH mice. Hepatol Int 2021. [PMID: 34014450 DOI: 10.1007/s12072-021-10210-w] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
715 Park JH, Choi IS, Han KD, Park H, Kim KH, Kim JS. Association Between Fatty Liver Index and Risk of Breast Cancer: A Nationwide Population-Based Study. Clin Breast Cancer 2020;20:e450-7. [PMID: 32192863 DOI: 10.1016/j.clbc.2020.02.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
716 Harris R, West J, Morling JR. Editorial: how widespread and serious is non-alcoholic fatty liver disease in the real world? Aliment Pharmacol Ther 2020;51:1199-200. [PMID: 32424922 DOI: 10.1111/apt.15714] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
717 Fadaei R, Meshkani R, Poustchi H, Fallah S, Moradi N, Panahi G, Merat S, Golmohammadi T. Association of carotid intima media thickness with atherogenic index of plasma, apo B/apo A-I ratio and paraoxonase activity in patients with non-alcoholic fatty liver disease. Arch Physiol Biochem 2019;125:19-24. [PMID: 29359590 DOI: 10.1080/13813455.2018.1429475] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
718 Yaghoubi M, Jafari S, Sajedi B, Gohari S, Akbarieh S, Heydari AH, Jameshoorani M. Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease: . European Journal of Gastroenterology & Hepatology 2017;29:1385-8. [DOI: 10.1097/meg.0000000000000981] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 3.2] [Reference Citation Analysis]
719 Younossi ZM, Ong JP, Takahashi H, Yilmaz Y, Eguchi Y, El Kassas M, Buti M, Diago M, Zheng MH, Fan JG, Yu ML, Wai-Sun Wong V, Alswat K, Chan WK, Mendez-Sanchez N, Burra P, Bugianesi E, Duseja AK, George J, Papatheodoridis GV, Saeed H, Castera L, Arrese M, Kugelmas M, Romero-Gomez M, Alqahtani S, Ziayee M, Lam B, Younossi I, Racila A, Henry L, Stepanova M; Global NASH Council. A Global Survey of Physicians Knowledge About Non-alcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00719-9. [PMID: 34229038 DOI: 10.1016/j.cgh.2021.06.048] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
720 Liu Y, Maya S, Ploss A. Animal Models of Hepatitis B Virus Infection-Success, Challenges, and Future Directions. Viruses 2021;13:777. [PMID: 33924793 DOI: 10.3390/v13050777] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
721 Safarpour AR, Askari H, Ejtehadi F, Azarnezhad A, Raeis-Abdollahi E, Tajbakhsh A, Abazari MF, Tarkesh F, Shamsaeefar A, Niknam R, Sivandzadeh GR, Lankarani KB, Ejtehadi F. Cholangiocarcinoma and liver transplantation: What we know so far? World J Gastrointest Pathophysiol 2021; 12(5): 84-105 [PMID: 34676129 DOI: 10.4291/wjgp.v12.i5.84] [Reference Citation Analysis]
722 Soleimani D, Ranjbar G, Rezvani R, Goshayeshi L, Razmpour F, Nematy M. Dietary patterns in relation to hepatic fibrosis among patients with nonalcoholic fatty liver disease. Diabetes Metab Syndr Obes 2019;12:315-24. [PMID: 30881075 DOI: 10.2147/DMSO.S198744] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
723 Zhao S, Wang Y, Wu W, Yang S, Feng L, Tao F, Ge W, Shen M, Xu W. Nonalcoholic fatty liver disease and risk of prostatic diseases: Roles of insulin resistance. Andrologia 2021;53:e14060. [PMID: 33782980 DOI: 10.1111/and.14060] [Reference Citation Analysis]
724 Gao F, Huang JF, Zheng KI, Pan XY, Ma HL, Liu WY, Byrne CD, Targher G, Li YY, Chen YP, Chan WK, Zheng MH. Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2020;35:1804-12. [PMID: 32246876 DOI: 10.1111/jgh.15055] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
725 Rinella ME, Tacke F, Sanyal AJ, Anstee QM; participants of the AASLD/EASL Workshop. Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD. Hepatology. 2019;70:1424-1436. [PMID: 31287572 DOI: 10.1002/hep.30782] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article